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Vitamin D plays a role in the prevention of rickets in children and osteomalacia in 
adults. However, direct activity of vitamin D and Vitamin D Receptor (VDR) in bone 
cells has not been fully understood. Vitamin D receptor activities in bone cells are 
modulated by the dietary calcium in endocrine and bone paracrine/autocrine pathways 
in various studies. However, confirmation of direct VDR activities in bone cells in 
conjunction with calcium interactions on genetically modified animals has not been 
previously evaluated. Studies in these settings will assist our understanding of Vitamin 
D activities and VDR physiology in bone cells to modulate bone structures. 
 
In chapter 3, a study on the generation and characterisation of transgenic over-
expression of VDR in mature osteoblast using the osteocalcin promoter in C57bl6/J 
background (ObVDR-B6) was conducted. Results of this chapter confirm the anabolic 
action of this transgene and demonstrate that the VDR activity in mature osteoblasts 
exerts gender-specific and anatomical specific activities.  
 
In chapter 4, the ObVDR-B6 mouse line was subjected to normal dietary calcium and 
phosphate intakes and extremely low dietary calcium (0.03 %) and phosphate (0.08 
%) levels (LowCaP diet) over short term (3w) and long term (17w) periods to 
investigate its effects on bone mineral and skeletal structure. The study provides 
evidence that VDR activities in mature osteoblasts are anti-catabolic for skeletal 






Whether deletion of VDR in mature osteoblasts using the Cre/lox-P system and 
osteocalcin promoter (ObVDR-KO) can rescue the skeletal structure of the mice when 
fed LowCaP diet is addressed in chapter 5. Results from this study confirmed that the 
activities of VDR in mature osteoblasts are modulated by the levels of dietary calcium 
and phosphate. Under normal calcium/phosphate levels, ObVDR-KO bone structures 
were not different from control mice. However, when fed LowCaP diet, the ObVDR-
KO has anomalous bone structure with very high cortical porosity and high serum PTH 
and 1α,25 dihydroxyvitamin D3 (1,25D) levels.  
 
Although these studies and the mouse models have several limitations, overall data 
have contributed to elucidating the role of VDR activities in mature osteoblasts in 
skeletal biology and physiology in regards to dietary calcium/phosphate and further 
strengthen the evidence of the direct activities of VDR in skeletal health and mineral 
homeostasis. However, skeletal sites, region examined, sex, and age of the animals 
significantly influenced the results. Therefore, careful adjustment and further studies 
are needed to reveal the activities of mature osteoblast VDR in both genders, various 
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CHAPTER 1: LITERATURE REVIEW 
 
THE ROLE OF DIETARY CALCIUM/PHOSPHATE IN VITAMIN D 
RECEPTOR MEDIATED ACTIVITIES IN BONE CELLS TO MODULATE 
BONE STRUCTURE AND MINERAL HOMEOSTASIS 
 
This literature review provides a summary of the interaction between vitamin D, 
vitamin D receptor (VDR), dietary calcium and phosphate in bone cells to maintain 
bone mineral homeostasis. VDR and calcium play multiple important roles in the 
modulation of skeletal structure as indicated in in-vitro and in vivo studies. However, 
the controversy of a direct action of vitamin D in mature osteoblasts to modulate 
skeletal structure persists. This controversy is, arises, in part,  from insufficient data 
on the role of dietary calcium on bone structure derived from in-vivo studies utilising 
specific mouse models in which the genes for VDR and vitamin D metabolising 
enzymes have been altered. Dietary calcium in vivo and extracellular calcium in vitro 
can enhance osteoblast maturation and improve skeletal structures. However, the 
interaction with bone cell vitamin D activity in-vivo and the possible mechanisms are 
not fully understood. This literature review briefly summarises the current research 
progress in vitamin D, dietary calcium, phosphate, and calcium/phosphate regulation 
of bone cell activities in both in-vitro and in-vivo studies as a guide towards the 




CHAPTER 1: LITERATURE REVIEW 
 
1.1. INTRODUCTION  
Osteoporosis is a metabolic bone disorder that is a worldwide health problem (1). The 
World Health Organization (WHO) has defined osteoporosis as “a disease 
characterized by low bone mass and micro-architectural deterioration of bone tissue 
leading to enhanced bone fragility and a consequent increase in fracture risk” (2) due 
to imbalance of bone remodelling especially in elderly people. In developing countries 
such as Indonesia, some 22.3 % of men & 32 % of women were reported to have 
osteoporosis in 2006 (3), while in a developed country such as Australia, 1 in 2 women 
and 1 in 4 men age over 60 years old have been diagnosed with osteoporosis (4). 
Several risk factors for the development of osteoporosis are well known including poor 
nutrition, decreased physical activity, smoking, alcohol consumption, and drugs (5). 
Geographical location also plays a role in the pathogenesis of osteoporosis due to the 
seasonal variations and degree of sunlight exposure which are determinants of vitamin 
D status (6). 
 
Vitamin D deficiency is significantly associated with osteoporosis (7) and increased 
incidence of fracture (8). The bone loss that occurs in osteoporosis is often undetected 
until a significant fracture occurs (5). The wrist, spine, and hip are the most common 
regions for osteoporotic fracture which can lead to disability, increased dependency 
and financial burden (9). Therefore, effective strategies to prevent the onset of 
osteoporosis are imperative to reduce the health and financial burdens to individuals 





Dietary intervention is a recognized method for treating mild osteoporosis (10) and 
calcium supplementation is known to be a useful treatment to improve bone health 
(11). Bone density in elderly females with osteoporosis (12), menopausal women (13) 
and adolescent girls (14) was increased while the risk of fractures was decreased with 
dietary calcium and/or calcium-rich foods (15,16). Calcium is an essential nutrient 
because plasma calcium levels affect various important cellular activities due to 
intracellular signalling pathways and other actions (17). Plasma calcium homeostasis 
is tightly regulated by the processes of renal tubular reabsorption of calcium, intestinal 
calcium absorption, and bone remodelling as sources of calcium for the plasma 
compartment (18). The calciotropic hormones, parathyroid hormone (PTH), calcitonin 
and vitamin D (19), play a key role in regulating plasma calcium homeostasis in a 
concerted manner. 
 
Vitamin D has been known as the bone vitamin since the beginning of the 20th century 
and plays a role in preventing the onset of rickets or osteomalacia which has re-
emerged in the 21st century (20). Osteomalacia is a bone disease characterised by the 
marked under-mineralization of bone which occurs due to the failure of maintaining 
plasma calcium and/or phosphate homeostasis (21). The role for vitamin D activity to 
prevent osteomalacia by maintaining plasma calcium and phosphate level was clearly 
demonstrated by studies with vitamin D receptor (VDR) knockout mice as described 
by Li et.al in 1998 (22) and Amling et.al in 1999 (23). They showed that hypo-
mineralized skeletal phenotype of VDR knockout mice was normalized by providing 





In addition to the role of vitamin D in preventing osteomalacia, there is a large body 
of data implicating vitamin D deficiency in the aetiology of the bone disease 
osteoporosis (7) and increased risk of fracture (24). However, results from the 
randomized controlled trials (RCTs) of vitamin D supplementations and fracture risk 
have been controversial (25-27). Meta-analyses of data from large RCTs indicate 
combination of vitamin D with calcium (28) are best to reduce osteoporosis and the 
risk of fractures. Although vitamin D activity is important to prevent bone loss and 
osteoporosis, the mechanism by which this occurs is not entirely clear. In osteoporotic 
hip fracture patients with low vitamin D status, there is no evidence of a calcium and 
phosphate malabsorption or disturbed calcium and/or phosphate homeostasis (29,30). 
Therefore, in addition to the role of vitamin D activity to maintain plasma calcium and 
phosphate homeostasis, it has been proposed that vitamin D can act directly on bone 
cells, particularly bone forming cell, osteoblasts, to promote bone mineralisation and 
to improve bone health (31)  
 
The discovery that bone cells are capable of synthesising 1α, 25 dihydroxyvitamin D3 
(1,25D) and respond to 1,25D to elicit autocrine and paracrine actions (32) has brought 
a new perspective on vitamin D metabolism and VDR-mediated activities in bone. 
Osteoblasts express the 25-hydroxyvitamin D 1α-hydroxylase (CYP27B1) enzyme 
which metabolizes the prohormone 25-hydroxyvitamin D (25D) to the biologically 
active 1,25D (33). In-vitro studies have demonstrated the importance of vitamin D in 
bone cells. Incubation of osteoblasts with 25D modulates osteoblasts activity, induces 
alkaline phosphatase (ALP) activity, osteocalcin (OC) and 25-hydroxyvitamin D 24-
hydroxylase (CYP24) mRNA expression, and enhances mineralization (34) for which 




precursor and mature osteoclasts such that incubation of 25D with human peripheral 
mononuclear cells (PMC) or mouse RAW264.7 cells up-regulate the expression of 
osteoclast transcription factor (nuclear factor of activated T cells-cytoplasmic 1 / 
NFATc1) and other osteoclast marker genes to generate osteoclasts with reduced 
resorptive capacity in both models (35). Various animal models have been used for in-
vivo studies of vitamin D metabolism and/or VDR activities. One mouse model 
overexpresses the human VDR gene under the control of the osteoblast-specific 
promoter of the gene for osteocalcin.  This transgene increased VDR protein levels 2 
to 3-fold in the bone of this mouse model (36). This mouse line, known as the OSVDR 
mouse, exhibited increased cortical and trabecular bone volumes due to increased 
periosteal mineral apposition rate (MAR) and reduced trabecular resorption surfaces 
(36) suggesting  distinct and diverse vitamin D regulatory pathways in bone forming 
cells with the  conclusion  that increased VDR in mature osteoblasts is anabolic for 
bone. 
 
Baldock et al. in 2006 (37) demonstrated that the anabolic effect of the osteoblast 
specific VDR overexpression is dependent on dietary calcium intake. A 
comprehensive study to determine the role of dietary calcium in vitamin D and/or VDR 
activities on bone cell will provide further insights on bone physiology and 
remodelling. Therefore, the main idea of this thesis is to evaluate the role of calcium 
in the direct activity of vitamin D and VDR in mature osteoblasts to maintain skeletal 




1.2. BONE STRUCTURE, PHYSIOLOGY & BIOLOGY 
The human skeleton serves as a unique organ in providing structures to protect vital 
organs but light enough to permit easy movement and locomotion (38). As cited by 
Clarke, 2008 (38), the adult human skeleton consist of 213 bones which are composed 
of two main structures, trabecular (cancellous) and cortical (compact) bone and 
collectively comprises the bone mass. The structure of compact bone which comprises 
80 % of whole bone mass based on their size scale is depicted in figure 1.1 to illustrate 
macroscopic and microscopic structure of the bone. Trabecular bone (or spongy bone) 
is less dense, highly vascular, has a higher ratio of surface area to mass, and is in close 
contact with bone marrow (39). Therefore it is softer, weaker and has flexible 
characteristics suitable for metabolic activity such as ion exchange while the cortical 
(compact) bone will determine bone mass and bone strength.  
 
Bone mass is the result of bone formation and bone resorption through periods of 
growth, maturity and senescence (40) with or without adequate calcium intake as 
depicted in figure 1.2. Osteopenia and osteoporosis are characterized by low bone 







Figure 1.1. Hierarchical Structure of Human Cortical Bone 
Human cortical bone consists of Harversian osteons with canaliculi, collagen fibres, 
and hydroxyapatite crystals providing a denser composition than trabecular bone. 
Therefore, cortical bone is harder, stronger, and stiffer. Any changes in macroscopic 
structures can be linked to changes of the hierarchical structure of bone at the 




Figure 1.2. Bone Mass Alteration in Women (Arbitrary Units) With Age 
Peak Bone Mass (PBM) is determined by various factors including calcium intake 
throughout life. Bone mass accrual still occurs with an inadequate calcium intake. 
However, PBM achieved with inadequate calcium intake is lower which determines 
susceptibility to osteopenia, osteoporosis and fracture later in life. Adapted from Ilich 




During growth and development in childhood and adolescence, the rate of bone 
formation exceeds the rate of bone resorption and a net gain of bone mass is achieved 
(38). This process is termed bone modelling by which bones change shape and 
structure leading to gradual adjustment of the skeleton and is affected by endogenous 
(genetic, hormonal) and exogenous (nutritional, mechanical or physical activity) 
factors (42). When peak bone mass is achieved at maturity or after the age of 25 years 
(43), bone formation and bone resorption come into equilibrium and bone mass 
remains stable until mid-life (40). At this age, bone remodelling predominates to 
renew, replace, and maintain bone strength and mineral homeostasis to meet metabolic 
demands in a tightly coupled manner (38). Cortical bone is remodelled at a lower rate 
than trabecular bone which suggests that the role of cortical bone remodelling is to 
maintain bone biomechanical strength while trabecular bone remodelling is mostly for 
mineral homeostasis (39). In contrast to bone modelling, bone remodelling occurs at 
the same location with cyclical timing beginning with the activation process, followed 
by bone resorption and ending with formation of new bone (42) as depicted in figure 
1.3. During senescence, beginning at the menopause in women and at about the age of 
55 in men, the bone remodelling equilibrium is disturbed (38). This results in a 
progressive decline of bone mass which continues to the end of life and increases the 





Figure 1.3. Phases of Bone Remodelling 
Bone remodelling starts from the quiescent phase (A) with flat bone lining cells (LC) 
covering the endosteal membrane. Activation of bone resorption produces the 
activation phase (B) characterised by lining cell retraction and recruitment of 
osteoclasts (OC) to start the resorption phase (C). When the resorption phase is ended, 
osteoblasts (OB) are recruited along the resorption pit to begin the formation phase 
(D). Osteoblasts synthesise extracellular matrix and begin to form new osteoid (pink) 
which is later mineralised to form bone (E). Some osteoblasts differentiate into lining 
cells while osteoblasts trapped within the osteoid become osteocytes (Oy/Ocy) and 
formation of the new bone is completed (F) or termination phase and progress towards 





Changes in the relationship between bone formation and bone resorption throughout 
stages of life are dependent on the activities of the three major types of bone cells; 
osteoblasts and osteocytes derived from mesenchymal stem cells (MSC) (46), and 
osteoclasts which arise from haematopoietic stem cells (HSC) (47). The osteoblasts 
and osteoclasts exist on the bone surfaces while the osteocytes are embedded in the 
mineralised collagenous matrix (38). The proliferation and activities of these cells are 
coordinated by mechanisms yet to be fully elucidated. 
 
1.2.1. Osteoblasts and Osteocytes  
Osteoblasts (48) and osteocytes (49) regulate bone formation and are derived from 
MSC which function to maintain the number of osteoblasts within bone throughout 
life. The exact locations of skeletal MSC are unknown, although it is suggested that 
they came from pericytes on the sinusoidal wall (50) and from the bone marrow MSC 
that differentiate into osteoblasts as a response to various hormonal, mechanical, or 
cytokine signals (46). Osteoblasts have at least four major functions; 1) secretion of 
bone extracellular matrix (ECM) which includes collagen, osteocalcin and alkaline 
phosphatase (51); 2) expression of genes for mineralization of ECM; (52) 3) 
controlling osteoclast differentiation thereby influencing bone resorption; (53) and 4) 
differentiation into osteocytes (54) as depicted in figure 1.4. Bone ECM consists of 
organic materials (85-90 % collagenous proteins, predominantly type I collagen, 10-
15 % of non-collagenous proteins (e.g. osteocalcin/osteonectin, proteoglycan) derived 
exogenously (55)) and inorganic materials (calcium hydroxyapatite/HA or 




Figure 1.4. Osteoblast Lineage during Osteoblastogenesis 
MSC undergo commitment to osteoprogenitor cells proliferating and maturing to 
become pre-osteoblasts, mature osteoblasts and lastly osteocytes depicted according 
to their differentiation steps (blue box). These processes are regulated by concerted 
expression of several transcription factors such as Runx2, -catenin, and ATF-4 (pink 
colour box). Bone formation by osteoblasts is regulated by local and systemic 
signalling factors such as BMP, TGF-, and PPAR- (green colour box) during bone 
modelling in development and throughout life. Mature osteoblasts can also 
differentiate into bone lining cells or undergo apoptosis. During certain physiological 
or pathological condition, osteocyte death can occur and dead osteocytes leave empty 




Osteocytes embedded within mineralized bone are terminally differentiated 
osteoblasts and they function to support bone structure and mineral metabolism (58). 
Osteocytes connect to each other and the bone surface via multiple filipodial processes 
which support intercellular adhesion and mineral exchange within the lacunae and 
canalicular networks (59). The connection between the filipodial processes of each 
osteocyte are known as gap junctions, which are also required for maturation, activity, 
and survival of osteocytes during bone turnover (60). Therefore, under normal 
condition, osteocytes can live for up to decades in the absence of bone turnover.  
 
The primary known function of osteocytes is mechanosensation (54). Osteocytes act 
as the transducer of stress signals for bone biological activity when subject to bending 
or stretching via the flow of fluid through the canalicular networks (61). The flow is 
believed to be a signal between osteocytes within the bone and osteoblasts on the bone 
surface to induce their cellular activities. Disruption of intercellular signalling at the 
gap junctions or cell–matrix interactions may cause osteocytes to become active or 
undergo apoptosis (54). Activated osteocytes became phagocytic cells due to their 
lysosomal enzymes and apoptotic osteocytes will produce empty lacunae within the 
bone resulting in a decrease of bone density and osteoporosis (38,60).  
 
Osteocytes also regulate bone turnover and assist in mineral metabolism due to their 
enormous surface area and location to easily dissolve bone mineral matrix (62). 
Osteocytes remodel their perilacunar/canalicular structures through an osteocyte-
mediated demineralization process in response to various stimuli such as parathyroid 
hormone and calcium restriction (63). This process is known as osteocytic osteolysis. 
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However, the exact mechanism by which this process occurs and is regulated is unclear 
and warrants further investigations. 
 
1.2.2. Osteoclasts  
Osteoclasts are bone surface cells that are able to resorb bone (47). They are 
multinucleated giant cells derived from mononuclear precursor cells of the monocyte 
macrophage lineage from the HSC (64) in a process called osteoclastogenesis 
(depicted in figure 1.5). Osteoclastogenesis requires the presence of stromal cells 
including osteoblasts because they secrete receptor activator of nuclear factor-κB 
ligand (RANKL) and macrophage colony stimulating factor (M-CSF) (65). These 
cytokines are critical for osteoclast formation, proliferation, survival, and 
differentiation as well as cytoskeletal rearrangement required for osteoclastic bone 
resorption (38). 
 
Osteoclastic bone resorption consists of several processes including 1) 
osteoclastogenesis, 2) activation phase, 3) bone resorption and 4) osteoclast apoptosis 
when the bone resorption process is completed (66). These processes are highly 
complex and regulated by various factors and conditions. During the activation phase, 
pre-osteoclasts will fuse to produce multinucleated giant cells, attach to calcified tissue 
and develop a ruffled border at the mineral interface to create a resorption 
compartment with an acidic microenvironment (67). In this compartment, hydroxy-
apatite crystals are solubilised and bone matrix proteins are degraded by the proteolytic 
enzymes secreted by the active osteoclasts to release calcium into the blood stream 
(67,68). Increased osteoclast activity and decreased osteoclast apoptotic rate have been 




D insufficiency particularly in elderly people (69). Therefore maintaining sufficient 





Figure 1.5. Osteoclast Lineage during Osteoclastogenesis  
Osteoclast development and stages of differentiation from HSC to become active 
osteoclasts are depicted in red coloured boxed. Transcription factors such as NK-B, 
NFATc-1 and MITF (pink box) regulating these differentiation stages and the bone 
resorption process are regulated by local and systemic signalling factors such as M-
CSF, RANKL, and MMP-9 (green colour box). Osteoclasts death is normally by 
apoptosis which serves as the termination signal of the bone resorption process. 






Calcium is an essential mineral and physiologically indispensable ion in the human 
body. It is an important cation in both the extracellular and intracellular spaces. 
Intracellular calcium acts as a second messenger controlling various cellular functions 
including exocytosis and secretion of cellular products, chemotaxis, intercellular 
adhesion, enzymatic activities, fertilization, proliferation, differentiation, and 
apoptosis (70). Extracellular calcium is crucial for a broad range of physiological 
function such as blood coagulation, release of neurotransmitters, nerve impulse 
transmission, heart and muscle contraction, and maintaining skeletal integrity (17). 
Thus, maintaining extracellular calcium homeostasis is essential for appropriate whole 
body functions.  
 
The total calcium is around 1 kg in an adult with 99 % of which is within the skeleton 
while the 1 % resides in plasma compartment which is the most regulated calcium 
compartment (71). Plasma calcium levels are approximately 2.2–2.5mmol/L which 
consist of 47.5 % calcium ion, 46 % protein-(such as albumin and globulins)-bound 
calcium, and 6.5 % in complexed fractions which bind to phosphate and citrate anions 
(72). The exchange of calcium across the various compartments is common but 
regulation of calcium concentration is based on the plasma ionised calcium level. 
 
The plasma calcium level is held in a very narrow range although calcium can move 
across cellular compartments due to physiological changes such as pH or hormonal 
effects (72). Various physiological conditions such as pregnancy, lactation, growth, 
aging, changes of calciotropic hormone level and activity, changes in other minerals 
(such as magnesium and phosphate), or pathological conditions such as cancer can 
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effect plasma calcium levels (18). Thus, several regulatory mechanisms are 
coordinated to maintain plasma calcium homeostasis in the context of large variations 
of calcium input and output of the body.  
 
The regulatory system of calcium homeostasis is mainly conducted by the intestine via 
intestinal calcium absorption, the kidney via renal tubular reabsorption, and the bone 
tissues through the bone remodelling process as sources of plasma calcium (19). 
Although it is tightly controlled, calcium loss is occurring all the time through urinary 
excretion because kidney can only reabsorb 97 – 99 % of filtered calcium (73). 
Therefore, adequate dietary calcium is essential to meet the obligatory calcium loss to 
maintain skeletal health. 
 
1.3.1. Recommended Daily Allowance of Calcium and Source of dietary calcium  
Calcium requirement is estimated from the dietary calcium intake needed for desirable 
calcium retention necessary for sufficient absorption to meet the obligatory calcium 
losses through skin (via sweating), bowel and urinary excretion (74). The requirement 
is calculated based on individual need within certain age, gender groups, physiologic 
conditions and presence of pathologic conditions. The Commonwealth Government of 
Australia, in 2006 has published guidelines for calcium recommended daily intakes 
(RDI) based on age, sex and physiological groups (i.e. pregnancy and lactation) (75) 
to meet the need of calcium and maintain health. To achieve the desirable calcium 
intake, a number of dietary calcium sources should be taken. Major calcium food 
sources are milk and milk-based foods, low-oxalate vegetables, bony fish, legumes, 




Meeting the RDI of calcium is essential to maintain calcium balance, normal body 
functions and minimize bone resorption. However, many adults, menopausal woman, 
and children do not meet this RDI of calcium through diet alone or supplemental 
calcium due to low compliance (77). These findings have highlighted the need for 
research on calcium metabolism and factors regulating calcium metabolism as 
important issues to maintain skeletal structure. 
 
1.3.2. Calcium Metabolism 
1.3.2.1. Intestinal Calcium Absorption  
Intestinal absorption of dietary calcium occurs by either an active transcellular 
transport or a passive non-saturable paracellular route (78). The active transport system 
occurs primarily within the duodenum of the small intestine while the passive 
absorption occurs via tight junctions between enterocytes or a direct exchange of 
calcium between two compartments (79). Calcium movement in the paracellular 
pathway is dependent on; 1) the concentration and electric gradients across epithelia, 
2) solubility of the calcium in the diet, and 3) diffusion rate between intestinal lumen 
and lymph or blood (80). During high dietary calcium, the passive absorption of 
calcium increases because of the short transit time in the intestine as well as the down 
regulation of proteins involved in the transcellular route (78). 
 
The active transcellular transport of calcium occurs across two plasma membrane 
barriers. Calcium entry into epithelial cells occurs via the calcium channels, transient 
receptor potential vanilloid (TRPV) 5 and TRPV6 (81). The cytosolic diffusion of 
calcium is mediated by calbindin-D 9k (CaBP-9k) (82) and extrusion of calcium across 
the basal membrane is facilitated by the calcium transporter, plasma membrane Ca2+-
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ATP-ase (PCMA), and Na2+/Ca2+-exchanger (NCX1)) (79). Therefore, absorption of 
calcium is the main instrument to maintain sufficient calcium absorption during low 
availability of dietary calcium, and/or during increased physiological demand. Active 
intestinal calcium absorption is mainly stimulated by vitamin D by influencing each 
step of active intestinal calcium transport (80).Vitamin D enhances the expression of 
TRPV5, TRPV6, CaBP-D9k, as well as the co-transporter such as Na2+/Pi co-transport 
proteins, thereby promoting the net absorption of calcium as well as phosphate in the 
intestine (78,79,83). 
 
1.3.2.2. Renal Tubular Reabsorption of Calcium  
The kidney plays a role to maintain calcium balance by regulating calcium excretion. 
On a daily basis, approximately 8g of calcium is filtered by the glomerulus but less 
than 2 % are excreted into the urine (84) in a process known as renal tubular 
reabsorption. Calcium enters the renal tubules through plasma ultrafiltration by the 
glomerulus, followed by calcium reabsorption across the renal tubule before being 
excreted through the urine (73). Within the proximal convoluted tubule (PCT) and the 
proximal straight tubule (PST), calcium is osmotically reabsorbed via passive 
paracellular route up to 80 % of the filtered calcium (85). This paracellular calcium 
transport route occurs due to differences in trans-epithelial electrochemical gradient 
generated by sodium and water reabsorption (73). Therefore, changes in water and 
sodium balance can affect calcium reabsorption by the kidney and hormones that 
control water and sodium reabsorption, such as alpha-adrenergic, angiotensin II, and 





Calcium is not reabsorbed along the thin segment of the loop of Henle. However, along 
the medullary ascending loop (MAL) and cortical ascending loop (CAL) of Henle, 
calcium is actively reabsorbed by active trans-cellular transport mechanism (73). 
Distal convoluted tubule (DCT) reabsorb around 10 % of the filtered Calcium, and 3% 
to 10 % are reabsorbed in the connecting tubule (CNT) (18). In these regions, fine 
regulation of calcium excretion in the kidney occurs. In contrast to the passive 
paracellular pathway, the transcellular pathway allows the kidney to regulate calcium 
reabsorption independent of sodium and water balance, or electrochemical gradient 
(86). Therefore, the human body can respond to fluctuations in dietary calcium and 
adapt to the demand of physiological changes such as growth, pregnancy, lactation, 
and aging (18). As such, disturbances in transcellular calcium reabsorption are usually 
accompanied by significant changes in calcium homeostasis. 
 
Transcellular calcium reabsorption occurs in a sequence of events similar to the 
intestinal calcium absorption process except for the calcium entry from lumen which 
is conducted by the epithelial calcium channel (ECaC) (87) which serves as a 
gatekeeper in transcellular calcium reabsorption. The transcellular calcium transport 
is a rate-limiting step and tightly controlled by the calciotropic hormones (Vitamin D, 
PTH, and calcitonin) (88). Vitamin D and PTH stimulate transcellular calcium 
transport in the CAL and DCT and increase calcium reabsorption while calcitonin 
controls calcium reabsorption in MAL where it acts to decrease it (85). Vitamin D 
increases calcium reabsorption via increasing expression of calbindin, and PTH-
dependent calcium transport in DCT (87). Vitamin D also modulates renal absorption 
of phosphate, and improves podocytes function and longevity, thus, maintaining renal 
function (89,90). Under steady-state conditions, urinary calcium excretion depends on 
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plasma calcium levels and therefore can correspond to calcium intake by the 
gastrointestinal tract. However, under other circumstances, the skeleton is called upon 
to act as a calcium source to maintain blood calcium levels (91) 
 
1.3.2.3. Bone Remodelling as Source of Calcium 
Total calcium content in a person weighing 70 kg is approximately 1250 g and almost 
99 % of it is predominantly incorporated into mineralized bone (30). During bone 
modelling, as the skeleton grows and bone mineral accumulates, the mass of human 
bone increases 7-fold from birth to puberty and a further 3-fold during adolescence 
(92). The skeleton acts as calcium reserve capable of releasing calcium into the blood 
stream during increased calcium demand or calcium depletion. About 1 % of total bone 
calcium is available as an exchangeable pool. When bone exchangeable pool cannot 
meet requirements, the non-exchangeable pool may be affected which causes bone loss 
and increasing the risk of fracture over the  long term (44). 
 
Bone remodelling is modulated by various factors. Vitamin D and PTH maintain 
calcium balance induced by changes of dietary calcium which can affect bone health 
as depicted in figure 1.6 (93). The mechanism by which dietary calcium is involved 
in altering bone health during physiologic adaptation to environmental changes has 
not been fully elucidated. Therefore, studies in vitamin D metabolism and/or VDR 
activities in relation to dietary calcium on bone cell activities are required especially 






Figure 1.6. Calcium Metabolism during Low Dietary Calcium Intake 
Schematic flow of the effects of low dietary calcium on calcium metabolism modified 




1.3.3. The Interaction between Calcium and Phosphate Metabolism  
As depicted in figure 1.6, calcium metabolism is tightly related to phosphate 
metabolism. Therefore, understanding phosphate metabolism is just as important as 
calcium metabolism in any dietary study, especially on bone metabolism. Phosphate 
is the most abundant anion and plays an important role in various biological functions, 
including bone mineralization, cell signalling via protein phosphorylation, nucleotide 
and energy metabolism, and maintaining acid-base homeostasis (94). Therefore, 
disorders in phosphorus homeostasis will affect various physiological processes. 
 
Phosphorus homeostasis is regulated by interplay of the intestine, kidney, bone, 
parathyroid gland, as well as the vitamin D system and phosphatonins (Figure 1.7) 
(95). The kidney modulates regulation of phosphate changes during short term 
condition while effects on intestinal phosphate absorption adapts to long term 
phosphate changes by hormonal mechanisms (96). Several phosphaturic peptides such 
as fibroblast growth factor 23 (FGF-23), FGF-7, matrix extracellular phosphoglyco-
protein (MEPE) and secreted frizzled-related protein-4 (sFRP-4) (97) have been 
shown to play a role in phosphate metabolism in genetic hypophosphatemic disorders 
by inducing phosphaturia and hypophosphatemia (98). Interestingly, despite the 
induction of hypophosphatemia by the FGF-23 in-vivo, serum 1, 25D is decreased or 
remains normal indicating an inhibitory effect of this hormone on renal Cyp27B1 
activity (99). Therefore, understanding vitamin D metabolism and its relation to bone 
remodelling, mineralisation, calcium and phosphate homeostasis is needed to further 





Figure 1.7. Regulation of Phosphate Balance with Low Dietary Phosphate Intake 
When serum phosphate is low, FGF-23 production in bone is reduced and PTH 
synthesis by the parathyroid glands is induced resulting in  increased synthesis of 
1,25D by the kidney Cyp27B1 enzyme, and increased expression of sodium-phosphate 
co-transporter (NaPi2a, NaPi2c). These changes increase phosphate reabsorption by 
the kidney and phosphate absorption in the intestine to restore phosphate balance. 




1.4. VITAMIN D AND VITAMIN D METABOLISM  
Vitamin D was discovered in the beginning of 20th century as a nutrient to prevent 
rickets, a disease in children characterized by defect in the growth plate and 
mineralization (21). Under normal physiological conditions, Vitamin D is mainly 
supplied by the skin through the conversion of 7-dehydrocholesterol (7-DHC) to pre-
vitamin D3 (pre-D3) by ultraviolet radiation and from dietary sources such as fatty 
fish, vegetable or fish oil, eggs and fortified vitamin D products (75). 
 
The Commonwealth Government of Australia, in 2006, made a recommendation of 
vitamin D adequate intake (AI) which is an estimated vitamin D intake observed or 
experimentally-determined in healthy individuals based on serum 25D level (75). The 
serum 25D is suitable for assessing vitamin D status because it accounts for vitamin D 
production from the skin and dietary intakes, and serves as a suitable biomarker for 
vitamin D status (100).  
 
However, there is a disagreement in the literature and clinical practice over the critical 
level for serum 25D required for optimal health function especially in the skeleton 
(101). A Working Group of the Australian and New Zealand Bone and Mineral 
Society, the Endocrine Society of Australia and Osteoporosis Australia in 2005 (102) 
has defined vitamin D deficiency as mild (25–50 nmol/L), moderate (12.5–25 nmol/L) 
and severe (<12.5 nmol/L) based on the serum 25D level. However, another 
recommendation suggests increasing the serum 25D levels above 75 nmol/L in elderly 
people to support optimal bone health (8). This recommendation was also supported 
by the evidence of vitamin D role in prevention (103) and treatment (104) of other 




(107). Although vitamin D is an important nutrient, a large proportion of the 
population do not achieve an adequate vitamin D status with increased evidence of 
vitamin D deficiency and/or insufficiency in newborn (108), adolescent (109), 
pregnant (110) or non-pregnant women (111) and across various sections of the 
population in Australia (112) and around the world (113). A clear understanding of 
vitamin D metabolism is needed to meet the required vitamin D status in the 
community (114) and to recognise the role of vitamin D in bone cells. 
 
1.4.3. Vitamin D metabolism 
Vitamin D undergoes an extensive metabolic pathway to generate the biologically 
active metabolite, 1,25D (Figure 1.8). Vitamin D from skin production and dietary 
sources are transported by lipoproteins, albumin, or vitamin D binding protein (DBP) 
to the liver where it is converted by the Vitamin D-25-hydroxylase (CYP2R1) to 25D 
(115). The 25D then undergoes the next hydroxylation step into 1,25D in the kidneys 
by the activity of 25-hydroxyvitamin-D-1α-hydroxylase (CYP27B1) and serves as the 
major source of plasma 1,25D. The renal production of 1,25D is tightly regulated by 
factors such as serum calcium and phosphorus levels, and by its own feedback 
mechanism (116). Increased 1,25D levels act as a negative inhibitor to CYP27B1 
expression and up regulate 25-hydroxyvitamin-D-24-hydroxylase (CYP24) 
expression, an enzyme responsible for catabolism of 25D to 24,25 dihydroxyvitamin-
D (24,25D) and 1,25D to 1,24,25 trihydroxyvitamin D (1,24,25D). This is the first step 
of the C-24 oxidation pathway which catabolises vitamin D to calcitroic acid which 




The kidney is not the sole organ which expresses the CYP27B1 gene. Extra-renal 
production of 1,25D has been widely described in the last few decades. The existence 
of the mRNA encoding CYP27B1, presence of CYP27B1 protein and/or its enzymatic 
activity have been demonstrated in normal and or pathologic human tissues (118). 
Such a wide spread distribution of enzyme expression and the fact that plasma 1,25D 
level largely arises from the renal synthesis, have led some to suggest that the 
expression of CYP27B1 in non-renal cells is responsible for autocrine and paracrine 
actions of vitamin D. These activities are achieved through interaction between its 
synthesis and its local actions in a manner which has not been clearly explained (119). 
The vitamin D receptor (VDR) is also widely expressed amongst tissues to elicit the 
actions of vitamin D (120). Local biological activity of vitamin D is apparently a 
combination of expression and activities of the synthesizing enzyme, CYP27B1, its 





Figure 1.8. Vitamin D Metabolism  
7-Dehydrocholesterol (7DHC) is converted to Pre-D3 and vitamin D3 by solar 
Ultraviolet B (UBV) light. Together with vitamin D3 from dietary intakes, vitamin D3 
is transported to the liver by lipoproteins, albumin, or vitamin D binding protein (DBP) 
to be converted to 25D by CYP2R1. 25D is transported to the kidney for the next 
hydroxylation by CYP27B1 to produce 1,25D or to be converted to 24,25D by CYP24. 
Extra-renal cell can utilise serum 25D or 1,25D to elicit its cellular activities by a 
similar mechanism. Active 1,25D will modulate serum calcium and phosphate levels 
by modulating intestinal absorption, bone calcification via bone formation or 
resorption and renal tubular reabsorption or excretion of calcium/phosphate. Serum 
1,25D can be converted to 1,24,25D by CYP24 in the kidney or within cells to produce 
calcitroic acid and excreted in the bile or urine. Modified from Holick and Chen, 2008 




1.4.4. Vitamin D Receptor (VDR)  
VDR was first discovered in around 1969 as a high-affinity nuclear receptor which 
acts as a ligand-activated transcription factor to modulate genes and affect diverse 
cellular processes (121). The VDR consist of 3 major domains, 1) ligand-independent 
transactivation function (activation function-1/AF-1) which is necessary for VDR-
mediated gene transactivation, 2) DNA-binding domain (DBD) which responsible for 
high-affinity interaction with specific DNA sequences called the Vitamin D-
Responsive Elements (VDREs) and 3) ligand binding domain (LBD), the retinoid X 
receptors (RXR) heterodimerization motif, and a ligand-dependent transactivation 
function, AF-2 (122). 
 
There are three major steps in VDR activation, 1) ligand binding followed by hetero-
dimerization with RXRs, 2) binding of the heterodimer to VDREs in the promoter 
region of vitamin D-responsive genes, and 3) recruitment of VDR-interacting nuclear 
proteins (coregulators) into the transcriptional pre-initiation complex via AF-1 region 
(123). Corepressors, such as Hairless, modify histone deacetylase activities resulting 
in chromatin compaction and gene silencing while coactivators, such as DRIP-TRAP, 
change the conformation and phosphorylation of the VDR heterodimer, promote 
histone acetylation, chromatin modification, and interaction with RNA polymerase 
machinery to stimulate gene transcription (122,124). Some coregulators can either be 
corepressors or coactivators, therefore, gene expression regulation by vitamin D-VDR 
complex is dependent on the ability to recruit co-regulatory protein complexes 






To elicit vitamin D biological activities, VDR can modulate the expression of vitamin 
D-responsive genes in three different ways; 1) regulate certain gene expression by 
binding to the VDREs of the gene’s promoter regions, 2) regulate transcription through 
changes in the recruitment of coregulatory complexes, 3) inhibit the expression of 
some genes by suppression of certain transcription factors (125). Other than genomic 
or the DNA binding-dependent actions, vitamin D can induce rapid non-genomic 
actions via activation of second messenger systems and cytoplasmic membrane-
associated events such as activation of mitogen-activated protein kinases (MAP 
kinases), 1α,25-dihydroxy-membrane associated rapid response steroid binding 
(MARRS), and rapidly-growing fibrosarcoma (Raf) kinase pathways (100). VDR is 
also able to influence calcium influx and release of calcium from intracellular stores 
via voltage-gated calcium opening, modulation of adenylate cyclase, protein kinases 
C and D, phospholipase C, or generation of other second messengers which also play 
a role in genomic actions (124). The non-genomic vitamin D effects are elicited by the 
nuclear VDR at the cytoplasmic membrane or by a plasma membrane VDR (126) 
which has been proposed to be located in caveolae of various cells such as 
keratinocytes, enterocytes, osteoblasts, or kidney. However the nature of the receptor 
remains controversial and the model has not been fully validated yet. 
 
The vast array of vitamin D-VDR-VDRE activities needs to be regulated to maintain 
normal body function. This process is thought to be conducted via 1) control of ligand 
accessibility to VDR; 2) control on VDR cellular content through cell-specific VDR 
regulation; 3) genetic and post-translational VDR modifications, and 4) availability 
and activation state of the nuclear co-regulators which effect vitamin D-VDR-VDRE 
activities (122,123). Therefore, VDR research is vast and challenging to identify and 
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recognize the mechanism and activities of Vitamin D VDR-VDRE in various cells 
including bone. 
 
1.4.5. Direct Vitamin D and VDR Activities in Bone Cells (Autocrine/Paracrine 
Actions of Vitamin D and VDR)  
Traditionally vitamin D has been thought to exert its beneficial anabolic effects by 
enhancing intestinal calcium absorption, reabsorption in the kidney, and create an 
endocrine loop to maintain calcium and phosphate balance. However, recent findings 
have shown that vitamin D is important for skeletal development and mineralization 
by contributing to the growth plate development (127) and optimal maintenance of 
osteoblastic bone formation and osteoclastic bone resorption through regulation and 
control of osteogenesis, osteoclastogenesis, osteoblastogenesis and mineralization (31) 
as depicted in figure 1.9. A discussion of current knowledge of the roles of vitamin D 





Figure 1.9. The Role of Vitamin D and VDR Activities in Bone Remodelling 
This image depicts cellular events during bone remodelling and the role of 25D 
metabolism and VDR in osteoblast (OB), osteoclast (OC) and Osteocytes (OCy). 
Conversion of 25D to 1,25D supports osteoclast differentiation and maturation in bone 
resorption process. New bone is laid down on the resorbed site by immature OB, which 
proliferate and differentiate into mature OB that lay down osteoid, some of which are 
entrapped within the osteoid to become mature OCy. The role of 1,25D conversion 
and VDR in the corresponding cells are inferred from the known effect of vitamin D 
and VDR in each bone cells as stated in this literature review. Adapted from Anderson 




1.4.5.1. Vitamin D and VDR-mediated Activities in Osteoclasts  
Osteoclast differentiation, activation, and survival is regulated by several factors 
including macrophage colony-stimulating factor (M-CSF), interleukin 1 (IL-1), 
receptor activator of nuclear factor (NF)-κB ligand (RANKL), and tumour necrosis 
factor-α (TNF-α) (66). The role of vitamin D in osteoclasts is one of the first 
established direct effects of 1,25D in which the generation of osteoclasts from bone 
marrow and spleen cells requires 1,25D (47) via its binding to VDR in osteoblasts 
(128). Vitamin D-VDR activities in osteoblasts stimulate osteoclast activation via 
expression of RANKL (65) while expression of osteoprotegerin (OPG), a decoy 
receptor, inhibits RANKL activity, thereby modulating osteoclastogenesis (129). 
1,25D also facilitates osteoclast precursor adhesion to stromal osteoblasts via 
increased expression of intercellular adhesion molecule-1 (ICAM-1) to direct the site 
for bone resorption (130). In-vivo studies using RANKL transgenic mice 
(TghuRANKL) demonstrated that the levels of huRANKL expression were correlated 
with bone resorption, disease severity and induced early-onset bone loss (131) similar 
to the findings in OPG knock-out mice (132). These findings are in contrast to 
transgenic mice in which the genes coding for OPG and RANKL were knocked out in 
mice which exhibited severe osteopetrosis and the complete absence of osteoclasts 
(133). These findings suggest that modulation of RANKL and OPG is essential for 
osteoclastic bone resorption. 
 
Osteoclasts express CYP27B1 and metabolize 25D into active 1,25D resulting in up-
regulation of osteoclast transcription factor, NFATc1, and a number of key osteoclast 
marker genes which associated with osteoclastogenesis (35). This suggests that 25D 




activity, and promoting the coupling of bone resorption to formation in-vitro. 
However, little is known regarding the in-vivo effects of osteoclast specific CYP27B1 
modulation which warrant further investigations. 
 
The presence of VDR in osteoclasts is still under debate due to difficulties in obtaining 
sections of undecalcified adult bone and lack of antibodies with the required 
specificity. One study shows mRNA expression of VDR was detected in osteoclast-
like cells (osteoclastoma) (134) suggesting that osteoclasts are able to modulate 
responses to 1,25D. However, another study using a specific immunohistochemistry 
method failed to demonstrate the presence of VDR in multinucleated osteoclasts, and 
chondroclasts (135). This latter finding suggests that osteoclasts and chondroclasts are 
minor targets of 1,25D and that osteoblasts are the main driver of vitamin D signalling 
in bone. Further study is needed to solve this controversy and to elucidate the role of 
VDR in osteoclasts during bone remodelling. 
 
1.4.5.2. Vitamin D and VDR-mediated Activities in Osteoblasts and Osteocytes 
The role of vitamin D and VDR in osteoblasts and osteocytes has been extensively 
studied in the last few decades. VDR is highly expressed in primary osteoblasts and 
various osteoblasts cell lines where it is co-expressed with the CYP27B1 to elicit 
autocrine/paracrine actions of vitamin D-VDR in these cells (33). The VDR expression 
can be regulated by 1,25D, PTH, glucocorticoids, transforming growth factor-β (TGF-
β), and epidermal growth factor (EGF) (136). VDR regulation of gene transcription in 
osteoblasts via interaction of various transcription factors, DNA and histone-
modifying proteins has been established (137). However, the regulation of VDR 
expression in osteoblasts by other factors than those mentioned above which influence 
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VDR expression, and its activities is still one of the most interesting areas of research 
in this field.  
 
CYP27B1 expression in osteoblasts is modulated by TGF-β (138), 1,25D, Interferon-
β, IL-1, and insulin-like growth factor-1 (IGF-1) (139). However, functional 
consequences of CYP27B1 activity for osteoblast biology were unclear due to limited 
data on the regulation of CYP27B1 in osteoblasts. Regulation of CYP27B1 expression 
in osteoblasts is more complex than in the kidney which involves local regulators and 
may differ depending on the differentiation stage of the osteoblasts (139). Therefore, 
further in-vitro and in-vivo studies on the activity of CYP27B1 in osteoblasts is needed 
to elucidate the role of CYP27B1 expression in osteoblast activity.  
 
Vitamin D-VDR activities in osteoblasts or osteoblast-like cells include; 1) increase 
expression and/or protein levels of osteocalcin and osteopontin, thus supporting bone 
matrix formation and improved bone mineralization (140), 2) increase expression of 
RANKL which is involved in the activation of osteoclasts for bone remodelling (141), 
3) shifting the expression of predominantly L-type to T-type voltage-sensitive calcium 
channels which alters calcium permeability to support differentiated functions of 
osteoblasts (142), 4) alter membrane lipid turn-over, prostaglandin production, 
protease activity or other second messengers which leads to modification of bone 
matrix, calcification or other cellular function (143), 5) repress phosphate regulating 
gene with homology to endopeptidases on the X-chromosome (PHEX) expression and 
FGF-23 to sustain phosphaturic activities for bone remodelling (144), and 6) up-




the cell cycle transition to control cell function, proliferation and differentiation during 
bone remodelling (145). 
 
Osteocytes produce FGF-23, an important regulator of serum phosphate and 1,25D 
levels (146). Elevated FGF-23 levels increase phosphate excretion, reduce serum 
phosphate levels, CYP27B1 activity and increasing PTH secretion (147). Thus, FGF-
23 plays an adaptive role in regulating serum phosphate in responses to changes of 
serum calcium (148) as a secondary endocrine loop with vitamin D/FGF-23/Phosphate 
axis superimposed physiologically on vitamin D/PTH/Calcium axis (149). This 
mechanism is thought to facilitate the integration of ion homeostasis and prevent bone 
over-mineralization and ectopic calcification in other soft tissues and kidney (150). 
Therefore, the vitamin D-VDR actions on bone are not limited to calcium metabolism 
and homeostasis but also phosphate metabolism and homeostasis to balance the effect 
of bone remodelling process. 
 
Studies of vitamin D-VDR-VDRE in the skin have shown a vitamin D-calcium 
paradox where vitamin D inhibits keratinocyte proliferation in psoriatic skin but 
induces epidermal proliferation in normal skin (126). Therefore, vitamin D-VDR-
VDRE activities in osteoblasts might have the similar properties during differences in 
calcium, phosphate and/or vitamin D status. This is an important notion for further 
understanding of the role of dietary calcium intake in vitamin D-VDR activities during 





Dietary calcium is considered to affect VDR gene responsiveness, bone size, and bone 
mass via insulin or insulin-like growth factor pathways (151) or by other pathways 
which need to be elucidated. In-vitro study using the mature osteoblast cell line MLO-
A5, suggested that extracellular calcium promotes mineral deposition via activity of 
nucleotide pyrophosphate phosphodiesterase (NPP1) (152) and in primary OSVDR 
calvarial bone culture, increased extracellular calcium enhanced mineral deposition 
(153). Interaction between dietary calcium and VDR activities in bone forming cells 
has not been established in in-vivo studies. Research is needed to shed more light on 
this relationship if we are to optimize calcium and vitamin D status in the population. 
This goal can be achieved through studies in animal models to explain the in-vivo 
phenomenon of dietary calcium and vitamin D-VDR-VDRE activities on bone 
forming cells. 
 
1.5. IN VIVO STUDIES ON THE ROLE OF CALCIUM, VITAMIN D AND 
VDR ALTERATIONS IN BONE CELLS  
 
1.5.3. Dietary modification of vitamin D and calcium  
Rat and mice are the most commonly used animals for dietary alteration in calcium, 
and or phosphate and/or vitamin D due to their similarities with human metabolism 
and ease of use. One dietary study which investigated the role of vitamin D in bone 
and bone cells activities was conducted by Anderson et al. in 2008 (154) using a rodent 
model of vitamin D depletion over a range of serum 25D levels (10 - 115 nM). In their 
study, the 7 months old rats demonstrated a positive association between bone volume 
and circulating 25D levels, osteoclast surface levels and RANKL to OPG mRNA ratio 




osteopenia arises at serum 25D levels below 80 nM due to increased 
osteoclastogenesis. Another model of vitamin D deficiency status in rats was 
conducted by Mailhot et al. 2007 (155) using an in-vivo depletion, repletion followed 
by redepletion of vitamin D to assess bone consequences with cyclic nutritional 
changes. This study showed the importance of dietary calcium/phosphate ratio to 
maintain optimum concentration of serum calcium/phosphate for bone health in 
growing animals during the cyclic changes of vitamin D levels.  
 
Calcium supplementation increases bone density in female adolescent (156) or elderly 
(12), ambulatory  subjects or post fracture patients (157). In animal models, increased 
dietary calcium also demonstrates beneficial effects on bone mineral status (158,159). 
Therefore, calcium supplementation has been used as a nutritional treatment for 
osteoporosis and other low bone density diseases (11). 
 
Dietary phosphate’s role on bone health is still currently under debate. In a human 
study, variation in dietary phosphate induced changes in FGF-23 and serum 1,25D 
levels as well as urinary phosphate excretion (160). Recent studies of inherited and 
acquired hypophosphatemia (X-linked hypophosphatemic rickets/osteomalacia 
(XLH), autosomal dominant hypophosphatemic rickets/osteomalacia (ADHR) and 
tumour-induced rickets/osteomalacia (TIO)), have identified novel genes (PHEX, 
FGF-23) in the regulation of phosphate homeostasis which are mainly controlled by 
bone cells (146,147). However, the detailed mechanism by which dietary phosphate 




1.5.4. Genetically-modified mice 
Genetically modified mice have been used to elucidate the role of a specific gene/s in 
various studies of physiological activities including vitamin D by modulating the genes 
encoding the VDR, or the enzymes controlling vitamin D metabolism (161). These 
genes can be completely ablated to create a global deletion mouse model or using 
specific promoters to delete the gene in specific cells and create conditional knock-out 
mouse models. These genes can also be inserted into the genome using specific 
promoters to produce overexpression of the genes in specific cells (the transgenic 
mouse models). Generation of these mouse models can be useful for generating data 
of direct activities of vitamin D in bone cells modulating bone turnover and mineral 
status.  
 
The first genetically modified mouse model to investigate VDR activities in bone cells 
was the global VDR-knock out (VDR-KO) mice (which was reported by Li et al. in 
1998 (22) and Amling et al. in 1999 (23)). They observed phenotypic abnormalities of 
the global VDR ablated mice and its relation to dietary calcium. Dietary regimens 
which normalized serum calcium and phosphate levels have prevented the 
development of osteomalacia or rickets but did not correct the alopecia occurring in 
these mice. The global VDR-KO mice revealed growth plate disorganization, matrix 
and bone fragility when fed a normal diet due to impaired intestinal calcium absorption 
and/or effects of secondary hyperparathyroidism due to hypocalcaemia. Thus, the 
apparent normalization of the bone phenotype when serum calcium and phosphate 
were normalized suggested that VDR activities on bone cells are not essential when 





The above conclusions were challenged by a study in aged global VDR-KO mice (17 
weeks old) by Panda et al. in 2004 (162). This study demonstrated that by feeding a 
rescue diet containing high calcium (2 %) and phosphorus (1.25 %), the normalization 
of plasma calcium and PTH levels was able to normalize cartilage and skeletal 
mineralization. However, the rescue diet was unable to overcome the bone loss that 
occurred in the global VDR-KO mouse line as they aged. Importantly, the bone loss 
that occurred in the VDR-KO mice was not due to increased bone resorption but was 
associated with a marked reduction of bone formation. This suggested that vitamin D 
activity in osteoblasts might be important for bone formation in aged mice and that 
calcium and vitamin D/VDR system may exert effects on bone co-ordinately or 
independently by mechanisms which have not been fully understood.  
 
Since the above study uses global knock-out model, it is difficult to distinguish the 
role of VDR in bone cells as endocrine or as an autocrine/paracrine effect in the 
physiology of bone. Therefore, direct effects of VDR on bone cells activities remains 
poorly understood due to the systemic defects on calcium metabolism in the global 
VDR-KO mice. The technology to design and make conditional knock out mouse lines 
using various promoters have been developed in the last few years (163,164). The most 
commonly used method to generate a conditional mouse model is the Cre/LoxP system 
which act as “genetic switches” to spliced the gene flanked with homozygous LoxP 
sites in the presence of Cre-recombinase (165). Therefore, this system provides a 
relatively straight-forward method to delete a gene within a specific type of cell 
creating a useful mouse models to study specific activity of the gene within the specific 




The VDR conditional knock out in chondrocytes using Cre-loxP system and Collagen 
2a1 promoter model demonstrated normal growth-plate chondrocyte development 
with impaired vascular invasion and a reduction of osteoclast number in 15 day old 
mice resulting in increased trabecular bone mass (166). Increase serum 1,25D levels, 
together with reduction of RANKL in their in-vitro study suggest VDR in 
chondrocytes is required for osteoclast formation during bone development. 
 
Conditional knock out of the VDR gene in osteoblasts using a similar system with the 
osteoblast-specific 2.3 kb collagen1a1 promoter also shows increased bone mass in 
radiological assessments without disturbance of mineral metabolism (167). Bone 
histomorphometry analyses in this study indicates that the phenotype occurs due to the 
reduction of bone resorption with decreased expression of RANKL suggesting VDR 
in osteoblasts is a negative regulator of bone mass. Interestingly, osteocyte specific 
knock out of VDR using Dmp1-cre mouse model shows no phenotype and no changes 
to RANKL expression (168). These data suggest that VDR in chondrocytes and 
immature osteoblasts is important for regulating RANKL expression under normal 
dietary calcium/phosphate intakes.  
 
Studies on the conditional knock out of VDR in the intestine using Villin-Cre+/–Vdrfl/fl 
(Vdrint-) mouse model showed decrease of TRPV5, TRPV6, and Calbindin D9K 
expression with a decrease of calcium absorption without a change in serum calcium 
(168). This mouse model also shows changes in the bone structure and inhibition of 
mineralisation suggesting that with normal VDR levels in bone, the endocrine effect 
from inhibition of calcium absorption is stronger than the local effect of VDR under 





Another model that had emerged in the study of VDR in osteoblasts cells is the 
overexpression of VDR solely in mature osteoblasts (OSVDR mice) which was 
generated to test the potential value of increasing VDR activity in osteoblasts. This 
mouse model demonstrated increased mineral content (169), decreased bone 
resorption, and increased cortical periosteal bone formation without changes to the 
calciotropic hormones (36). More recently, the OSVDR mouse model was used by 
Baldock et al. 2006 (37) and Lam et al. 2014 ((170) to show that increased bone 
volume in OSVDR mice was dependent on the levels dietary calcium but not on 
vitamin D status. OSVDR mice demonstrated an increased in bone volume when fed 
a normal level of dietary calcium (1 %) but lost this phenotype when fed moderately 
low calcium diet due to increased RANKL/OPG ratio. This finding signifies the 
importance of direct vitamin D anabolic activity in osteoblasts in the pathways of 
maturation and mineralisation of osteoblastic cells as well as to indirectly inhibit 
osteoclastogenesis and osteoclastic bone resorption. 
 
All ligand-inducible nuclear transcription factors such as the VDR recognizes the 
hormone responsive elements in the promoter of its target genes such as osteocalcin 
(171). Osteocalcin or also known as bone ‑carboxyglutamic acid protein (BGLAP) is 
expressed to supports bone matrix formation and improved bone mineralization (140) 
which are the characteristics of mature osteoblasts. Osteocalcin expression is induced 
by the VDR which acts on the osteocalcin promoter to drive its osteoblast-specific 




A thorough investigation of the role of dietary calcium/phosphate on vitamin D-
mediated activities in bone cells have yet to be conducted. Similar setting, background, 
treatment and conditions must be made for a comparable and comprehensive study in 
VDR-mediated activities of the bone forming cells. Thus, studies which utilised over-
expression/transgenic and conditional knock out mouse models of the VDR in mature 
osteoblasts using osteocalcin promoter during dietary restriction of calcium/phosphate 
are needed to elucidate the bone physiology with regard to VDR activities on mature 
osteoblasts. 
 
1.6. RESEARCH QUESTION 
In order to investigate the interaction between dietary calcium and VDR-mediated 
activities in bone cells, this research aims to answer the following question: 
 What are the effects of dietary calcium/phosphate intakes on VDR activities 
within mature osteoblasts to modulate plasma calcium and phosphate levels, 
calciotropic and phosphate regulating hormone levels, skeletal structure and 
bone mineral status? 
 
1.7. HYPOTHESIS AND AIMS 
1.7.1. Hypothesis 
Dietary calcium intake sufficient to maintain calcium balance will modulate direct and 
indirect activities of VDR to alter gene expression and protein production in bone 







In order to answer the questions above, the studies in this theses has the following 
objectives; 
a. To characterize mouse models with regard to bone structure and plasma 
calcium homeostasis in which the expression of Vdr gene is modified in bone 
forming cells. 
b. To describe VDR actions in bone forming cells activities that modulate bone 
structure. 
c. To explore the interaction between dietary calcium/phosphate intakes and 




The studies described in this thesis addresses the following specific aims;  
a. Establishing the physiological role of VDR in mature osteoblasts in bone 
structure and mineral homeostasis 
b. Determining the effects of dietary calcium/phosphate on the bone structure, 
biochemical parameters, and gene expression of the genetically modified 
mouse models in which the VDR is either a) overexpressed in mature 
osteoblasts (ObVDR-B6) or b) specifically deleted in the mature osteoblasts 
(ObVDR-KO). 
c. Characterise the structural, biochemical, cellular and molecular mechanisms 





1.8. SIGNIFICANCE OF PROJECT  
Current knowledge of the role of VDR in skeletal health is ONLY to regulate serum 
calcium and phosphate homeostasis via the modulation of intestinal calcium/ 
phosphate absorption. Recent findings have proposed a direct role of vitamin D in 
skeletal health. However, few have disputed this hypothesis due to little in-vivo 
evidences to support the direct role of vitamin D and VDR within osteoblasts to change 
bone structure and or modulate mineral homeostasis. Therefore, the proposed studies 
within this thesis are required to elucidate and further strengthen the evidence of the 





CHAPTER 2: MATERIALS AND METHODS 
 
2.1. MATERIALS 
Consumables and chemicals used in these experiments were purchased from Sigma 
Chemical Company (Sigma-Aldirch, New South Wales, Australia), unless stated 
otherwise. 
 
2.2. ANIMALS  
Animals used in the experiments were male and female mice on C57Bl6/J genetic 
background obtained from breeding programmes either within the South Australia 
Pathology Animal Facility (SA Pathology, Adelaide), the University of South 
Australia Reid Animal Facility, (RAF) or the University of Adelaide, Laboratory 
Animal Services (LAS). Records on birth, date of tissue specimen (tail) collection for 
genotyping, day of injection, and culling date were maintained on clinical record sheets 
(CRS) in accordance to requirements of the University of Adelaide Animal Ethics 
Committee for each project. All studies were approved by the University of Adelaide 
Animal Ethics Committee Medical project number M-2012-092, RM No. 
0000013478. Ethics approval is attached in the appendix section. Concurrent ethical 
clearance was obtained from the University of South Australia and SA Pathology 
Animal Ethics committees.  
 
2.2.1. Wild Type (WT) 
The wild-type (WT) mouse from C57Bl6/J genetic background were used as control 
animals for the transgenic mouse model ObVDR-B6. WT mice used in the studies 
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were either purchased and or litter-matched depending on the experiment as indicated 
in each corresponding experiment.  
 
2.2.2. Overexpression of Vitamin D Receptor in Mature Osteoblasts Transgenic 
Mice (ObVDR-B6) 
The transgenic mouse model in which the gene for the human vitamin D receptor is 
over-expressed in mature osteoblasts on the FVB/N genetic background (OSVDR) was 
provided by the Garvan Institute (Darlinghurst, Sydney, NSW, Australia). The 
OSVDR were backcrossed onto the C57bl6/J genetic background for more than 6 
generations resulting in 98.4 % C57Bl6 congenicity. This new mouse line was labelled 
as ObVDR-B6.  
 
2.2.3. Mature Osteoblasts Specific Vitamin D Receptor Knockout Mice (ObVDR-
KO) 
The osteoblast-specific vitamin D-receptor knock out mouse model (ObVDR-KO) was 
generated using Cre-LoxP methods under the supervision of A/Prof. Rachel Davey, 
University of Melbourne at the Austin Animal Facility, Melbourne, Victoria. Mice 
homozygous for the floxed VDR gene, in which exon 2 of the VDR is flanked by lox-
P sites or the VDRfl/fl mice, supplied by Professor S. Kato (University of Tokyo, 
Japan), were mated with osteocalcin promoter driven-cre recombinase (OcnCre+/-) 
transgenic mice, supplied by Professor T.L. Clemens (University of Cincinnati, USA) 
to produce ObVDRfl/flCre+ (ObVDR-KO). Control animals used in the study were 





2.3. HOUSING  
All mice were housed in 22 – 24oC room with a 12h light/dark cycle and exposed to 
standard lighting. All mice were weaned at 20 to 21 days of age and housed in 2 – 5 
mice/cage. Cage conditions were kept constant throughout the projects (e.g. bedding, 
boxes, toys, cage cleaning, etc.). Mice were provided ad-libitum diet in accordance to 
the study conducted and free access of water. Diets were modified for each project as 
described in the corresponding chapter.  
 
2.4. TISSUE COLLECTIONS AND STORAGE 
All animals were humanely killed in accordance to the procedures and ethics 
requirements. In brief, mice were anaesthetised using isoflurane prior to cardiac 
puncture and cervical dislocation. The tissue collection and storage of tissue were 
performed immediately after death. Right femora and vertebrae were stored 
immediately in 10 % formalin for 4 – 6 days prior to micro-CT analyses and 
histological sectioning. For RNA analyses, the right tibia, left radius, heart, lung, liver, 
spleen, kidney, proximal intestine, muscle, and skin tissues were immersed in 
RNALater® (Ambion ®, Life technologies, Austin, Texas, USA) overnight at 4oC and 
then stored at -80 oC. Other tissues such as scapulae were wrapped in gauze, and 




2.5. BLOOD BIOCHEMISTRY 
2.5.1. Serum Collections 
Cardiac blood specimens were immediately placed on ice. Serum was collected by 
centrifugation for 15 to 20 minutes at 4500 rpm and stored in -80 oC until required for 
analyses.  
 
2.5.2. Serum Calcium, Phosphate and Alkaline Phosphatase 
Serum calcium and phosphate were measured on chemical analyser Konelab® 
20/20XT using reagents manufactured by Thermo Fisher Scientific (Vantaa, Finland). 
 
2.5.3. Serum 1,25-dihydroxyvitamin D3 
Serum 1,25-dihydroxyvitamin D3 was measured using ImmunoDiagnostic Systems 
chemiluminescent immunoassay according to the manufacturer’s instructions.  
 
2.5.4. Serum Fibroblast Growth Factor-23 (FGF-23) 
Serum FGF-23 was measured using Enzyme-Linked ImmunoSorbent Assay (ELISA) 
kit for quantitative determination of mouse FGF-23 manufactured by Immutopics 
International (San Clemente, USA). This kit uses goat polyclonal antibodies which 
bind specifically to epitopes within the carboxyl-terminal (C-term) region of the mouse 
FGF-23.  The assay was performed in accordance to the manufacturer’s instructions.  
 
2.5.5. Serum Parathyroid Hormone (PTH) 
Serum PTH was quantified using mouse PTH 1-84 enzyme-linked immunosorbent 
assay (ELISA) kit from Immutopics International (San Clemente, USA). The kit uses 




active intact form of PTH. The biotinylated antibody targets the mid-region /c-terminal 
portion (39-84) and the second antibody conjugated with horseradish peroxidase 
(HRP) targets the N-terminal region (1-34).  Assays were performed in accordance to 
the manufacturer’s instructions.  
 
2.5.6. Serum C-terminal Telopeptides of Type 1 Collagen 
The fragments of C-terminal telopeptides of type 1 collagen (CrossLaps) in mouse 
serum were measured using enzyme immunoassay (EIA) kit from IDS 
(ImmunoDiagnostic System, USA). The RatLapsTM polyclonal antibodies react 
against synthetic peptide (sequence EKSQDGGR) specific for C-terminal telopeptide 
α-1 chain of type 1 collagen in rats. Assays were conducted according to the 
manufacturer’s instructions.  
 
2.5.7. Serum Tartrate-resistant Acid Phosphatase-5b (TRAP5b) 
Serum concentrations of TRAP5b were measured using solid phase immuno-fixed 
enzyme activity assay (IEA) with MouseTRAPTM assay from IDS (ImmunoDiagnostic 
System, USA). The MouseTRAPTM kit uses polyclonal antibodies which react to 
recombinant mouse TRAP5b antigen that can be used as confirmation or prediction of 
osteoclast number.  Assays were conducted based on manufacturer’s instructions.  
 
2.6. X-RAY IMAGERY AND MICRO-COMPUTED TOMOGRAPHY 
2.6.1. Femur 
Femoral bone was analysed by micro-CT using a Skyscan 1076 scanner 
(Kartuizersweg, Belgium). Femora were de-fleshed and placed inside a 5mL 
polypropylene tube containing 10 % formalin for up to 6 days at 4oC prior to storage 
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in 70 % ethanol. Prior to micro-CT scanning, femora were X-ray imaged (Faxitron 
LX-60, Tucson, AZ, USA) with X-ray voltage at 31kV, and an exposure time of 11.5 
– 16.5 ms. Each bone was then inserted into a sealed drinking straws containing 70 % 
ethanol prior to micro-CT scanning. Bones were then scanned at a voxel size of 9 µm 
with a 0.5 mm aluminium filter, X-ray source current of 110 µA, voltage 50 kV, and 
camera exposure time of 5890 ms. At the end of each scan, reconstructions of TIF 
image datasets into Z-stack BMP datasets were conducted using NRecon software 
(version 1.6.9.18). The settings for NRecon included ring artefact correction at 12, 
beam hardening correction at 30 % and smoothing set radius of 1. Reconstructed 
images were realigned using Dataviewer (version 1.5.1.2) to ensure comparable 
alignment of all bones. Realigned z-stack BMP datasets were than analysed CTAn 
software (Skyscan/Bruker, version 1.14.4.1) as described in section 2.6.3 and 2.6.4 
below. 
 
2.6.2. Vertebral Bone 
For vertebra, micro-CT analyses were performed using Skyscan 1174 scanner 
(Kartuizersweg, Belgium). Vertebrae were placed in 5mL polypropylene tubes 
containing 10 % formalin for up to 6 days at 4 oC prior to storage in 70 % ethanol. 
Muscle and fasciae surrounding the vertebrae were removed while keeping the lower 
ribs intact and attached as markers for the position of Vertebra Lumbar-1 (L-1). Bones 
were tightly packed using gauze soaked with 70 % ethanol.  
 
Image acquisition was obtained with voxel size of 6.5 µm with X-ray source voltage 
of 50 kV, source current at 800 µA, exposure of 2,600 ms and a 0.25 mm aluminium 




NRecon program (version 1.6.9.18) as described in Section 2.6.1. Realignment and 
image data analyses were conducted in the same manner as described in Section 2.6.1. 
 
2.6.3. Anatomical Definitions 
To measure specific compartment of bone anatomy, the manually delineation of each 
anatomical region was done using CTAn software (Skyscan/Bruker, version 1.14.4.1). 
For metaphyseal trabecular bone, distal femoral secondary spongiosa was investigated. 
A volume of interest (VOI) for distal femoral secondary spongiosa was defined by a 
region devoid of primary spongiosa and cortical bone and encapsulating a metaphyseal 
regions equivalent to either 10 % or 20 % of the full femur length depending on the 
study. The distal boundary of each VOI was set based on a defined distance from 
outermost aspect of the epiphyseal cortical bone. For VOI’s based on 20 % of full-
femur length, the set distance was 1.8mm. For VOI’s based on 10 % of full-femur 
length, 2.3mm was the set distance.  
 
For femoral cortical bone, mid-shaft diaphyseal bone was isolated as being exactly 
mid-point of the full femur length. Depending on the study, a volume of cortical bone 
was defined by either 2mm or 10 % of the femur length, evenly spanning the mid-
point. The cortical bone was devoid of trabecular bone in this region. 
 
For vertebra, trabecular bone was analysed using a fitted elliptical region of interest 
(ROI) placed within the vertebral body, which excluded cortical bone. For 6 week old 
mice, the VOI included 1.2mm or 185 trans-axial slices. For all older mice, the VOI 




2.6.4. Segmentation Methods. 
To binarize the grey-scale image stacks for each VOI, a different method was adopted 
for trabecular and cortical bone segmentation. For trabecular bone analyses, an 
adaptive threshold technique was used. Adaptive thresholding, using CTAn software, 
was set with the upper and lower pre-thresholding limits of 255 and 60 respectively. 
The pre-threshold effectively delineates a region of interest in which adaptive 
thresholding is applied. All pixels outside the pre-threshold white mask are excluded 
from adaptive thresholding and set as black (space). The radius was set to 5 pixels. 
The radius defines the circle/sphere in which the threshold is calculated. To remove 
any residual artefact signal from the VOI z-stack, black and white bodies with radius 
less than 10 pixels was removed by a despeckling process. 
 
For cortical analyses, a global thresholding technique was used whereby upper 
threshold was set to 255 and lower threshold set to at 60 or 80 for full femur length 
analyses or mid-shaft cortical analyses respectively. To remove any residual artefact 
signal from the VOI z-stack, black and white bodies with radius less than 10 pixels 
was removed by a despeckling process. 
 
2.6.5. Calculated Bone Parameters 
Trabecular bone was calculated based on 3D methods using a marching-cubes 
algorithm set by the software and results are reported as follows and according to the 
guidelines for assessment of bone microstructure in rodents by Bouxsein et al 2010 
(173). 
o Bone volume per total volume (BV/TV); a ratio of segmented bone volume to 





o Trabecular thickness (Tb.Th); Mean thickness of trabeculae based on direct 3D 
methods. 
o Trabecular number (Tb.N); Average number of trabeculae/unit length. 
o Trabecular separation (Tb.Sp); Mean distance between trabeculae. 
o Connectivity density (Conn.D); a measure of connectivity of the trabeculae 
normalized by tissue volume indices. 
o Structural model index (SMI); indicator for structure of trabeculae in which 
SMI will be 0 for parallel plates and 3 for cylindrical rods. 
 
For mid-shaft cortical analyses, a shrink wrap ROI in 2D space was applied prior to 
analysis. Using 2D analysis, the measures reported include periosteal perimeter 
(Ps.Pm) and bone perimeter (B.Pm) which were used to derive endosteal perimeter 
(Es.Pm). Using 3D analysis, the measures reported include cortical bone volume (BV) 
and cortical thickness (Cort.Th).  
 
2.7. BONE HISTOLOGY 
2.7.1. Injections of Fluorochrome Labels 
Fluorochrome labels used in the studies were calcein and xylenol orange to label active 
bone forming surfaces. Calcein was prepared by mixing 0.1 g of calcein (C3H26N2O13) 
and 0.1 g of sodium bicarbonate (NaHCO3) in 10 mL of 0.9 % sterile saline to produce 
10mg/mL stock solution. Xylenol orange was prepared by adding 0.45 g xylenol 
orange (C31H28N2Na4O135) and 0.2 g sodium bicarbonate into 10mL of 0.9 % sterile 
saline to produce 45 mg/mL of stock solution. At 7 and 2 days prior to death (or as 
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otherwise stated), animals were intra-peritoneally injected with 10 mg/kgBW of 
calcein and 90 mg/kgBW of xylenol orange respectively as previously described (174).  
 
2.7.2. Bone Preparation for Dynamic Histomorphometry 
Bones were cut using slow speed saw from Beuhler Ltd (Lake Bluff, Illinois, USA) 
equipped with diamond edged blade bathed in 70 % ethanol to expose the metaphyseal 
and diaphyseal region. For dehydration, bones were submersed in 90 % ethanol for 24 
hours and room temperature followed by two 24 hours periods in 100 % ethanol. Bones 
were then transferred into 2mL softener solution containing 100 % methyl 
methacrylate/MMA and 10 % v/v polyethylene glycol/PEG 400 and left at room 
temperature for 10 - 14 days. 
 
To embed bone in resin, solutions of 100 % MMA and 10 % PEG 400 were mixed 
with 0.4 % Peroxydicarbonate (perkadox-16) in a 5 mL polypropylene container and 
placed in the oven at 37 C for 24 hours. Distal femora exposed on the metaphyseal 
region were placed facing down while the proximal ends were placed flat on the 
bottom of the tube. The proximal end of the femoral bones was also processed and 
place flat on the bottom of the tube during embedding process. 
 
Once set, samples were then removed from the tube and fixated to an aluminium stub 
(Biorad, Gladesville, NSW, Australia) with either Araldite™ glue (Selleys, Padstow, 
NSW, Australia) or co-extruded epoxy putty (Selleys, Padstow, NSW, Australia), 
giving care to ensure that the bone specimen was aligned according to the desired 




sagittal surface, while the proximal end was placed upright to reveal its trans-axial 
shaft region.  
 
Resin embedded bones, fixed to aluminium stubs were trimmed to expose the bone 
surface area by removing the plastic excess using a motorized microtome (Leica 2255, 
Germany). When the bone alignment and shape was satisfactory, 5μm sections were 
then mounted onto slides and immersed in heated spreading solution for 2-4 minutes. 
Spreading solution was made by adding 30 %: 70 % ethylene glycol and mono-ethyl-
ether in 70 % ethanol solution. Sections were dipped 2-3 times into 65 – 70 oC 
spreading solution, covered with plastic film and flattened onto slides prior to 
clamping with blotting paper and placed into 37 oC oven for 12 – 24 hours. 
 
2.7.3. Double Label Fluorochrome Measurement 
Double label fluorochrome measures were conducted on unstained slides by removing 
the polyethelene (resin) plastic with acetone for 12 – 15 minutes followed by dipping 
into xylene (2 x 100 %) before being mounted in xylene-based mounting medium 
(DePex mounting medium Burr, Prolabo, BDH Laboratory Supplies, England).  
 
Slides were analysed using fluorescence microscope on filter 3 (Olympus DP73 and 
Olympus BX 53) using OsteoMeasureTM software version 3.3.O.2. In brief, secondary 
spongiosa from each section was analysed, with 10x objective magnification, starting 
from the top upper growth plate down to approximately 2cm towards diaphysis 
(Figure 2.1). A total 16 visual fields were analysed by drawing a bone map consisting 
of double label, single label and bone perimeter which were automatically computed 
and tabulated by the software. Results reported were histology BV/TV, Label 
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Perimeter (L.Pm), Mineral Apposition Rate (MAR), Mineralising Surface/Bone 
Surface (MS/BS), and Bone Formation Rate/Bone Volume (BFR/BV). 
 
2.7.4. Toluidine Blue Bone Staining and Analysis of Osteocyte Density 
Toluidine blue (TolB) staining is used to visualise osteoblasts and measure cortical 
osteocyte density on paraffin or resin sections. TolB stains were made by mixing 0.1g 
of toluidine blue O (ProSciTech, Kirwan, Qld, Australia) with 0.1 g of sodium 
tetraborate in 100 mL distilled water, filtered into a bottle wrapped with aluminium 
foil and stored as 0.1 % stock solution in 2 – 8 oC. 
 
TolB staining was performed on resin sections (or as otherwise stated) by removal of 
resin from slides and placing them on a 90 – 95 oC heating block. A few drops of 
0.01% TolB working solution were placed over the bone tissue for 2 minutes and 
blotted onto filter paper prior bathing in distilled water. Slides were sequentially 
dipped into 1 x 50 % ethanol, 2 x 100 % ethanol, 2 x 100 % xylene before being cover-
slipped with xylene based mounting medium. 
 
To assess osteocyte density, slides were imaged using 4x and 200x magnification 
(Olympus Microscope, DP73 and BX 53) and analysed using OsteoMeasureTM 
software (V3.3.0.2). Measurements were performed on 1mm length cortices of distal 
metaphysis starting from 0.5 – 0.6 mm from the edge of growth plate (Figure 2.2) and 
results reported as Metaphyseal Cortical Bone volume (BV), Number of Osteocytes 





2.7.5. Tartrate Resistant Acid-phosphatase (TRAP) Staining of Osteoclasts 
Sections for TRAP stains were placed in Coplin jar and resin was removed with 
acetone processing. Tris-HCl buffer pH 9.4 was added and placed in the oven at 37oC 
prior to washing with demineralised H2O. Acid-phosphatase (AcP) stain was prepared 
using a formula for 1 Coplin jar (8 slides). Briefly; 100 μL of 0.4 g sodium nitrite in 
10 ml dH2O solution was added with 100 μL basic fuchsin until a fetid scent was 
produced. Tartaric acid (0.035g) in 35 mL sodium acetate buffer (pH 5.2) were added 
and mixed with 0.04 g napthol ASBI Phosphate in 2 mL dimethlyformamide (DMF). 
The final solution has pink tinge and was used to incubate the slides for 1 hour at 37oC 
in the oven. Demineralised water was used to rinse the slides prior to counter-staining 
with Haematoxylin for 1 minute followed by few dips in acid carbonate solution. 
Slides were sequentially dipped into 2 x 100 % ethanol baths followed by xylene, 
before being cover-slipped using mounting medium. 
 
Using an Olympus microscope with OsteoMeasureTM (V3.3.0.2), maps of tissue area 
were drawn on 40x magnification which encompassed approximately 1.8 – 2.2 mm 
region in the trabecular distal metaphysis. To determine osteoclast number, size, 
perimeter and attachment surface, analyses were conducted on 200x magnification on 
top of the first maps and the second maps (with bone and osteoclast measures) were 
created. Result were reported as Number of Osteoclasts (N.Oc), Total Osteoclast 
Area/Size (Oc.Ar), Average Osteoclast Area/Size (AveOc.Ar), Osteoclast perimeter 
(Oc.Pm), Number of Osteoclast/Bone Perimeter (N.Oc/B.Pm) and Osteoclast 




2.8. THREE POINT BENDING MECHANICAL TESTING 
Biomechanical properties were evaluated in the long bones. Left femur wrapped in 
Phosphate Buffer Solution (PBS) soaked gauze were slowly brought to room 
temperature and dissected to clean the remaining soft tissue then placed inside room 
temperature PBS prior to three-point bending tests using Instron 5944 Single Column 
Table Top Systems (Instron Pty Ltd. Bayswater, Melbourne, Victoria). Femurs were 
dried using gauze prior to being placed condyles face down on top of 2 x 100 mm anvil 
with a 6 mm gap. Load was applied, midway between the lower anvils, at a rate of 
0.01 mm/s with 0.01 N increments. Time, load, and energy in which the femurs reach 
yield, maximal load and break point were recorded and analysed. 
 
2.9. GENE EXPRESSION 
2.9.1. DNA Extraction and Genotyping 
ObVDR-B6 were genotyped by identifying the presence of human-Vdr gene within 
the genome while the VDRfl/fl control and ObVDR-KO mice were determine by the 
presence of Cre gene in the DNA specimen from the tails of 10 days old mice. DNA 
from a tail specimen was extracted using isopropanol method. Briefly, approximately 
0.3 mm of tail specimen was digested overnight with 12.5 μL of proteinase K in 500 
μL of tail buffer on 60 °C heating block. Tail buffer was made by adding 2 mL of 10 
% SDS, 1 mL of 1 M Tris-HCl, 400 μL of 500 mM EDTA, 500 μL of 4 M NaCl and 
16.1 mL MQ water. The digested samples were mixed and spun at 13,000 rpm for 5 
minutes at room temperature. Approximately 450 μL of supernatant from each sample 
was collected and mixed with 1mL of 100 % isopropanol and gently mixed for 2-3 
minutes then spun at 8,000 rpm for 5 minutes to precipitate DNA. The supernatant 




μL of 1x Tris-EDTA-buffer (TE buffer) was added to each tube and heated to 60 oC 
heating block for 2-3 minutes. The DNA concentration for each sample was quantified 
using a nanodrop spectrophotometer (Nanodrop 1000, Thermo Scientific, Wilmington 
USA). Working DNA samples were made by diluting the DNA to 20 ng/μL for each 
sample prior to conducting quantitative real time polymerase chain reaction (PCR) 
analyses, as detailed in section 2.8.2.4. 
 
2.9.2. Gene Expression Analyses 
2.9.3. Extraction of Total RNA  
Tissues were immediately placed in RNALater® (Ambion ®, Life technologies, 
Austin, Texas, USA) following collection and placed in 2 - 8oC for 24h prior to storage 
at -80 oC as described earlier. Around 50 mg – 100 mg of tissue were used for RNA 
extraction by placing it in 1 mL TRIzol® (Invitrogen, Australia) inside a 5 mL 
polypropylene tube or 1.5 mL Eppendorf tube. Biopulverizer (BioSpec 59013N, 
Canada) or basic electric homogenizer (IKA T10, IKA, Germany) were used to extract 
RNA from bone tissue or a micro-pestle was used to homogenise soft tissue samples, 
which were then centrifuged at 12,000 rpm at 4 oC for 10 minutes. 
 
Approximately 850-900 μL of supernatant from each sample was collected and 200μL 
of chloroform added, vortexed and then incubated at room temperature for 4 minutes. 
Samples were then centrifuged at 12,000 rpm at 4 oC for 15 minutes before removal 
of supernatant into a fresh tube with 0.5 mL isopropanol and 2 μL of 5 mg/mL 
glycogen solution. Solutions were vortexed and then placed on ice for 1h prior to 




To precipitate the RNA, samples were centrifuged at 12,000 rpm at 4 oC for 15 
minutes. The supernatant from each tube was then carefully and completely discarded. 
The precipitated RNA pellet was then washed with 1 mL 75 % ethanol and spun at 
7,500 rpm at 4 oC for 10 minutes. The supernatant was carefully and completely 
discarded from each tube and remaining RNA pellet was left to air dry for 5 minutes 
prior to addition of 35 – 50 μL of TE buffer, which was then heated for 2 minutes at 
60 oC to assist in the complete dissolution of RNA pellet into solution.  
 
2.9.4. Quantification of RNA 
RNA quantification and purity were determined using a nanodrop spectrophotometer. 
A 1.5μL of solution from each RNA sample was measured against TE buffer blank at 
260 and 280 nm. RNA was considered of sufficient purity when the absorbance ratio 
of A260/A280 was equal to or greater than 1.9 and with absorbance ratio of A260/A230 
above 1.4. Assessment of the integrity of RNA was performed using an Agilent 2100 
Bioanalyzer on selected samples as per manufacturer’s instructions.  An RNA Integrity 
Number (RIN), as determined by 28S:18S ratio, of 5 and above was considered 
adequate for qRT-PCR analyses. 
 
2.9.5. Removal of DNA Contamination of RNA samples 
For hVDR gene expression quantification in bone and other tissues, RNA preparations 
were treated with DNase to ensure all genomic DNA was destroyed.  Briefly, 2 μg 
RNA was combined with DNA-se mixed solution containing 0.5 μL DNA-se, 1μL 
DNase buffer, and brought to 11.5 μL total volume with DEPC-treated H2O, which 
was then incubated at 37 oC for 10 minutes. The reaction was then stopped by adding 





2.9.6. Complementary DNA (cDNA) Synthesis 
Complementary DNA for each RNA sample was generated using Transcriptor First 
Strand cDNA Synthesis Kit (Roche Diagnostic, Indianapolis, USA) based on the 
manufacturer’s instructions. 2μg of RNA was combined with 1μL of OligoDT and 
brought to 12μL with DEPC-treated H2O. Samples were briefly vortexed and 
centrifuged prior to incubation at 65 °C for 5 minutes and rapidly chilling at 4°C. A 
7μL master mix solution was then added to each sample consisting of 4μL reaction 
buffer, 0.5 μL RNase inhibitor, 2 μL nucleotide mix and 0.5 μL of transcriptor enzyme. 
Samples were briefly vortexed and centrifuged prior to incubation at 50 °C for 60 
minutes, followed by enzyme denaturing at 70 °C for 5 minutes. Samples were then 
cooled to 4 °C and then stored at -80 °C prior to qRT-PCR analyses. 
 
2.9.7. Messenger RNA (mRNA) Analysis 
Messenger RNA for genes of interest were analysed by quantitative Reverse 
Transcriptase Polymerase Chain Reaction (qRT-PCR) using SYBR green 
incorporation technique. Each PCR was conducted using RotorGene 5000 machine 
(Corbett Research, USA) or otherwise stated. All PCR results were validated by melt 
curve analyses of product’s peak based on the amplicon size constructed from Primer-
Blasts programme (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) according to the 
primer used. Relative expressions of mRNA were quantified using RotorGene 
software comparative cycle threshold (CT) value and was normalised against the 




PCR were conducted as follows; DNA or cDNA samples were thawed at room 
temperature and briefly heated at 50 °C to allow complete dissolution. DNA (3 μL) or 
cDNA (1 μL) was combined with 7 μL or 9 μL of PCR master-mix respectively. PCR 
master-mix consisted of 5μL iQ-SYBR supermix (Bio-Rad Laboratories, USA), 0.5μL 
forward primer, and 0.5 μL reversed primer (Gene-works, Adelaide, Australia) and 
brought to 20 μL with DEPC-treated H2O. The PCR cycling conditions were 95 °C for 
15 minutes, 35 cycles of 95 °C for 30 seconds, 60 °C for 30 seconds, and 70 °C for 30 
seconds. These settings were followed by incubation at 72 °C for 4 minutes and a melt 
curve analysis with an incremental increase from 72 °C to 95 °C over 5 minutes. 
 
All primers were designed in house, except for the hVDR primer which used primers 
as described by Gardiner et al., 2000. All primers used are listed in table 2.1. 
 
2.10. STATISTICAL ANALYSES 
All analyses were conducted using Graphpad Prism, version 6.05. 
 
2.10.1. Two tail Independent t-test 
Two tail Independent student t-test analyses were used for 2 group studies with the 
confidence interval () set at 95 % and a p-value < 0.05 with Levene’s test for equality 
of variance above 0.05 (equal variances assumed) was considered statistically 
significant. 
 
2.10.2. Two way analysis of variance (Two Way ANOVA) 
Two-way analysis of variance (ANOVA) was applied to analyse the interactions 




age and genotype. The confidence interval () was set at 95 %. Statistical significance 
was set at a p value < 0.05. 
 
2.10.3. Post-hoc Test 
A Least Significant Difference (LSD) post-hoc test was used to identify the group/s 
that were significantly different within the data sets analysed by Two-Way ANOVA 
and p < 0.05 is considered as statistically significant. All analyses were conducted with 




















Table 2. 1 Primer Sequences Used in the Studies 




Forward AGG GTG TGA TGG TGG GAA T 
NM_007393.3 721 
Reverse GCT GGG GTG TTG AAG GTC T 
mVdr 
 
Forward CTG AAT GAA GAA GGC TCC GAT 
NM_009504.4 171 
Reverse AGC AGGACAATCTGGTCATCA 
hVDR 
Forward GGA CGC CCA CCA TAA GAC CTA  
KR710973.1 380 
Reverse CTC CCT CCA CCA TCA TTC ACA 
OSVDR 
Forward TCA TTC TGA CAG ATG AGG AAG TGC  
Specific Design N/A 
Reverse TCC TGG TAT CAT CTT AGC AAA GCC 
mCyp27b1 
 
Forward GAC CTT GTG CGA CGA CTA A 
NM_010009.2 167 
Reverse TCT GTG TCA GGA GGG ACT TCA 




Gene  Sequence (5’to 3’) of the oligonucleotide primers Gene bank accession number 
Amplicon 
size (bp) 
 Reverse GTC ACC ATC ATC TTC CCA AAT 
mRunx2 
 
Forward ACA AGG ACA GAG TCA GAT TAC AGA T 
NM_001146038.2 (isoform 1) 
NM_001145920.2 (isoform 2) 
NM_001271630.1 (isoform 3) 
NM_001271631.1 (isoform 4) 
122 
Reverse CGT GGT GGA GTG GAT GGA T 
mOpg 
 
Forward GTC CCT TGC CCT GAC CAC T 
NM_008764.3 151 
Reverse GGT AAC GCC CTT CCT CAC AC 
mRankl 
 
Forward TGA AGA CAC ACT ACC TGA CTC CTG 
NM_011613.3 198 
Reverse CTG GCA GCA TTG ATG GTG AG 
mOcn 
 
Forward AGA CCT AGC AGA CAC CAT GA 
NM_031368.4 118 
Reverse GAA GGC TTT GTC AGA CTC AG 
mSost 
 
Forward CCA CCA TCC CTA TGA CGC CAA 
NM_024449.5 73 72 
Reverse TGT CAG GAA GCG GGT GTA GT 
70 
 





Forward GGA AGC CTG ACC CAC CTG T 
NM_022657.3 133 36 
Reverse CGG CGT CCT CTG ATG TAA TC 
mPhex 
Forward GAA AAG CTG TTC CCA AAA CAG AG 
NM_011077.2 156 
Reverse TAG CAC CAT AAC TCA GGG ATC G 
mDmp1 
 
Forward GAA AGC TCT GAA GAG AGG ACG GG 
NM_016779.2 121 
Reverse TGT CCG TGT GGT CAC TAT TTG CCT 
mEnpp1 
 
Forward AAG CGC TTA CAC TTC GCT AAA AG 
NM_008813.3 87 
Reverse TGA TGG ATT CAA CGC AAG TTG 
rNaPi2a 
Forward GCT GTC CTC TAC CTG CTC GTG TG 
BC078876.1 91 
Reverse GCG TGC CCA CTC CGA CCA TAG 
rNaPi2c 
Forward TTG CTG CCG CTG GAG AGT GC 
N/A N/A 





CHAPTER 3: SKELETAL CHARACTERIZATION OF AN 
OSTEOBLAST-SPECIFIC VITAMIN D RECEPTOR 
TRANSGENIC (OBVDR-B6) MOUSE MODEL. 
 
As published in the Journal of Steroid Biochemistry and Molecular Biology, 2016 
Nov 164:331-336, doi: 10.1016/j.jsbmb.2015.08.009. Epub 2015, Sep 4 
 
The aim of this chapter was to characterize the ObVDR-B6 at 3, 9 and 20 weeks (w) 
of age to address the backcrossing of OSVDR from FVB/N background onto the 
C57black6/J genetic background. The rationale behind this study was to determine 
whether the human Vdr gene is truly present in the backcrossed mice and to assess the 
bone properties and characteristics of the backcrossed mice considering that the 
C57black6/J is known to have low bone mass and different mouse strain characteristics 
compared to the FVB/N. Therefore, this study attempted to evaluate serum, bone and 
histological properties of ObVDR-B6 mice and observed any differences with its 
predecessor, the OSVDR or OSV3 mouse model. 
 
The serum, skeletal and histomorphometry were analysed at 3w, 9w, and 20w of age 
male and female ObVDR-B6 Mice and published in J Steroid Biochem Mol Biol. 2016 
Nov. 164:331-336, doi: 10.1016/j.jsbmb.2015.08.009. Epub J Steroid Biochem Mol 
Biol. 2015 Sep 4. S0960-0760 (15) 30046-7, as attached. In this chapter the 
supplementary data and the data not shown in the publication are also presented. 


Journal of Steroid Biochemistry & Molecular Biology 164 (2016) 331–336Review
Skeletal characterization of an osteoblast-specific vitamin D receptor
transgenic (ObVDR-B6) mouse model
Rahma Trilianaa,b, Nga N. Lamb, Rebecca K. Sawyerd, Gerald J. Atkinsc,
Howard A. Morrisb,d,1, Paul H. Andersond,*,1
a Faculty of Medicine, Islamic University of Malang, Malang, East Java 65144 Indonesia
b School of Medicine, Faculty of Health Science, The University of Adelaide, Adelaide, 5000 SA, Australia
cCentre for Orthopaedics and Trauma Research, The University of Adelaide, Adelaide, 5000 SA, Australia
d School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, 5001 SA, Australia
A R T I C L E I N F O
Article history:
Received 15 June 2015
Received in revised form 5 August 2015
Accepted 11 August 2015





A B S T R A C T
Background: Overexpression of the human vitamin D receptor (hVDR) transgene under control of the
human osteocalcin promoter in FVB/N mice (OSVDR) was previously demonstrated to exhibit increased
cortical and trabecular bone volume and strength due to decreased bone resorption and increased bone
formation. An important question to address is whether the OSVDR bone phenotype persists on an
alternative genetic background such as C57Bl6/J.
Methods: OSVDR mice (OSV3 line) were backcrossed onto the C57Bl6/J genetic background for at least
6 generations to produce OSVDR mice with 98.4% C57Bl6/J congenicity (ObVDR-B6 mice). Hemizygous
male and female ObVDR-B6 and littermate wild-type (WT) mice were fed a standard laboratory chow
diet and killed at 3, 9 and 20 weeks of age for analyses of biochemical and structural variables and
dynamic indices of bone histomorphometry.
Results: At 9 weeks of age, both cortical and trabecular femoral bone volumes were increased in both male
and female ObVDR-B6 mice, when compared to WT levels (P < 0.05), without systemic changes to
calciotropic parameters. The increase in femoral trabecular bone volume was associated with increase in
MAR (P < 0.01) and reduced osteoclast size (P < 0.05). However, in female mice trabecular bone volume
was unchanged in femoral metaphysis of 20 weeks mice and in vertebra both at 9 and 20 weeks of age.
Increased cortical bone in both male and female ObVDR-B6 mice was due largely to increased periosteal
expansion and was associated with increased cortical strength at 20 weeks of age.
Conclusion: Overexpression of the human VDR gene in mature osteoblasts of C57Bl6/J mice increases
cortical and trabecular bone volumes and confirms the previous reports of increased bone in OSVDR mice
on the FVB/N background. However, site-specific and gender-related differences in bone volume suggest
that the effects of osteoblast-specific VDR overexpression are more complex than hitherto recognised.
Crown Copyright ã 2015 Published by Elsevier Ltd. All rights reserved.
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The vitamin D receptor (VDR) is expressed in wide variety of
bone cells, including osteoblasts and osteocytes where it mediates
vitamin D-stimulated osteoclastic bone resorption and bone loss
[1,2] as well as the inhibition of mineralisation when exposed to
high 1,25-dihydroxyvitamin D (1,25D) levels [3]. In contrast, VDR-
mediated activities have also been shown to enhance osteoblast
differentiation and mineralisation [4], and inhibit osteoblast
apoptosis [5,6]. Current evidence suggests that the stage of
osteoblast differentiation as well as the level of dietary calcium
and phosphate may play a role in determining whether VDR
mediates anabolic or catabolic activities on bone mineral [7,8].
Previously, the transgenic overexpression of the human gene
for VDR under the regulation of human osteocalcin promoter
(OSVDR) on the FVB/N mouse genetic background was shown to
enhance trabecular bone volume in female caudal vertebrae [9].
This increase in trabecular bone volume was associated with
increased trabecular thickness and reduced osteoclast activity. In
addition, tibial and femoral cortical bone areas of OSVDR mice
were increased associated with increased strength and periosteal
mineral apposition rate (MAR) [9,10]. While we previously [11]
reported that the bone phenotype of OSVDR was partially
preserved during vitamin D deficiency, Baldock et al. [12] reported
that the OSVDR bone phenotype was abrogated when fed low
dietary calcium.
The FVB/N genetic background is a common inbred mouse
strain used for transgenic mouse models due to its high
reproductive performance, large litter size and prominent
pronuclei which assist microinjection of DNA constructs [13].
However, since bone density, extrinsic femoral strength and cross-
sectional geometry vary between mouse genetic backgrounds
[14,15], a question remains as to whether the bone phenotype
elicited by overexpression of the hVDR transgene is dependent on
the genetic background of the mouse line. We now report bone
structures on hVDR transgenic mice on the C57Bl6/J genetic
background using advanced micro-computed tomography meth-
ods providing 3D assessment of bone structures.Table 1
Body weight and blood biochemistry of WT and ObVDR-B6 mice. ALP, alkaline
phosphatase; 1,25D, 1,25-dihydroxyvitamin D. Values are mean  SEM, * P < 0.05 vs.
WT mice. N/A; not available.
9 weeks
WT ObVDR-B6
Female (n) (11) (10)
Body weight (g) 18.6  0.3 20.3  0.6*
Calcium (mmol/L) 2.35  0.04 2.36  0.08
Phosphate (mmol/L) 1.62  0.21 1.87  0.15
ALP (U/L) 175.0  10.0 181.3  10.0
1,25D (pmol/L) 140.9  18.8 134.9  65.5
Male (n) (12) (10)
Body weight (g) 24.3  0.5 24.1  0.7
Calcium (mmol/L) 2.51  0.08 2.62  0.09
Phosphate(mmol/L) 1.70  0.16 2.05  0.11
ALP (U/L) 141.5  11.7 170.7  13.2
1,25D (pmol/L) N/A N/A2. Materials and methods
2.1. Animals
FVB/N transgenic mice overexpressing hVDR transgene under
the control of the human osteocalcin promoter (OSVDR) was
provided by Dr Edith Gardiner and colleagues (Garvan Institute,
Darlinghurst, Sydney, NSW, Australia). The pOSVDR construct was
previously generated by inserting a human VDR cDNA 2.1 kb EcoRI
fragment from phVDR1/3 [16] into the human osteocalcin-based
pGOSCAS vector [17] followed by SV40 small t-antigen splice and
polyadenylation signals immediately downstream. OSVDR trans-
genic mice were then generated by pronuclear injection of FVB/N
embryos. The OSV3 line carries a single insertion of 10 copies of the
transgene, as previously described [9]. OSVDR mice (OSV3 line)
were then backcrossed onto the C57bl6/J genetic background for at
least 6 generations to produce OSVDR mice with 98.4% C57Bl6/J
congenicity (ObVDR-B6 mice). Male and female hemizygous
ObVDR-B6 and litter-matched wild-type (WT) mice were housed
in groups of five in individually ventilated cages maintained at
22–23 C. All animals received free access to water and chow diet,
containing 0.8% calcium and 0.7% phosphate. All animal proce-
dures were approved and performed in accordance to require-
ments of the animal ethics committees for the University of
Adelaide, University of South Australia and SA Pathology/CALHN.
2.2. Biochemistry
Serum calcium, phosphate and alkaline phosphatase were
measured by the Konelab1 20/20XT chemical analyser using
standard reagents (Thermo Fisher Scientific, Vantaa, Finland).
Serum 1,25-dihydroxyvitamin D levels were measured using solid-
phase immunoextraction followed by quantitative determination
on the IDS-iSYS automated immunoassay system (Immunodiag-
nostic System, Boldon, UK).
2.3. Micro-CT
Mice were killed at 3, 9 and 20 weeks of age. At death, mice
were weighed and the right femora and vertebrae collected and
fixed with 10% formalin for 5 days and stored in 70% ethanol at 2–
8 C prior bone scanning. Femoral length was measured using
digital callipers. Femora and vertebrae were scanned by micro-CT
(Skyscan 1076, Bruker/Skyscan, Belgium) at a pixel size of 8.65 mm.
X-ray tube potential of 48 kV and 110 mA, rotation step of
0.8 degrees and in a scan medium of 70% ethanol. Acquired
X-ray images were reconstructed using nRecon (v1.6.9, Skyscan)
with an isotropic voxel size of 8.65 mm. Volumetric analyses of
cortical bone used a 2 mm segment of midshaft femoral cortical
bone. A secondary spongiosa volume representing 20% of the
femur length, was isolated in the distal femoral metaphysis to
quantify trabecular bone volume. The inferior trabecular bone of
the L1 vertebrae was isolated to quantify the trabecular bone
volume in this region. Cortical parameters (volume, cortical width,
periosteal and endosteal circumference) and trabecular bone
parameters (volume, thickness, number) were all were calculated
Table 2
Cortical bone measurements at the femoral mid shaft of WT and ObVDR-B6 female and male mice at 3, 9 and 20 weeks of age. Ct.BV, cortical bone volume; Ct.Th, cortical
thickness; P.Pm, periosteal perimeter; E.Pm, endosteal perimeter. Values are mean  SEM. P < 0.05 for ANOVA analyses in (a) genotype, (b) age and (c) interaction. *P < 0.05 vs.
WT mice, | P < 0.05 vs. 3 weeks mice, ^ P < 0.05 vs. 9 weeks mice.
3 weeks 9 weeks 20 weeks
WT ObVDR-B6 WT ObVDR-B6 WT ObVDR-B6
Female (n) (7) (7) (11) (10) (13) (13)
Femur Length(a,b) 10.7  0.1 11.1  0.1* 14.6  0.1| 14.9  0.1*| 16.1  0.1^ 16.1  0.1^
Ct.BV(mm3)(a,b) 0.74  0.03 0.68  0.12 1.38  0.03| 1.52 + 0.05*| 1.72  0.02^ 1.81  0.02*^
Ct.Th (mm) (a,b) 113.2  3.5 117.3  3.5 176.6  2.9| 184.9 + 3.2*| 209.8  1.9^ 216.3  1.89*^
P.Pm (mm) (a,b) 4.17  0.08 4.37  0.09* 5.06  0.03| 5.30 + 0.08*| 5.31  0.03^ 5.44  0.04*
E.Pm (mm) (a,b) 3.46  0.06 3.64  0.08* 3.88  0.02| 4.10 + 0.07*| 3.91  0.02 4.04  0.04*
Peak load (N) – – – – 16.76  0.41 21.07  0.74*
Modulus (GPa) – – – – 4.46  1.53 5.58  1.27*
Male (n) (9) (5) (12) (10) (8) (8)
Femur length(b) 10.9  0.2 10.9  0.2 15.1  0.1| 15.2  0.1| 16.1  0.1^ 15.9  0.1^
Ct.BV (mm3)(a,b,c) 0.76  0.03 0.78  0.06 1.57  0.04| 1.84 + 0.05*| 1.91  0.02^ 2.09  0.04*^
Ct.Th (mm) (a,b,c) 117.0  3.2 116.4  5.3 190.4  5.5| 212.8 + 4.1*| 213.6  2.1^ 241.3  3.6*^
P.Pm (mm) (b,c) 4.21  0.09 4.29  0.13 5.43  0.05| 5.72 + 0.10*| 5.89  0.05^ 5.79  0.06
E.Pm (mm) (b,c) 3.47  0.08 3.59  0.12 4.17  0.08| 4.32 + 0.09| 4.56  0.07^ 4.26  0.04*
Peak load (N) – – – – 14.01  0.31 18.27  0.26*
Modulus (GPa) – – – – 3.56  1.79 4.62  1.66*
R. Triliana et al. / Journal of Steroid Biochemistry & Molecular Biology 164 (2016) 331–336 333using direct 3D and 2D approaches using CTan software (v1.7,
Skyscan).
2.4. Three point mechanical testing
Biomechanical properties of femora from 20 weeks old mice
only were evaluated. The left femur from each mouse was placed
centred between anvils with a 6 mm gap. Load was applied at a rate
of 0.01 mm/s in 0.01 Newton increments. Load, compression, and
break point were recorded for each femur allowing for the
calculation of Young’s Modulus and Maximum Load (Instron 5944,
Instron Pty Ltd., Melbourne, Australia).
2.5. Dynamic histomorphometry
Formalin-fixed femurs were bisected in the sagittal plane with a
diamond-tipped cutting blade using a slow speed saw and
processed for resin embedding as previously described [18].
Sequential sagittal sections were cut to 5 mm thickness. For bone
mineralisation analyses of the distal femoral metaphysis, un-
stained fluorochrome labelled sections were prepared by placing
in acetone for 15 min and protected from light. Measures of
mineral apposition rate (MAR, mm/day) and bone formation rate
(BFR, mm3/m m2/day) were obtained from these sections. For bone
resorption analyses, sections were stained for tartrate-resistant
acid phosphatase (TRAP) to identify TRAP-positive osteoclasts.
Briefly, resin-embedded sections are de-waxed in acetone for
15 min before 60 min incubation in Tris–HCL buffer (pH 9.4) at
37 C followed by two washes in distilled water. Sections are then
incubated at 37 C for 60 min in an acid phosphatase (AcP) stain
prepared by adding (A) 0.035 g of tartaric acid dissolved in 35 ml of
sodium acetate (pH 5.2) to (B) 100 ml basic fuchsin in a 100 ml
solution containing 0.4 mg of sodium nitrite. This solution is then
added to a solution containing 0.04 g Napthol ASBI phosphate in
2 ml dimethylformamide before being counter-stained with
haematoxylin. Histomorphometric analyses were performed using
OsteoMeasure (v3.3.O.2, Osteometrics Inc GA, USA).
2.6. Statistical analysis
Two-way analysis of variance was used to determine the effect
of age and genotype on bone structure. Least significant difference
(LSD) post-hoc analysis was used to identify groups reachingsignificant differences. Significance was set at P < 0.05 using
GraphPad Prism, version 6.05.
3. Results
The human VDR transgene demonstrated high expression in
bone samples and was undetected in brain, heart, liver, spleen,
intestine, lung, muscle, and kidney similar to that demonstrated
for the FVB/N mice [9] (data not shown). The mean body weight of
female ObVDR-B6 mice body weight was 9% greater at 9 weeks of
age (P < 0.05, Table 1). However, the body weight of 3 weeks and
20 weeks female ObVDR-B6 mice and male ObVDR-B6 at all ages
and was unchanged (data not shown). Serum calcium, phosphate,
ALP and 1,25D level were unchanged in ObVDR-B6 mice when
compared to WT mice (Table 1).
At 3 and 9 weeks of age, femur length was increased by 4% and
2% (P < 0.05) respectively when compared to WT mice (Table 2).
Growth plate width was unchanged in ObVDR-B6 mice (data not
shown). Although cortical bone volume (Ct.BV) was unchanged in 3
weeks old ObVDR-B6 mice, a 5% increase in both periosteal
perimeter (P.Pm) and endosteal perimeter (E.Pm) were observed in
female ObVDR-B6 mice only (P < 0.05, Table 2). At 9 weeks and
20 weeks of age, both male and female ObVDR-B6 mice
demonstrated increased Ct.BV. In male ObVDR-B6 mice, Ct.BV
was increased by 17% at 9 weeks (P < 0.05) and 9% at 20 weeks of
age (P < 0.05). In female ObVDR-B6 mice, Ct.BV at 9 weeks and
20 weeks was increased (10% and 5% respectively) when compared
to WT mice (P < 0.05) (Fig. 1; Table 2). The sub-regional bone
mineral cross-sectional area of ObVDR-B6 femora demonstrated
largely uniform increases in bone mineral across the diaphysis in 9
weeks and 20 weeks mice (Supplementary Fig. 1). At 9 weeks of
age, in both male and female, the increase in Ct.BV mice was due to
a 5% increase in P.Pm (P < 0.05) despite an increase in E.Pm which
reached significance in female mice only (5%, P < 0.05, Table 2).
While the more modest increase in Ct.BV in 20 weeks female
ObVDR-B6 mice was related to 2.4% increase in P.Pm (P < 0.05), the
increase in Ct.BV in 20 weeks male ObVDR-B6 mice was due to a 6%
reduction in E.Pm (P < 0.01) and without change to P.Pm. These 20
weeks male ObVDR-B6 mice demonstrated a 30% increase in peak
load and modulus when compared to WT mice (P < 0.05, Table 2).
At 9 weeks of age, femoral metaphyseal trabecular bone
volumes (BV/TV) were increased in both male and female ObVDR-
B6 mice (female 13% P < 0.05; male 24% P < 0.05) due to increased
Fig. 1. Fermoral bone from 9 weeks female ObVDR-B6 and WT femora representing
(a) coronal X-ray images, (b) 3D reconstructed metaphyseal trabecular bone and (c)
mid shaft cortical bone.
Table 3
Trabecular bone measurements at the femoral distal metaphysis of WT and
ObVDR-B6 female and male mice at 9 and 20 weeks of age. BV/TV, trabecular bone
volume/total volume; Tb.N, trabecular number; Tb.Th, trabecular thickness. Values
are mean  SEM. P < 0.05 for ANOVA analyses in (a) genotype, (b) age, and (c)
interaction. * P < 0.05 vs. WT mice, ^ P < 0.05 vs. 9 weeks mice.
9 weeks 20 weeks
WT ObVDR-B6 WT ObVDR-B6
Female (n) (11) (10) (13) (13)
BV/TV (%)(a,b,c) 9.7  0.28 11.0  0.40* 6.4  0.3^ 6.3  0.23^
Tb.N (#/mm) (b,c) 2.47  0.08 2.81  0.09* 1.61  0.07^ 1.52  0.06^
Tb.Th (mm) (b,c) 39.6  0.5 39.16  0.5 39.8  0.6 41.6  0.6*^
Male (n) (12) (10) (8) (8)
BV/TV (%)(a,b) 12.6  1.0 15.6  0.9* 8.9  0.3^ 11.4  0.8*^
Tb.N (#/mm) (a,b) 3.19  0.22 3.76  0.19* 1.90  0.07^ 2.18  0.14^
Tb.Th (mm)(a,b) 39.2  0.7 41.6  0.5* 47.1  0.3^ 51.9  0.8*^
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thickness (Tb.Th) (Fig. 1 and Table 3). At 20 weeks of age, only male
mice exhibited increased BV/TV (28%, P < 0.05) due to increase Tb.
N (14%, P < 0.05). However, Tb.Th was increased in both 20 weeks
male (10%, P < 0.05) and female (5%, P < 0.05) ObVDR-B6 mice.
With regards to vertebral trabecular bone, only male ObVDR-B6
mice demonstrated an increase in BV/TV%, both at 9 weeks (9%,
P < 0.05) and 20 weeks (16%, P < 0.05) of age. This increase in BV/TV
was due to increased Tb.Th and, at 20 weeks of age only, due to
increased Tb.N (Table 4).
The increased femoral trabecular bone volume in 9 weeks
female ObVDR-B6 mice was associated with 15% increase in
mineral apposition rate (MAR) (P < 0.05) (Table 5). However, these
mice also demonstrated unchanged bone formation rate (BFR/BV)
due to a strong trend towards reduced mineralising surface (MS/
BS). In addition, the mean osteoclast size (Ocl. Ar) was reduced by
22% (P < 0.05) in female 9 weeks ObVDR-B6 mice which was
associated with a trend to decreased osteoclast attachment surface(Ocl. S/BS). However, no significant reduction in osteoclast
numbers (N.Oc/B.Pm) was determined in the female 9 weeks
ObVDR-B6 mice femora when compared to WT mice (Table 5).
4. Discussion
We backcrossed the OSVDR transgenic mouse line (OSV3 line)
from the FVB/N genetic background onto the C57bl6/J background
to generate ObVDR-B6 mice, in order to assess whether the
reported increase in bone mineral in OSVDR mice persisted on
another genetic background. As was shown for OSVDR mice [9], we
demonstrated specific expression of the VDR transgene in the bone
of ObVDR-B6 mice under the control of the human osteocalcin
promoter. In ObVDR-B6, no apparent perturbations in systemic
calciotropic measures were observed and, aside from 9 weeks
female mice, body weight was unchanged in the other ObVDR-
B6 age groups and in ObVDR-B6 male mice, suggesting that
enhanced osteoblastic VDR levels principally regulates local
activities of bone remodelling, at least under normal circum-
stances.
The femoral cortical bone mineral volumes of male and female
ObVDR-B6 mice were increased at both 9 weeks and 20 weeks of
age due largely to increased periosteal expansion, which is
consistent with the bone phenotype of the OSVDR mouse [9].
The sub-regional analyses of femora from ObVDR-B6 mice
demonstrated uniform increases in bone mineral occurred across
the diaphysis. Interestingly, by 20 weeks of age, male ObVDR-
B6 mice demonstrated that despite a cessation in further periosteal
expansion, cortical bone volume increased due to reduced
endosteal circumference. While reasons for gender-related differ-
ences in cortical remodelling are not clear, one possibility may be
related to differences in growth and mechanical loading. As
previously described, the overexpression of VDR by the human
osteocalcin-promoter results in increased VDR expression within
osteocytes as well as osteoblasts [9]. Given that osteocytes
coordinate the bone remodelling process in response to mechani-
cal changes, elevated VDR in the transgenic mice, may alter the
osteocytic-driven cortical remodelling differently in male mice.
While it is not possible to draw such a conclusion from the current
study, gender-related differences in skeletal acquisition of mature
heterozygous global VDR-KO mice [19], suggesting that further
investigations in relation to interactions between VDR, gender and
mechanical loading are warranted.
With regards to trabecular bone, female ObVDR-B6 mice
demonstrated an increase in BV/TV at 9 weeks of age, specifically
in the femoral metaphysis. In contrast, in male ObVDR-B6 mice
trabecular bone volumes at the femoral distal metaphysis and
lumbar vertebra both were increased. Previously, female OSVDR
Table 4
Trabecular bone measurements of vertebral body lumbar-1 in WT and ObVDR-B6
female and male mice at 9 and 20 weeks of age. BV/TV, trabecular bone
volume/total volume; Tb.N, trabecular number; Tb.Th, trabecular thickness. Values
are mean  SEM. P < 0.05 for ANOVA analyses in (a) genotype, (b) age and (c)
interaction. * P < 0.05 vs. WT mice, ^ P < 0.05 vs. 9 weeks mice.
9 Weeks 20 Weeks
WT ObVDR-B6 WT ObVDR-B6
Female (n) (11) (10) (13) (13)
BV/TV (%) 19.2  0.4 19.2  0.4 19.2  0.7 18.6  0.7
Tb.Th (mm)(b) 39.5  0.3 40.0  0.4 44.08  0.43^ 44.5  0.6^
Tb.N (#/mm)(b) 4.85  0.07 4.79  0.08 4.35  0.15^ 4.18  0.15^
Male (n) (12) (10) (8) (8)
BV/TV (%)(a,b) 20.8  0.7 22.6  0.6* 17.6  0.6^ 20.5  0.5*^
Tb.Th (mm)(a) 39.5  0.6 41.9  0.3* 38.9  0.7 42.0  0.4*
Tb.N (#/mm)(a)(b) 5.26  0.12 5.39  0.11 4.52  0.09^ 4.88  0.07*^
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volume [9], which is consistent with the male, but not female,
ObVDR-B6 bone phenotype. In 9 weeks female ObVDR-B6 mice,
the increase of metaphyseal bone volume was associated with
increased MAR, a modest decrease in osteoclast size and no change
to osteoclast numbers, which is consistent with findings in the
OSVDR mice [9].
Recently, the conditional deletion of VDR in osteoblasts using
the Col1a1-Cre founder mouse line was performed to demonstrate
that increased bone volume occurred at 16 weeks of age in male
osteoblast-specific VDRKO mice [1]. This increase in bone, which
did not occur in younger mice, was associated with both reduced
tibial cortical RANKL expression and osteoclast numbers, and
without change to MAR. Thus, while the deletion and over-
expression of VDR in osteoblasts both result in increased bone
volume, differences occur with respect to the temporal, spatial
development of the bone phenotype as well as the mechanisms by
which the increased bone volume develops. Overexpression of
VDR in osteoblasts increases periosteal and trabecular bone in
young mice associated with increased MAR. Whereas the deletion
of VDR in osteoblasts appears to principally impair bone resorption
in adult mice [1]. The direct comparison of these two mouse
models is limited, however, given that the deletion and over-
expression of VDR were performed using different promoters and
thus potentially representing different pools of osteoblast-lineage
cells. Furthermore, while the overexpression of VDR using the
osteocalcin promoter has been shown to increase VDR within
osteocytes [9], the deletion of VDR using the Col1a1-Cre curiously
does not appear to reduce VDR expression in osteocytes [1]. Thus,
further studies with appropriate mouse models would be of value
to be able to directly compare and contrast the bone remodelling
effects of overexpression and conditional deletion of VDR in
osteoblasts.Table 5
Dynamic histomorphometry of 9 weeks old female WT and ObVDR-B6 mice. Values
are mean  SEM. MS/BS, mineralising surface/bone surface; MAR, mineral
apposition rate; BFR/BS, bone formation rate /bone surface; Ocl. Ar, osteoclasts
size; Ocl. S/BS, osteoclast surface/bone surface; N.Oc/B.Pm, osteoclast number/bone
perimeter.
WT ObVDR- B6 P-value
(n) (5) (5)
MS/BS (%) 34.95  1.44 29.05  3.00 0.053
MAR (mm/d) 2.73  0.09 3.13  0.13 0.018
BFR/BS (mm3/m m2/d) 0.96  0.05 0.90  0.08 0.303
Ocl. Ar. (mm2) 0.0213  0.0018 0.0167  0.0016 0.047
Ocl. S/BS (%) 23.15  1.01 18.40  2.58 0.062
N.Oc/B.Pm (#/mm) 8.54  0.29 7.30  0.85 0.1025. Conclusion
The over expression of the human VDR gene in mature
osteoblasts plays a significant role on bone mineral accrual at
cortical and trabecular sites of C57Bl6/J transgenic mice similar to
the OSVDR mice on the FVB/N genetic background. While skeletal
structural differences are observed between male and female mice,
a consistent increase in cortical bone volume and strength for both
female and male ObVDR-B6 mice indicates that VDR plays an
importantly role in cortical bone remodelling, possibly through
enhancing VDR-mediated activities in osteocytes as well as
osteoblasts. Further studies are required, however, to establish
the role of osteoblastic VDR under pathological conditions.
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Supplementary Figure 3. 1. Tissue Expression of hVDR (A) and Specificity 
Testing hVDR and OSVDR Primers on Various Tissue of WT Mice 
Gene expression of hVdr (A) on the brain, heart, intestine, liver, lung, muscle, 
spleen, kidney and bone of the ObVDR-B6 mice. Vdr and OSVDR primers were 
tested for specificity in amplifying the hVdr on WT tissues (Figure 1B and C) 
suggesting that the hVdr and OSVDR primer design was not specific and may result 
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Supplementary Figure 3. 2. Body Weight (A, B) and Femur Length (C, D) of 
Male and Female 3w, 9w, 20w WT and ObVDR-B6 Mice. 
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Supplementary Figure 3. 3. Femoral Segmental Bone Mineral Area in 3w (A 
and B), 9w (C and D), and 20w (E and F) of Female and Male WT and ObVDR-
B6 Mice. 
Comparison of femoral bone mineral cross-sectional area at every 2.5 % sub-regional 
area of the femur in WT and ObVDR-B6 at 3w, 9w, 20w in Female and Male Mice. 
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Supplementary Figure 3. 4. Tibial Gene Expression of WT and ObVDR-B6 
Mice at 9w. 
Tibial gene expression of OSVDR (A), hVdr (B), mCyp27B1 (C) mCyp24 (D), 





Supplementary Table 3. 1. Blood biochemistry of WT and ObVDR –B6 mice 
  3w  20w 
  WT ObVDR-B6   WT ObVDR-B6  
Female (n)  (7) (7)  (13) (13) 
Calcium(b)  3.00 + 0.09 3.19 + 0.13  3.13 + 0.18 3.14 + 0.15 
Phosphate(b)  2.69 + 0.17 2.69 + 0.15  2.29 + 0.16 1.97 + 0.18 
ALP(b)  771.97 + 71.53 704.46 + 78.41  167.94 + 10.26 108.87 + 7.71 
1,25D(b)  533.52 + 125.82 385.81 + 117.23  70.66 + 8.66 85.04 + 17.32 
Male (n)  (9) (5)  (8) (8) 
Calcium(a)(b)(c)  3.21 + 0.16 3.07 + 0.18  2.58 + 0.14 3.45 + 0.21*  
Phosphorus(b)(c)  2.57 + 0.31 2.72 + 0.33  1.76 + 0.09 2.33 + 0.17* 
ALP(b)  902.54 + 88.93 841.08 + 65.48  81.30 + 4.57 75.56 + 7.03 
1,25D(b)  474.32 + 133.41 635.86 + 212.66  173.58 + 46.8 190.70 + 3.18 
Values are mean + SEM, Two-way Anova significant at p < 0.05 for Interaction (a), 
Age (b), and genotype (c). Least Significant Difference (LSD) of Wild type vs. 
ObVDR-B6 animals * p < 0.05, **p < 0.001, p < 0.05 for 3 weeks vs. 9 weeks and 





Supplementary Table 3. 2. Trabecular bone measurements of vertebral body 
lumbar-1 in WT and ObVDR-B6 mice 
  9 Weeks  20 Weeks  
  WT ObVDR-B6   WT ObVDR-B6   
Female (n)  (11) (10)  (13) (13)  
BV/TV (%)  19.2 + 0.4 19.2 + 0.4  19.2 + 0.7 18.6 + 0.7  
Tb.Th ( m)(b)  39.5 + 0.3 40.0 + 0.4  44.08 + 0.43 44.5 + 0.6  
Tb.N (#/mm)(b)  4.85 + 0.07 4.79 + 0.08  4.35 + 0.15 4.18 + 0.15  
Male (n)  (12) (10)  (8) (8)  
BV/TV (%)(a)(b)  20.8 + 0.7 22.6 + 0.6*  17.6 + 0.6 20.5 + 0.5*  
Tb.Th ( m)(a)  39.5 + 0.6 41.9 + 0.3*  38.9 + 0.7 42.0 + 0.4**  
Tb.N (#/mm)(a)(b)  5.26 + 0.12 5.39 + 0.11  4.52 + 0.09 4.88 + 0.07*  
Values are mean + SEM, p < 0.05 for ANOVA analyses in Genotype (a), Age (b), and 
Interaction (c). * P < 0.05 vs. WT mice,  P < 0.05 for 9 vs. 20w within the same 
genotype. Trabecular bone volume (BV/TV), Trabecular thickness. (Tb.Th); 




CHAPTER 4: THE INTERACTION OF VDR IN MATURE 





The bone phenotype of OSVDR mice is dependent on dietary calcium intake, with 
increased bone mineral when fed an adequate calcium diet which is lost when fed a 
low calcium diet. I have investigated the overexpression of VDR in mature osteoblasts 
on the C57bl6/J genetic background (ObVDR-B6) mouse model using an extremely 
low dietary calcium and phosphate with the aim of exacerbating the effects of the 
increased VDR activities under conditions of elevated calciotropic hormones. 
 
Three week old female Wild Type (WT) and ObVDR-B6 mice were fed a diet 
containing calcium (0.03 %) and phosphorus (0.08 %) (LowCaP) for a period of 3w 
(short term) and 17w (long term) at which time they were compared to mice fed a 
normal calcium (1 %) and phosphorus (0.625 %) (NormCaP) diet. 
 
At 3w of age, no apparent changes in body weight, femur length, serum biochemistry 
or bone structure are observed between WT and ObVDR-B6. When fed LowCaP diet 
for a short term (3w), femur length is decreased with femoral structural changes in 
ObVDR-B6 mice are evident without visible changes to the growth plate. An increase 
in femoral mid-shaft cortical porosity is observed in ObVDR-B6 mice suggesting 
skeletal integrity is compromised at some sites. In contrast, increased trabecular bone 




short term LowCaP diet compared to WT fed the same diet suggesting that increased 
osteoblast VDR maintains trabecular bone at particular sites even when calciotropic 
hormones are elevated by low calcium/phosphate intakes.  
 
With long term treatment (17w), the LowCaP diet induced marked changes in bone 
structure of the ObVDR-B6 mice with splaying of the metaphysis, disrupted growth 
plate and increased of cortical porosity compared to WT mice fed similar diet while 
the NormCaP fed ObVDR-B6 has increased trabecular bone volume in the distal 
metaphysis and vertebrae and increased cortical bone in mid-shaft. These structural 
changes of the ObVDR-B6 mice arose from a decrease of bone resorption in the 
ObVDR-B6 NormCaP fed mice and an increase of bone resorption in the LowCaP fed 
mice. Most interesting is the evidence that VDR activities in mature osteoblasts can 
modulate plasma levels of calciotropic hormones. ObVDR-B6 mice fed the LowCaP 
diet for 17w demonstrated a 50 % decrease in serum FGF-23 and a 100 % increase in 
serum 1,25D levels compared to WT mice fed the identical diet. These changes suggest 
that VDR in mature osteoblasts can modulate both anti-catabolic and catabolic 






A transgenic model in which the human vitamin D receptor (Vdr) gene is solely over-
expressed in mature osteoblasts under the control of the human osteocalcin promoter 
in FVB/N genetic background (OSVDR mice) was reported by Gardiner and 
colleagues in 2000 (36). This mouse model demonstrated increased bone mass due to 
an increase in mineral apposition rate and reduction in bone resorption without changes 
to calciotropic hormone levels. Using OSVDR mice, Baldock et al. in 2006 (37) 
reported that the increased bone volume in this mice was dependent on the level and 
duration of dietary calcium with no differences in bone mineral volumes between wild 
type (WT) and OSVDR mice when fed a moderately low calcium diet up to 6 months 
of age.  
 
Backcrossing the OSVDR mice from the FVB/N background onto the C57Bl6/J 
background (ObVDR-B6), as reported in chapter 3, confirmed that when fed a standard 
chow diet (0.8 % calcium / 0.7 % phosphorus), overexpression of human Vdr gene in 
mature osteoblasts results in increased cortical and trabecular bone volumes. However, 
the findings also illustrated site-specific and gender-related differences suggesting the 
effects of osteoblast-specific VDR overexpression are more complex than previously 
recognised. 
 
Dietary calcium affects bone mineral levels through modulation of calciotropic 
hormones to maintain plasma calcium and phosphate homeostasis (18). A low dietary 




hormone (PTH) to stimulate calcium fluxes across the kidney, intestine and bone (91). 
Ionised calcium activates the Calcium Sensing Receptor (CaSR) modulating a range of 
activities in numerous cell types including osteoblasts. Adequate dietary calcium can 
improve bone volume in rat models while low dietary calcium can decrease bone 
volume by increasing osteoclastogenesis (37).  
 
The current study examined the effects of over-expression of VDR in mature 
osteoblasts in female ObVDR-B6 mice fed a very low dietary calcium/phosphate diet 
compared to WT mice fed the same diet and these mice fed an adequate calcium and 
phosphate diet. This study aimed to generate further evidence of VDR activities in 






4.2.1. Animals and Dietary Used 
WT and ObVDR-B6 mice were housed as described in Chapter 2, Section 2.3 and 
fed semi-synthetic diets containing either 1 % calcium / 0.625 % phosphorus 
(NormCaP/SF12-076, Specialty Feeds, Glen Forrest, Western Australia) or 0.03 % 
calcium / 0.08 % phosphorus (LowCaP/SF12-077, Specialty Feeds, Glen Forrest, 
Western Australia) from weaning (3w) until 6w of age (short term treatment) and 20w 
of age (long term treatment). Given the time constraints of the project, only female 
mice were studied. The semi-synthetic diet was formulated with whey-based protein 
to achieve low phosphate levels while maintaining adequate levels of other nutrients 
such as amino acids, vitamins and fatty acids. The differences between the two diets 
were calcium and phosphorus levels derived from calcium carbonate, monocalcium 
phosphate and potassium dihydrogen phosphate. Detailed dietary composition of the 
diets used in this study is attached in the Appendix section. 
 
Calcein and xylenol orange fluorochrome labels were injected intra-peritoneally at 8 
and 2 days prior to death as described in Chapter 2, Section 2.7. At time of death, 
blood was drawn using external cardiac punctures techniques while femora and 
vertebrae were collected for micro-CT analyses and histology. Right tibia, kidney and 
other tissues were collected in RNA-Later® (Ambion ®, Life technologies, Austin, 
Texas, USA) for further analyses. All animal details and procedures were recorded on 
clinical record sheets (CRS) in accordance the University of Adelaide Animal Ethics 





To assess bone structure before commencing the experimental diets, 3w old female 
WT and ObVDR-B6 were culled and serum biochemistry and femoral skeletal 
structures were analysed as a baseline. 
 
4.2.2. Serum Biochemistry 
Serum calcium, phosphate, ALP, 1,25D, FGF-23, PTH, CrossLapsTM and TRAP5b 
levels were measured as previously described in Chapter 2, Section 2.5. 
 
4.2.3. Micro-Computed Tomography 
Right femora were initially imaged using X-ray imaging (Faxitron LX-60, Tucson, 
AZ, USA) to visualise bone prior to microstructure analyses using micro-CT system 
at 9um/pixel (1076 Skyscan, Bruker, Germany) as described previously (Chapter 2, 
Section 2.6.1). Vertebrae were scanned on 6.5um/pixel micro-CT system (1174 
Skyscan, Bruker, Germany) as described in Chapter 2, Section 2.6.2. Total and 
segmental bone mineral content on full length femora were analysed followed by 
femoral cortical and trabecular bone analyses. Cortical bone analyses were measured 
over a region comprising 10 % of the femur length at the mid-shaft while trabecular 
bone analyses were performed from a region starting 0.6 mm from end of visible 
growth plate (roughly 2.2 - 2.3 mm from the start of bone) extending 10 % of the femur 
length at the femoral distal metaphysis. Regional femoral bone assessments were 
modified due to significant differences in femur length between groups and visible 
changes of bone structure in some of the groups. Vertebral trabecular analyses were 




4.2.4. Histomorphometric Analyses 
4.2.4.1. Paraffin Sections 
Whole femora were cleaned of surrounding tissue and fixed with 4 % 
paraformaldehyde for 2 days. Femora were decalcified by immersing bones in 10 % 
ethylenediamine-tetra acetic acid (EDTA) solution for 7 - 10 days. During the 
decalcification process, bones were imaged consecutively using Faxitron X-ray 
imaging to assess the decalcification process. Once bones were decalcified, they were 
packed inside paraffin cassettes for processing and embedded longitudinally in 
paraffin. They were left for 24 hours to allow the paraffin to set prior to sectioning. 
Paraffin sections of 5 µm thickness were prepared using a motorized microtome (Leica 
2255, Germany) and stained with Toluidine Blue as described in Chapter 2, Section 
2.7.4. 
 
4.2.4.2. Resin Sections 
After being scanned, the right femora were cut using a slow speed saw to reveal the 
metaphyseal area followed by graded-ethanol dehydration and embedded in methyl 
methacrylate as previously described in Chapter 2. Sections of 5 µm thickness were 
stained with Tartrate Resistant Acid- Phosphatase (TRAP) for analysis of osteoclasts 
as previously described in Section 2.7.5 while unstained sections were used to measure 
double fluorochrome labels. Results are reported using terminology and units in 
accordance with the American Society of Bone Mineral Research Histomorphometry 





4.2.5. Quantitative Real Time PCR 
mRNA was extracted from kidney and left tibia using TRIzol® methods, and cDNA 
was generated using reverse transcriptase enzyme as described in Section 2.8. Tibial 
cDNA was analysed for genes related to bone formation and bone resorption while 
kidney cDNA was analysed for gene expression of vitamin D metabolism/activities 
and FGF-23 responsive genes using PCR primers as listed in table 2.1 in chapter 2. 
 
4.2.6. Statistical Analyses 
Two-tail independent student t-test analyses were conducted for studies of 3w and 6w 
groups. Two-way ANOVA was conducted to analyse the effects of genotype, diet and 
interactions between genotype and diet on skeletal structure of the 20w groups with a 
confidence interval () set at 95 % and p value < 0.05 was considered as statistically 
significant. Least Significant Difference (LSD) post-hoc tests were applied to identify 
the group/s that were significantly different. Variables which were not normally 
distributed based on Kolmogorov-Smirnov normality test were then analysed using the 





4.3.1. Transgenic Over-Expression of VDR in Mature Osteoblast mice (ObVDR-
B6) at 3w-Age and following Short Term LowCaP Feeding  
At weaning female and following short term LowCaP feeding WT and ObVDR-B6 
have similar body weights (Figure 4.1).  There are no significant changes in serum 
calcium and phosphate or bone turnover markers between WT and ObVDR-B6 at 3w 
of age or following short term LowCaP dietary feeding (Table 4.1). Serum 1,25D is 
increased in the 6w ObVDR-B6 mice with a trend for an increase of PTH (p = 0.07) 
and a decrease of FGF-23 (p= 0.1) (Mann Whitney tests).  
 
Femur length, total mineral content and segmental analyses of WT and ObVDR-B6 at 
3w are not significantly different (Figure 4.3. A, B, and C). However, after short term 
LowCaP feeding, femur length is decreased in ObVDR-B6 mice together with 
disruption of the growth plate compared to WT fed this diet without a change in total 
mineral content (Figures 4.2. B, 4.3. A and B). Segmental analyses of the full length 
femur (Figure 4.3. D) demonstrate site specific structural changes in ObVDR-B6 fed 
short term LowCaP diet apparent in the Faxitron images (Figure 4.2. A). Significant 
differences between WT and ObVDR-B6 are identified in segments 7 – 15 (distal 
metaphyseal region) and segments 23 – 31 (third trochanter region) (Figure 4.3. D). 
While cortical bone volume is unaltered with short term LowCaP diet, significantly 
thicker cortices in ObVDR-B6 mice arise from small non-significant variations of 
periosteal and endosteal perimeters (Table 4.2). Most importantly cortical porosity is 
markedly increased (20-fold) in ObVDR-B6 mice fed the LowCaP diet for 3w 









Figure 4.1. Body Weight of WT and ObVDR-B6 mice at Weaning (3w) and at 6w 
of Age Fed LowCaP.  
Values are Mean + SEM, n = 7/groups (at 3w) and 8/groups of the 6w LowCaP. 
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Table 4.1. Serum Biochemistry of WT and ObVDR-B6 Mice at 3w and 6w Old Fed LowCaP Diet for 3w 
 
 3w Old  6w Old Fed LowCaP Diet for 3w 
 WT ObVDR-B6  WT ObVDR-B6 
(n)  (7) (7)  (8) (8) 
Calcium (mmol/L)  3.00 ± 0.09 3.19 ± 0.13  
2.29 ± 0.04 
 
2.42 ± 0.09 
Phosphate (mmol/L)  2.69 ± 0.17 2.69 ± 0.15  1.93 ± 0.11 2.08 ± 0.20 
ALP (mmol/L)  771.97 ± 71.53 704.46 ± 78.41  859.04 ± 100.78 990.35 ± 85.49 
1,25(OH)D (pmol/L)  533.52 ± 125.82 385.81 ± 117.23  1351.55 ± 134.17 1870.66 ± 234.26* 
CrossLaps (ng/mL)  N/A N/A  72.29 ± 2.73 79.63 ± 2.30 
FGF-23 (pg/mL)  N/A N/A  92.26 ± 17.42 56.38 ± 8.41 
PTH (pg/mL)  N/A N/A  35.40 ± 14.18 165.26 ± 79.70 




3w Old 6w Old Fed LowCaP Diet for 3w 
       WT ObVDR-B6           WT ObVDR-B6 
A. Full length Long Bones (Femur)  
  
  
B. Transaxial Section of Growth Plate Region 
    
C. Transaxial Section of Distal Metaphysis Region  
    
D. Transaxial Section of Mid-shaft Point 
    
Figure 4.2. X-ray Images of  Whole Femora (A) and Micro-CT Transaxial 
Sections of  Growth Plate (B), Distal Metaphysis (C) and Mid-shaft (D) from WT 













Figure 4.3. Femur Length (A), Full Length Total Mineral Content (B), and Sub-
Regional Femoral Analyses of 3w Old (C) and 6w Old (D) Fed LowCaP Diet in 
WT and ObVDR-B6 Mice 
Values are mean + SEM, * P < 0.05 vs. WT mice, n = 7/groups for 3w and n = 8/groups 




Table 4.2. Cortical Parameters of Mid-shaft Region of Female 3w Old and 6w 
Old Fed LowCaP WT and ObVDR-B6 Mice 
 
 3w Old  6w Old Fed LowCaP  
 WT ObVDR-B6  WT ObVDR-B6 
(n)  (7) (7)  (8) (8) 
Cort. BV (mm3)  0.74 ± 0.03 0.68 ± 0.12  0.62 ± 0.02 0.66 ± 0.04 
Cort.Th (μm)  113.18 ± 3.52 117.29 ± 3.52  126.07 ± 2.88 147.04 ± 4.82* 
Ps.Pm (mm)  4.17 ± 0.08 4.37 ± 0.09*  4.79 ± 0.04 4.83 ± 0.07 
Es.Pm (mm)  3.46 ± 0.06 3.64 ± 0.08*  4.02 ± 0.03 3.94 ± 0.07 
Porosity (%)  N/D N/D  0.0047 ± 0.0047 0.0952 ± 0.0432* 
Values are mean + SEM, * P < 0.05 vs. WT mice within same group. Cortical Bone 
volume, (Cort.BV); Cortical thickness. (Cort.Th); Periosteal perimeter (Ps.Pm); and 




Trabecular bone analyses at the femoral distal metaphysis and vertebra-L1 
demonstrate significant increases in trabecular bone volume due to increased 
trabecular number with decrease of trabecular thickness and almost double 
connectivity density in ObVDR-B6 even when fed the LowCaP diet for 3 weeks 
(Table 4.3). Trabecular separation is unchanged in distal metaphysis but is decreased 





Table 4.3. Trabecular Bone Analyses of Femoral Distal Metaphysis and Vertebral 
Body of L-1 of 6w Old Mice Fed LowCaP Diet for 3w 
  Femoral Distal Metaphysis  Vertebra Body L-1 
 WT ObVDR-B6  WT ObVDR-B6 
(n)  (8) (8)  (8) (5) 
L-1 Height (mm)  N/A N/A  2.34 ± 0.04 2.29 ± 0.03 
BV/TV (%)  3.27 ± 0.15 4.37 ± 0.41*  11.01 ± 0.22 12.95 ± 0.71* 
Tb.Th (μm)  51.10 ± 0.86 47.57 ± 0.84*  34.53 ± 0.39 32.91 ± 0.60* 
Tb.N (1/mm)  0.64 ± 0.03 0.92 ± 0.09*  3.18 ± 0.05 3.95 ± 0.25* 
Tb.Sp (μm)  755.4 ± 20.7 736.8 ± 33.2  182.4 ± 3.8 163.3 ± 11.2* 
Conn.D (1/mm3)  14.95 ± 1.02 37.65 ± 4.38*  334.1 ± 25.5 620.8 ± 112.4* 
SMI   2.28 ± 0.02 2.18 ± 0.05  2.12 ± 0.04 2.14 ± 0.04 
Values are mean + SEM, * P < 0.05 vs. WT mice within same group. Trabecular Bone 
Volume (BV/TV), Trabecular Thickness (Tb.Th), Trabecular Separation (Tb.Sp), 
Structural Model Index (SMI), Connectivity density (Conn.D). 
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4.3.2. Effects of Transgenic Over-expression of VDR in Mature Osteoblasts Fed 
NormCaP and LowCaP Diets for Long Term (17w) 
Body weights of WT and ObVDR-B6 mice fed NormCaP and LowCaP diet for 17w 
show no significant differences between groups from the start of treatment until 20w 
of age (Figure 4.4. A and B). When fed NormCaP, there are no significant changes in 
serum calcium, phosphate, CrossLaps, TRAP5b, or 1,25D levels between WT and 
ObVDR-B6 but serum FGF-23 levels are significantly lower with decreased 
CrossLaps/TRAP5b ratio in ObVDR-B6 mice. Long term LowCaP feeding 
significantly increases the serum ALP, CrossLaps, TRAP5b, 1,25D and FGF-23 levels 
in WT and/or ObVDR-B6 mice. Between genotype analyses of WT vs ObVDR-B6 
mice on LowCaP diet indicated no significant differences in serum levels of calcium, 
phosphate, ALP, Crosslaps, TRAP5b and CrossLaps/TRAP5b ratio (Table 4.4). 
Serum 1,25D levels are significantly higher in ObVDR-B6 while serum FGF-23 levels 
are significantly lower than the WT mice. Changes in serum PTH between NormCaP 
and LowCaP diet or between genotype were not detected, likely due to technical errors 
during serum storage or PTH analyses (data not presented). 
 
Bone images are depicted in Figure 4.5 indicating no detectable differences between 
WT and ObVDR-B6 fed NormCaP. However, flat bones (scapula) and femora show 
distinct changes in skeletal structures when ObVDR-B6 mice are fed LowCaP diet. 
The scapula of LowCaP fed ObVDR-B6 mice are smaller, narrower and the structure 
of the upper curve is changed relative to the other groups (Figure 4.5. A). Femur length 
is obviously decreased with the LowCaP feeding in both groups but the changes are 
more marked in the distal metaphysis region and marked widening of the femur 




is disrupted in ObVDR-B6 mice fed LowCaP diet with obvious increased cortical 
porosity in the distal metaphysis (Figure 4.5. C and D). Trabecular bone at the femoral 
distal metaphysis and vertebra is increased in ObVDR-B6 mice compared to the WT 
mice fed the same diet although more marked at the vertebra than the metaphysis and 
even when fed LowCaP (Figure 4.5. E and F). Cortical bone at the femoral mid-shaft 
was largely intact although ObVDR-B6 mice fed LowCaP demonstrated increased 
resorption surfaces compared to LowCaP fed WT  mice (Figure 4.5. G and H).  
 
Femur length is not significantly different in NormCaP fed mice (Figure 4.6. A) but 
total mineral content is increased in ObVDR-B6 mice (Figure 4.6. B) especially in the 
diaphyseal region of the femur (Figure 4.6. C). When fed LowCaP diet, femur length 
is significantly decreased in ObVDR-B6 compared to WT mice. Interestingly even 
with LowCaP diet, total mineral content of ObVDR-B6 mice remains higher than WT 
due to significant increases in almost all segments of the femur (Figure 4.6. B and D).  
 
Femoral mid-shaft cortical analyses show similar findings to the segmental analyses 
of femora (Table 4.5). A near significant increase of cortical bone volume (8 %, p = 
0.057) is observed on NormCaP fed ObVDR-B6 due to increased periosteal and 
endosteal perimeters suggesting a larger increase in the periosteal perimeter than the 
endosteal perimeter. Feeding the LowCaP diet reduces cortical volumes and 
thicknesses and reduces the effect of the VDR transgene on cortical bone volume. 
LowCaP fed ObVDR-B6 still have increased periosteal and endosteal perimeters. No 
porosity in the femoral mid-shaft is detectable in WT and ObVDR-B6 on NormCaP 
diet but cortical porosity is markedly increased in ObVDR-B6 mice fed LowCaP 







Figure 4.4. Body Weight at 20w (A) and Growth Chart during 17w of Dietary 
Treatment (B)  




Table 4.4. Serum Biochemistry of WT and ObVDR-B6 Mice Fed with NormCaP and LowCaP Diet for 17w (20w of age) 
 
 NormCaP  LowCaP 
 WT ObVDR-B6  WT ObVDR-B6 
(n)  (7) (7)  (7) (9) 
Calcium (mmol/L)  2.31 ± 0.05 2.26 ± 0.12  2.30 ± 0.09 2.24 ± 0.05 
Phosphate (mmol/L)  1.16 ± 0.05 1.28 ± 0.05  1.09 ± 0.14 1.01 ± 0.11 
ALP (mmol/L)(b,c)  124.04 ± 3.01 67.64 ± 12.29  274.03 ± 28.45 370.12 ± 57.30 
CrossLaps (ng/mL)(b)  21.69 ± 1.76 26.39 ± 2.77  36.39 ± 5.70 42.42 ± 3.34 
TRAP5b (ng/mL)(b)  4.51 ± 0.53 5.82 ± 0.36  7.52 ± 1.14 7.41 ± 0.51 
CrossLaps/TRAP5b  5.34 ± 0.99 4.53 ± 0.32*  4.91 ± 0.36 5.80 ± 0.42 
1,25(OH)D (pmol/L) (a,b,c)   182.35 ± 30.50 145.86 ± 8.56  872.82 ± 70.48 1345.5 ± 122.9* 
FGF-23 (pg/mL)(a,b)  358.97 ± 33.56 254.78 ± 30.63*  176.17 ± 25.14 105.91 ± 14.61* 
PTH (pg/mL)  189.96 ± 40.52 234.71 ± 54.66  165.85 ± 60.09 241.78 ± 56.98 
Values are mean + SEM, Two-way ANOVA significant at p < 0.05 for genotype (a), dietary (b), and interaction (c). * p < 




WT ObVDR-B6 WT ObVDR-B6 
A. X-ray Images of Flat Bone (Scapula)  
    




C. 3D Reconstruction of Growth Plate Region 
    
D. 3D Reconstruction of Distal Metaphysis Region 





E. 3D Reconstruction of Trabecular Bone at Distal Metaphysis 
    
F. 3D Reconstruction of Trabecular Bone at Vertebral Body of Lumbar-1 
    
G. 3D Reconstruction of Cortical Bone at Mid-shaft Region 
    
H. Transverse section at Mid-Point 
    
 
Figure 4.5 X-Ray Images of Flat Bone (Scapula) (A) and Long Bone (Femur) (B), 
3D Reconstruction of Growth Plate (C), Distal Metaphysis (D), Trabecular Bone 
(E and F), Cortical Mid-Shaft (F) and Transaxial Images at Mid-point (H) 













Figure 4.6. Femur Length (A), Full Length Femoral Mineral Content (B), and 
Femoral Segmental Bone Mineral Area (C) of WT and ObVDR-B6 Mice Fed 
NormCaP and LowCaP for 17w. 





Table 4.5. Cortical Variables at Femoral Mid-shaft Region of WT and ObVDR-
B6 Mice Fed NormCaP and LowCaP for 17w 
 
 NormCaP  LowCaP 
 WT ObVDR-B6  WT ObVDR-B6 
(n)  (7) (7)  (7) (9) 
Cor. BV (mm3)(b, c)  1.57 ± 0.06 1.70 ± 0.02  1.19 ± 0.03 1.22 ± 0.05 
Cor.Th (μm) (b)  237.12 ± 3.06 245.15 ± 2.43  183.77 ± 3.38 187.88 ± 4.38 
Ps.Pm (mm) (a,b,c)  5.34 ± 0.05 5.61 ± 0.03**  5.34 ± 0.08 5.86 ± 0.04* 
Es.Pm (mm) (a,b,c)  3.85 ± 0.04 4.09 ± 0.04*  4.19 ± 0.07 4.69 ± 0.06* 
Porosity (%)  N/D N/D  N/D 0.0213 + 0.0140 
Values are mean + SEM, Two-way ANOVA significant at p < 0.05 for genotype (a), 
dietary (b), and interaction (c). * p < 0.05 vs. WT mice,  = p < 0.05 vs. NormCaP 
within same genotype. Cortical Bone Volume (Cor.BV), Cortical Thickness (Cor.Th), 




Trabecular bone analyses at the femoral distal metaphysis of ObVDR-B6 fed 
NormCaP diet (Table 4.6) show a significant increase of trabecular bone volume due 
to increased trabecular number and improved connectivity density. Increased 
trabecular bone volume is still maintained by LowCaP fed ObVDR-B6 due to increase 
trabecular number. Feeding the LowCaP diet decreases trabecular bone volume, 
trabecular number and connectivity density and increase trabecular separation 
irrespective of genotype. Interestingly, structural model index (SMI) is decreased in 
ObVDR-B6 mice but unchanged by dietary treatment indicating that the number of 
trabecular parallel plates is increased by over-expression of the VDR gene in mature 
osteoblasts even under the conditions of high bone turnover resulting from the 
LowCaP diet. 
 
Similar to the finding of NormCaP fed ObVDR-B6 in the femoral distal metaphysis, 
trabecular bone volume in the vertebral body of L-1 is increased due to an increase in 
trabecular number and connectivity with a decrease in SMI indicating increased 
number of trabecular plates (Table 4.6). Interestingly, when fed LowCaP, the 
increased trabecular bone volume observed in distal metaphysis is lost in the vertebra 
although a decrease of trabecular separation is now apparent and the trabecular plates 
are preserved as indicated by the preservation of the decreased SMI. The LowCaP 
treatment decreases trabecular bone volume, trabecular number and connectivity 
density while increasing trabecular separation irrespective of genotype similar to 
effects on trabecular bone in the femoral distal metaphysis. The height of the vertebral 





Table 4.6. Trabecular Bone in Distal Metaphysis and Vertebral Body of L-1 after 
Long Term Dietary Treatment in WT and ObVDR-B6 Mice  
     DISTAL METAPHYSIS   
 
 NormCaP  LowCaP 
 WT ObVDR-B6  WT ObVDR-B6 
(n)  (7) (7)  (7) (9) 
BV/TV (%)(a,b)  3.15 ± 0.11 5.19 ± 0.42*  0.96 ± 0.15 1.98 ± 0.45* 
Tb.Th (μm)  49.40 ± 1.22 50.30 ± 0.41  53.59 ± 3.03 48.10 ± 4.39 
Tb.N (#/um) (a,b)  640.03 ± 24.88 1032.88 ± 83.52*  178.54 ± 23.86 377.89 ± 80.91* 
Tb.Sp (um) (b,c)  363.44 ± 6.38 313.77 ± 8.56  672.66 ± 30.29 866.82 ± 91.73* 
Conn.D (#/mm3)(a,b,c)  4.85 ± 0.70 20.54 ± 3.69*  1.13 ± 0.19 6.21 ± 1.35 
SMI(a)  2.75 ± 0.04 2.53 ± 0.05*  2.87 ± 0.06 2.50 ± 0.09* 
     VERTEBRA    
L-1 Height (mm)  2.78 ± 0.03 2.73 ± 0.04  2.80 ± 0.03 2.74 ± 0.03 
BV/TV (%)(a,b)  18.47 ± 0.94 22.12 ± 0.89*  8.92 ± 0.48 10.38 ± 0.59 
Tb.Th (μm)(b)  47.29 ± 0.49 48.86 ± 0.83  39.98 ± 0.48 40.80 ± 0.54 
Tb.N (#/mm)(a,b)  3.90 ± 0.18 4.53 ± 0.16*  2.23 ± 0.10 2.54 ± 0.14 
Tb.Sp (μm)(a,b)  200.48 ± 5.03 180.54 ± 6.27  300.34 ± 10.07 275.08 ± 8.97* 
Conn.D (#/mm3) (a,b,c)  269.83 ± 24.38 394.34 ± 23.27*  194.00 ± 19.51 236.43 ± 30.39 
SMI (a)  1.45 ± 0.06 1.28 ± 0.06*  1.58 ± 0.06 1.53 ± 0.08* 
Values are mean + SEM, Two-way ANOVA significant at p < 0.05 for genotype (a), 
dietary (b), and interaction (c). * p < 0.05 vs. WT mice,  = p < 0.05 vs. NormCaP 
within same genotype. Trabecular Bone Volume (BV/TV), Trabecular Thickness 
(Tb.Th), Trabecular Separation (Tb.Sp), Structural Model Index (SMI), Connectivity 
density (Conn.D).  
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Histology of the distal femora confirmed the disruption of growth plate in the ObVDR-
B6 mice fed LowCaP as indicated by changes in growth plate width and growth plate 
area compared to WT fed the same diet or ObVDR-B6 fed NormCaP (Figure 4.7). 
Masson trichrome stain indicates growth plate (in green) in m-shape feature which was 
clearly disrupted in the ObVDR-B6 mice fed LowCaP diet.  
 
Dynamic histomorphometry at this site shows distinct double fluorochrome labels in 
trabecular and cortical bone indicating normal mineralisation and no evidence of 
osteomalacia. No significant changes in bone formation rate between WT and 
ObVDR-B6 fed NormCaP is detected (Table 4.7, Figure 4.8). MS/BS and MAR are 
not significantly different between WT and ObVDR-B6 fed NormCaP. TRAP stain 
analyses demonstrate a significant decrease of osteoclast number per bone perimeter 
and a trend toward decrease (p = 0.0612) in osteoclast attachment surface (Oc.S/BS) 
between WT and ObVDR-B6 fed NormCaP diet (Table 4.7, Figure 4.9). The distal 
metaphyseal region was not suitable for dynamic histomorphometry in mice fed 
LowCaP because there was too little trabecular bone available for meaningful 
measurements. Osteocyte density in the cortical region of distal metaphysis shows no 


















Figure 4.7. Histological Assessment of Growth Plate Width (A), Area (B) and 
Images of Masson Trichrome Stains of WT and ObVDR-B6 Mice after Long 
Term Dietary Treatment  
M shape in green illustrates the growth plate, at 20x magnification. The ObVDR-B6 
growth plate is visually disrupted. Values are mean + SEM, * p < 0.05 vs. WT, # p < 




WT ObVDR-B6 WT ObVDR-B6 
A. Full Sagittal Sections Fluorochrome Labels (20X Magnification) 
    
B. Fluorochrome Labels at Cortical Area of Distal Metaphysis (100X Magnification) 
    
C. Fluorochrome Labels at Trabecular Area of Distal Metaphysis (200X Magnification) 
    
Figure 4.8. Images of Double Fluorochrome Labels at Full Section (A), Cortical 
Region (B) and Trabecular Region (C) of WT and ObVDR-B6 Mice Fed 
NormCaP and LowCaP for 17w. 
At 20x magnification, growth plate disruption is evident in ObVDR-B6 fed LowCaP. 
Distinct double labels are evident in all bones indicating normal mineralisation even 
when fed LowCaP and irrespective of genotype. In the cortices at 100x magnification, 
increased cortical porosity in distal metaphysis region near growth plate is evident in 
ObVDR-B6 fed LowCaP. Although trabecular bone is scarce in the LowCaP fed 





WT ObVDR-B6 WT ObVDR-B6 
A. Full Sagittal Sections TRAP-Stain (20X Magnification) 
    
B. TRAP Stain at Growth Plate Region (100X Magnification) 
    
C. TRAP Stain at Cortical Region Distal Metaphysis (100X Magnification) 
    
D. TRAP Stain at Trabecular Region Distal Metaphysis (100X magnification) 
    
Figure 4.9. Images of Tartrate-Resistant Acid Phosphatase (TRAP) Stain at Full 
Sagittal Sections (A), Growth Plate Region (B), Cortical Region (C), and 
Trabecular Region of Distal Metaphysis (D) of WT and ObVDR-B6 Mice Fed 
NormCaP and LowCaP for 17w 
Growth plate disruption is evident in ObVDR-B6 fed LowCaP. Cortices at 100X 
magnification indicate increased cortical porosity in the distal metaphysis region near 
the growth plate in ObVDR-B6 fed LowCaP with TRAP +ve cells evident.  
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Table 4.7. Trabecular Dynamic Histomorphometry at the Femoral Distal 
Metaphysis of WT and ObVDR-B6 Mice Fed NormCaP for 17w. 
 
 NormCaP  LowCaP 
 WT ObVDR-B6  WT ObVDR-B6 
Double Label (n)  (7) (7)    
MS/BS (%)  43.09 ± 1.94 41.51 ± 1.24  N/A N/A 
MAR (μm/day)  2.21 ± 0.12 2.28 ± 0.10  N/A N/A 
BFR/BS (µm2/µm/d)  0.94 ± 0.05 0.94 ± 0.05  N/A N/A 
TRAP +ve cells (n)  (7) (7)    
Oc.Ar (mm2)  0.0105 ± 0.0014 0.0107 ± 0.0017  N/A N/A 




9.27 ± 0.55 7.07 ± 0.50* 
 
N/A N/A 
Values are mean + SEM, * p < 0.05 vs. WT mice. Mineralising Surface/Bone Surface 
(MS/BS), Mineral Apposition Rate (MAR), Bone Formation Rate (BFR), Total 
Osteoclasts Area (Oc.Ar), Osteoclasts attachment surface or Osteoclasts Surface/Bone 














Figure 4.10. Osteocytes Density of WT and ObVDR-B6 Mice Fed after Long 
Dietary Treatment and Images of Toluidine Blue Staining on Cortical Regions. 
Images of the distal metaphyseal cortices for osteocyte density measurements at 100x 




Messenger RNA levels of a range of target genes show significant reduction of Rankl 
mRNA in ObVDR-B6 fed NormCaP in comparison to WT with no significant 
differences detectable for the other genes (Figure 4.11. A to J). The LowCaP diet 
decreased Sost, and Dmp-1 mRNA levels in WT compared to NormCaP levels while 
in ObVDR-B6, the LowCaP significantly increased Rankl, Rankl/Opg mRNA ratio 
and Dmp-1 mRNA levels compared to WT on this diet.  
 
No significant changes of mRNA levels were detected for genes coding for vitamin D 
metabolising enzymes or FGF-23-responsive genes in the kidneys of WT and ObVDR-
B6 fed NormCaP (Figure 4.12. A to D). However, when fed LowCaP, a significant 
increase in Cyp27B1 mRNA levels in both WT and ObVDR-B6 mice with a trend 
towards a greater increase in ObVDR-B6 mice compared with WT were observed. WT 
mice increased Cyp24 mRNA levels increased with LowCaP but there was no increase 
in ObVDR-B6 mice fed LowCaP. The NaPi2 gene mRNA levels were unaffected by 
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Figure 4.11. Tibial Gene Expression of WT and ObVDR-B6 Mice Fed NormCaP 
and LowCaP for 17w (20w old mice) 









Figure 4.12. Kidney Gene Expression of WT and ObVDR-B6 Mice after Long 
Term Dietary Treatment. 







4.4.1. Effect of Short Term Dietary LowCaP Treatment 
Tailing at 10 days of age showed the expression of human Vdr transgene, however, at 
weaning (3w of age), no significant differences between WT and ObVDR-B6 were 
found for most of the measured variables suggesting that mature osteoblast VDR had 
only minor activities during foetal and neonatal growth. However, these ObVDR-B6 
weanling mice did have increased mid-shaft cortical size arising from increased 
cortical perimeters compared to WT suggesting some role for VDR in mature 
osteoblasts to modulate bone size even at this very early age. Further analyses of gene 
expressions at foetal, neonatal and weaning are needed to confirm the exact period 
during the development that the Vdr transgene has been over-expressed and started 
elicit its effect on bone. 
 
Foetal and neonatal bone health is largely determined by the mother’s nutritional status 
including calcium and vitamin D intakes (176). The role of VDR in mature osteoblasts 
during pregnancy and lactation in maintaining mother’s and infant’s skeletal health is 
poorly understood. Current knowledge emphasises the role of vitamin D to stimulate 
osteoclastic-bone resorption through modulation of the RANKL/RANK/OPG system 
contributing to the regulation of bone modeling and remodeling (177). Increased 
periosteal and endosteal perimeters observed in ObVDR-B6 mice at 3w of age 
suggested a role of osteoblast VDR in increasing bone resorption at the endosteal 
surface as well as increasing bone formation at the periosteal surface although direct 
measurements of the osteoclasts using histomorphometry analyses were not conducted 
on these surfaces. During bone modelling, increased mineral accrual and expansion of 
the periosteal and endosteal perimeters changes bone size, shape (178) and increasing 
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bone strength (179). Transgenic expression of human Vdr gene in osteoblasts 
consistently demonstrated increased cortical bone in male and female during growth 
and adulthood as reported and discussed in chapter 3. These data indicated that such 
activities commenced at the earliest stages of growth since the expression of transgenic 
hVdr gene was shown at 10 days of age. 
 
Very young, actively growing mice, irrespective of genotype, maintained normal 
serum calcium and phosphate levels when fed LowCaP for 3 weeks indicating that 
plasma mineral homeostasis was adequate irrespective of osteoblast VDR status. 
However in ObVDR-B6 mice, this homeostasis increased the serum 1,25D levels with 
a trend towards increased serum PTH levels and decreased serum FGF-23 levels. 
These data suggest that osteoblast VDR contributed to the endocrine feedback loop 
regulating serum PTH, 1,25D and FGF-23 contributing to mineral homeostasis and 
skeletal structure particularly when stressed by low dietary calcium and phosphate 
intakes even during pre-pubertal growth over the short-term period.  
 
At the end of short term LowCaP treatment, femur length was decreased in ObVDR-
B6 mice compared to WT mice fed the same diet although the full length femoral 
mineral content was similar suggesting a VDR transgene effects to reduce bone growth 
but not overall mineral accrual. Reduced bone growth was associated with the 
disrupted growth plate. The osteocalcin promoter used to drive the expression of the 
VDR transgene was expressed in the growth plate, especially in young mice, as well 
as in mature bone (180). Segmental analyses adjusted for femur length revealed that 
the bones from LowCaP fed WT mice had similar shape and mineral distribution to 




in figure 4.6. C and D unlike ObVDR-B6 femora. Thus, prepubertal WT mice were 
capable of maintaining femoral bone structure during short term LowCaP diet in 
contrast to ObVDR-B6 femora in which the structure was disrupted. This outcome was 
possibly due to the effects of high serum 1,25D and increased VDR expression on the 
growth plate, affecting the development and formation of cortical and trabecular bone 
in the femoral distal metaphysis. Idelevich et al. in 2011 (127) demonstrated the 
negative effects of 1,25D on growth plate and bone development using short term 
consecutive and long term intermittent injections of 1,25D in rats. Treatment with 
1,25D increased chondrocyte proliferation, altered chondrocyte maturation, and 
induced apoptosis of the terminal hypertrophic cells with reduced cortical thickness 
and increased cortical porosity as indicated by micro-CT structural analyses. Thus the 
LowCaP diet had similar effects to 1,25D injection with WT mice demonstrating mild 
cortical porosity. The transgenic overexpression of VDR in mature osteoblasts further 
enhanced the effects of LowCaP diet on cortical porosity.  
 
Interestingly, even when fed the LowCaP diet, the transgenic VDR expression in 
mature osteoblasts had increased cortical thickness and maintained increased femoral 
trabecular bone volumes compared to WT mice as observed in ObVDR-B6 mice 
during growth (see female 9w group in chapter 3). The increased trabecular bone 
volume in the ObVDR-B6 mice was due to increased trabecular number and thickness 
suggesting both effects to increase bone formation and reduce resorption. Further 





4.4.2. Effect of Long Term Dietary NormCaP and LowCaP Treatments 
ObVDR B6 mice fed either the NormCaP or chow diet until 20w of age confirmed the 
improved cortical structural changes as described in Chapter 3. Femoral total mineral 
content, periosteal perimeter and endosteal perimeter were increased consistent with 
the increased strength of bones from these mice as reported in Chapter 3. Feeding the 
slightly higher calcium/phosphate diet than chow (NormCaP had 1 % Calcium and 
0.625 % Phosphorus) demonstrated increased trabecular BV/TV in distal femoral 
metaphysis and vertebrae compared to the WT mice which were not detected in the 
chow diet (see female 20w group in chapter 3). Trabecular bone volumes were 
increased with marked increased trabecular number and conectivity and decreased 
trabecular separation. Interestingly the SMI also decreased which indicated a larger 
ratio of trabecular plates to rods, a change likely to increase bone strength. These data 
suggest that VDR in mature osteoblast interacted with adequate dietary calcium and 
phosphate levels to preserve and improve cortical and trabecular bone compartments. 
Improvement of bone mineral content, increased bone mineral density (BMD) and 
vertebral calcium content in aging rats (181) and trabecular bone volume in mice (182) 
had been reported with increased dietary calcium intake and adequate vitamin D diet. 
Therefore, overall data on NormCaP groups were consistent with previous findings. 
 
The major question here is the mechanism by which increased osteoblast VDR can 
elicit this increase in bone mineral accrual. The structural changes to trabecular bone 
were consistent with a reduction in bone resorption. No major effects on serum 
calcium, phosphate, CrossLaps, Trap5B, 1,25D or PTH levels were observed in 
ObVDR B6 mice, although a significant decrease in serum CrossLaps/Trap5B ratio 




osteoclast activity. Histological analyses for osteoclasts with TRAP staining 
demonstrated a significant decrease of the number of osteoclasts per bone surface 
(N.Oc/B.Pm) and a trend towards a decrease in osteoclast attachment surface 
(Oc.S/BS). These changes were associated with lower Rankl mRNA levels in bone. 
Collectively, these data indicated that increased VDR in mature osteoblasts may 
reduce bone resorption in trabecular bone confirming previous in vitro data (37) which 
may contribute to the increased bone mineral volume and strength. These data also 
confirmed that an adequate vitamin D status combined with adequate dietary calcium 
can reduce bone Rankl mRNA levels and osteoclast surface while increasing trabecular 
bone volumes in rats (154). 
 
Bone formation parameters assessed as double fluorochrome labels at the femoral 
metaphyseal trabecular bone region showed no significant differences between WT 
and ObVDR-B6 mice. A previous study on OSVDR mice demonstrated an increase in 
periosteal bone MAR with increase of tibial and femoral diameters (36). The structural 
changes to cortical bone, particularly the increase in periosteal perimeter at the femoral 
mid-shaft of the ObVDR-B6 mice, were consistent with an increase in bone formation 
suggesting similar process to that of the previous study. 
 
A further factor which can modulate bone mineralization is the FGF-23/FGFR system 
which links the bone-kidney axis through regulation of the renal handling of phosphate 
and renal synthesis of 1,25D (144). Serum FGF-23 was significantly reduced and 
lower bone Fgf-23 mRNA expression was observed in the NormCaP fed ObVDR-B6 
compared to WT. These data suggested that VDR activities in mature osteoblasts may 
inhibit FGF-23 production by a mechanism which is not fully understood. Phosphate 
126 
 
is a key component of hydroxyapatite (HA) and is essential for calcium deposition 
within mineralised tissue (183). Seeding of hydroxyapatite (HA) within the collagen 
fibrils is regulated by propagators and inhibitors of calcification including inorganic 
phosphate (Pi) and inorganic pyrophosphate (PPi). Therefore, Pi/PPi homeostasis 
plays a critical role in biomineralisation (184).  
 
Long term LowCaP treatment exerted a considerable stress on mineral homeostasis in 
WT and ObVDR-B6 mice as indicated by significantly increased serum CrossLaps, 
TRAP5b, ALP and 1,25D levels although the high bone turnover was able to maintain 
normal serum calcium and phosphate levels. Serum FGF-23 levels were decreased 
with the LowCaP diet presumably as a result of the very low phosphate content since 
dietary phosphate regulates serum FGF-23 level (160,185). Changes to PTH levels 
with LowCaP diet were unable to be detected unlike the the short term LowCaP diet 
study, possibly due to technical errors with multiple freeze thawing of the serum 
specimen during storage. Serum PTH is known to be influenced by storage 
temperature, repeat freeze-thaw and is relatively unstable compared to the EDTA-
plasma samples (186) which may play a role in the unchanged PTH levels on the long 
term LowCaP fed study. 
 
Significant structural changes to cortical and trabecular bone compartments were 
elicited with LowCaP diet. The high bone turnover state reduced cortical bone volume 
and cortical thickness and increased endosteal perimeter. Trabecular bone volumes 
were markedly reduced at the femoral distal metaphysis and vertebral body of L-1 with 
a greater than 50 % reduction in BV/TV as a result of 3-fold reduction of trabecular 




The changes in the vertebra were not as marked as in the femoral metaphysis although 
they achieved statistical significance. 
 
The ObVDR-B6 mice fed long term LowCaP diet demonstrated remarkable structural 
changes throughout the skeleton with marked changes to both long and flat bones 
indicating the effects of over-expression of VDR in osteoblasts on intramembranous 
and endochondral bone formation during growth. As an example, scapula are 
illustrated in figure 4.5. The ObVDR-B6 scapula was smaller than the WT with an 
abnormal edge suggesting a defect in bone modelling under these conditions. 
Decreased femur length, disorganised growth plate, cortical splaying and pronounced 
intra-cortical porosity were all observed in ObVDR-B6 mice fed LowCaP diet 
compared to WT fed the same diet. Interestingly, these bone changes occurred without 
hypocalcaemia, or hypophosphatemia which indicated maintenance of serum calcium/ 
phosphate through high bone turnover. Most importantly, the clearly defined double 
fluorochrome labels illustrated in figure 4.8 demonstrated that mineralization was 
unimpaired under these conditions in both WT and ObVDR-B6 mice. Therefore, the 
structural changes did not appear to be the result of a mineralization defect and warrant 
further investigations. 
 
A major question arising from these findings is why do increased osteoblast VDR 
activities, arising from increased VDR levels, disrupt bone structure during growth? 
As stated above, markers of bone turnover including serum ALP and CrossLaps were 
increased similarly in WT mice. Interestingly, the increase in serum 1,25D levels in 
ObVDR-B6 mice on the LowCaP diet was some 50 % greater than WT mice on this 
diet reaching some 1.8 nM, almost 10-fold greater than with the NormCaP diet. While 
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serum FGF-23 levels was decreased in both genotypes on the LowCaP diet, the 
significant decrease in the OBVDR-B6 mice compared to the WT was maintained. 
These data confirmed the endocrine impact of mature osteoblast VDR on serum FGF-
23 levels and suggested that on the LowCaP diet, the difference in serum FGF-23 
levels was sufficient to elicit a significant difference in serum 1,25D levels and 
markedly increased the endocrine activities of 1,25D in the ObVDR-B6 mice 
compared to WT mice.  
 
One likely consequence of this increased level of 1,25D and osteoblast VDR was the 
increased Rankl mRNA levels in ObVDR-B6 bone compared to WT on LowCaP diet 
and compared to the NormCaP diet, unlike WT for which there was no detectable 
change. There was also an increased ratio of Rankl/Opg mRNA levels in the ObVDR-
B6 bones. It is likely that these changes were responsible for increased osteoclast 
surface and the number of osteoclasts per bone perimeter compared with the ObVDR-
B6 fed NormCaP diet. The actual change that occurred with the ObVDR-B6 mice was 
that on the NormCaP diet these osteoclast variables were reduced compared to WT 
while on the LowCaP diet ObVDR-B6 they were increased. Therefore, with adequate 
dietary calcium and phosphate, VDR in mature osteoblasts reduces osteoclastogenesis 
through reducing expression of bone Rankl mRNA while under low dietary 
calcium/phosphate intakes, VDR in mature osteoblasts increases Rankl mRNA to 
enhance bone resorption thus maintaining serum calcium/phosphate levels. These data 
support the concept that the mature osteoblast VDR contributes to plasma calcium and 
phosphate homeostasis with effects on bone mineral homeostasis and that over-
expression of the human Vdr gene under the control of the human osteocalcin promoter 





Osteocytes are major targets for hormonal control of bone remodelling. The osteocyte 
specific deletion of the mouse Rankl gene using the Dmp1-Cre model demonstrated a 
blunted response in bone Rankl expression and failure to increase osteoclasts number 
during short term low dietary calcium (187). These data indicated that mature 
osteoblasts/osteocytes were the main source of Rankl expression and regulation of 
bone resorption with low dietary calcium. Our data demonstrated increased cortical 
porosity in the distal metaphysis and in mid-shaft regions of the ObVDR-B6 mice fed 
LowCaP diet suggesting that increased mature osteoblast/osteocyte VDR initiated the 
increased bone resorption by osteocytes. Since osteocyte density in this cortical region 
was unaffected by dietary calcium/phosphate or genotype, it can be inferred that 
increased bone resorption was the major cause of cortical porosity and not osteocyte 
death or apoptosis. Assessment of the osteocyte lacunae structure and size would be 
beneficial to evaluate the possibility of osteocytic osteolyses in the formation of 
cortical porosity of the ObVDR-B6 mice fed LowCaP diet. 
 
Higher serum 1,25D levels in LowCaP fed mice on both genotypes were associated 
with increased kidney Cyp27B1 mRNA in ObVDR-B6 mice suggesting increased 
renal synthesis of 1,25D and providing a source for their higher serum 1,25D levels. 
Furthermore, ObVDR-B6 mice fed LowCaP diet had significantly lower kidney Cyp24 
mRNA expression compared to the WT indicating reduced catabolism of 1,25D 
contributed to the increased serum 1,25D levels.  
 
These data are consistent with the lower serum FGF-23 in ObVDR-B6 mice as this 
hormone decreases renal Cyp27B1 and increases renal Cyp24 expressions. Lower 
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expression of bone Fgf23 mRNA level strengthened the evidence of decreased serum 
FGF-23 in ObVDR-B6 mice. The significantly increased Dmp-1 mRNA levels in the 
ObVDR-B6 mouse bone was a possible contributor to the reduced Fgf23 mRNA since 
the DMP-1 protein inhibits the production of bone FGF-23. DMP-1 is critical for 
mineralization of bone mineral. In undifferentiated osteoblasts, DMP-1 regulated the 
expression of osteoblast-specific genes while in mature osteoblasts, it is 
phosphorylated and exported to extra-cellular matrix and orchestrates mineralized 
matrix formation (188). Endocytosis of DMP-1 has been shown to increase 
intracellular free calcium, induces Runx2 expression and regulates osteoblast 
differentiation (189). However, an in-vitro study on murine cementoblasts (OCCM-
30) and osteocyte-like cells (MLO-Y4 and MLO-A5) on the effects of 1,25D on Dmp1 
expression demonstrated a decrease in Dmp1 mRNA levels via VDR dependent 
mechanism (190). The mechanisms by which DMP-1 regulates FGF-23 expression is 
poorly understood and several mechanisms have been proposed including modulation 
of FGF Receptor-1 signaling (144), DMP-1 as a transcription factor (188,191), 
changes in local extra-cellular matrix to stimulate FGF-23 production or interactions 
between PHEX/DMP-1 with unknown genes and proteins (190). The mechanism of 
this process and its interaction with dietary calcium intakes or extracellular calcium 
level is unknown and warrant further studies. 
 
This study has provided strong evidence on the delicate relationship between plasma 
calcium homeostasis, plasma phosphate homeostasis, bone mineral homeostasis and 
vitamin D activities involving both endocrine and bone autocrine/paracrine activities.  
Therefore, the ObVDR-B6 is a suitable mouse model for further studies on the 






This study demonstrated the effects of VDR activities in mature osteoblasts in mice as 
modulated by dietary calcium/phosphate. On a normal dietary calcium and phosphate 
intake, VDR in mature osteoblasts reduces bone resorption by direct effects on 
osteoclastogenesis combined with some indication of enhancement of periosteal bone 
formation, increasing cortical and trabecular bone volumes. With prolonged low 
dietary calcium/phosphate intakes, VDR in mature osteoblasts disrupted bone growth 
and stimulated bone turnover with increased cortical porosity, decreased trabecular 





CHAPTER 5: Vdr GENE ABLATION IN MATURE 
OSTEOBLASTS EXACERBATES SECONDARY 




Overexpression of VDR in mature osteoblasts increased bone resorption when 
ObVDR-B6 mice are fed very low dietary calcium/phosphate. Whether ablation of 
VDR in mature osteoblast has a protective effect during LowCaP treatment is 
unknown. To address this question, 3w old female VDRfl/fl as control mice and 
ObVDR-KO were fed 1 % Calcium / 0.625 % Phosphorus (NormCaP) or 0.03 % 
Calcium / 0.08 % Phosphorus (LowCaP) for 17 weeks (17w) whereupon they were 
culled and tissues were collected for analyses. In contrast to the ObVDR-B6 mice 
which gain trabecular bone with NormCaP diet, ObVDR-KO mice on this diet 
demonstrate no significant skeletal changes at 20w of age compared to the VDRfl/fl 
control. When fed LowCaP diet, ObVDR-KO mice have shorter femora, obvious 
splaying of metaphysis and very disturbed growth plate as a major clinical sign of 
rickets which also affects flat bones. Interestingly, the VDRfl/fl mice which are the 
control animals for this model are not identical to WT on LowCaP diet described in 
chapter 4. Overall, these data support a critical role of osteoblastic VDR activities in 
contributing to plasma calcium and phosphate homeostasis under conditions of 






VDR activities in osteoblasts contribute to bone mineral accrual and bone health which 
is dependent on the stage of maturation of the osteoblast (36,37,136,192). Mice in 
which the gene for VDR is over-expressed in mature osteoblasts (ObVDR-B6) have 
increased bone volumes when fed chow or NormCaP diet (Chapters 3 and 4) at 20w 
of age due to decreased bone resorption and possibly parameters indicating increased 
bone formation such as increased in periosteal circumference. However, when these 
mice are fed LowCaP diet, ObVDR-B6 exhibit increased bone turnover resulting in 
bone catabolism suggesting that the VDR in mature osteoblasts is contributing to the 
maintenance of plasma mineral homeostasis during periods of severe dietary calcium 
and phosphate restriction.  
 
The osteoblast-specific VDR knock out mouse model (ObVDR-KO) is a conditional 
knockout created using Cre-loxP system driven by the human osteocalcin promoter. 
This mouse model is the opposite of ObVDR-B6 mice. The ObVDR-KO mice were 
shown to have deletion of the VDR in calvarial and femoral bone but not in the liver, 
intestine and kidney (193) and shown to have increased trabecular BV/TV at 6w of 
age due to increased trabecular number (194). However, at 12w and 26w of age, there 
were no significant differences in the trabecular BV/TV between VDRfl/fl (control) and 
the ObVDR-KO mice suggesting an age specific activities of the VDR in mature 
osteoblast. The cortical bone phenotypes of the ObVDR-KO were not as pronounced 
as their trabecular bone phenotype. Female ObVDR-KO mice had increased cortical 
bone due significant expansion of periosteal perimeter at 6w but not at 12w or 26w of 
age (193). Gene analyses suggested that the absence of VDR in mature osteoblasts 
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contributed to the regulation of mRNA expression for genes regulating both bone 
formation and bone resorption to maintain bone volume (193,194). 
 
Since osteoblastic VDR contributes to maintain plasma calcium and phosphate 
homeostasis under conditions of severe dietary restriction, it was important to assess 
the effects of this condition on mice in which the VDR gene in mature osteoblasts is 
ablated and to test whether such ablation will interfere with the mobilization of calcium 




5.2.1. Animal Models, Housing, and Care 
The osteoblast-specific vitamin D-receptor knock out mouse model (ObVDR-KO) was 
generated using Cre-LoxP methods as described in Chapter 2, Section 2.3. Littermate 
VDRfl/fl control (ObVDRfl/flCre-) and ObVDR-KO (ObVDRfl/flCre+) mice were produced 
by mating the homozygous LoxP mice with osteocalcin-promoter driven-cre 
recombinase (OcnCre+/-) transgenic mice. Homozygous LoxP mice were determined 
by PCR and gel analyses of PCR product using VDRloxP forward primer 5’-CCT 
TGG TGA GCT GAG TTT ACT CTT-3’ and reversed primer 5’-CAG GAG TGG 
GAT TAC TGA TAT-3’. Products were 491kb of WT band and 575bp of VDR-lox 
band which splits into 145bp and 429bp products with EcoR1 digestion. Genotype 
were determined by the presence of universal Cre gene assessed using PCR analyses 
with a forward primer 5’-GCG GCA TGG TGC AAG TTG ATT-3’ and a reverse 





Mice were housed and maintained as described in Chapter 2, Section 2.3 and received 
free access to water and synthetic diets containing either 1 % calcium / 0.625 % 
phosphorus (NormCaP) (SF12-076, Specialty feeds, Glen Forrest, Western Australia) 
or 0.03 % calcium / 0.08 % phosphorus (LowCaP) (SF12-077, Specialty feeds, Glen 
Forrest, Western Australia) from weaning (3w) for 17w. Diets were formulated and 
designed as described in appendix section. At 8 and 2 days prior to death, calcein and 
xylenol orange fluorochrome labels were administered as described previously. 
 
At 20w of age, serum, right femur, and vertebrae were collected and stored as 
described in Chapter 2, Section 2.4 for micro-CT and histology analyses. Animal 
details and treatments were recorded in the clinical record sheets (CRS) in accordance 
the University of Adelaide Animal Ethics Committee for project number M-2012-092. 
 
5.2.2. Serum Biochemistry 
Serum calcium, phosphate, alkaline phosphatase, 1,25D, FGF-23, PTH, and 
CrossLaps levels were analysed as described in Chapter 2, Section 2.5.  
 
5.2.3. Micro-computed Tomography 
Microstructures of right femora were assessed using micro-CT system at 9 um/pixel 
(1076 Skyscan, Bruker, Germany) as described in Chapter 2, Section 2.6.1. The 
vertebrae were scanned on 6.5 um/pixel micro-CT system (1174 Skyscan, Bruker, 
Germany). Total mineral content and segmental slice analysis were measured on full 
length femora as described in Chapter 2, Section 2.6.4. Cortical bone volume and size 
analyses were conducted on the mid-shaft region constituting 10 % of the femur length, 
followed by a full femur segment analyses. Trabecular bone was analysed at the 
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femoral distal metaphysis and vertebral body of Lumbar-1 (VBL-1) as described in 
Chapter 2, Section 2.6.2. Bone measurements and quantification were performed in 
accordance to the micro-CT settings described in Chapter 2, Section 2.6.4.  
 
5.2.4. Dynamic Histomorphometry 
Femora were cut with a slow speed saw to reveal the metaphyseal area followed by 
graded-ethanol dehydration and embedding in methylmetacrylate as described in 
Chapter 2, Section 2.7.2. Sagittal sections, 5 μm thick, were cut using a motorized 
microtome (Leica 2255, Germany) and stained for Tartrate Resistant Acid- 
phosphatase (TRAP) analysis of the TRAP+ cells and Toluidine Blue (TolB) for 
osteocytes analyses in the cortical region of distal metaphysis as described in Chapter 
2, Section 2.7.4 and 2.7.5. Double label fluorochrome measures were measured on an 
unstained section as described in Chapter 2, Section 2.7.3 using Olympus Microscope 
(Olympus DP73 and Olympus BX 53) and OsteoMeasureTM morphometry system 
version 3.3.O.2 (Osteometrics, Atlanta, GA, USA).  
 
5.2.5. Statistical Analysis 
Two-way analysis of variance (ANOVA) was used to determine the contribution of 
diet and genotype on each of the variables. Least Significant Difference (LSD) post-
hoc analyses were used to identify group/s which achieved significant differences at 





Body weights of VDRfl/fl and ObVDR-KO fed NormCaP for 17w were not 
significantly different (Figure 5.1. A and B). The LowCaP fed ObVDR-KO mice 
were lighter than VDRfl/fl at 20w of age, an effect which was apparent from 6w of age 
 
When fed NormCaP diet, serum calcium, phosphate, CrossLaps, or 1,25D were not 
different between VDRfl/fl and ObVDR-KO while ALP was significantly lower in 
ObVDR-KO mice. The ObVDR-KO has higher levels of PTH (mean increase of 60%) 
but this difference did not reach statistical significance. LowCaP diet for 17w 
increased serum ALP, PTH, 1,25D, and CrossLaps levels with decreased serum 
phosphate and FGF-23 levels in VDRfl/fl and/or ObVDR-KO mice. 1,25D and PTH 
levels are significantly higher (3-fold and 2-fold, respectively) in ObVDR-KO mice 
compared to VDRfl/fl mice fed LowCaP diet while serum calcium, phosphate, ALP, 
FGF-23 and CrossLaps levels were not different between the mouse genotypes (Table 
5.1). 
 
Bone structures (Figure 5.2. A and B) reveal marked changes in both flat and long 
bones after 17w of LowCaP diet with ObVDR-KO revealing a greater level of 
disruption than VDRfl/fl mice. Significant bulging, thinning and bending of the scapula 
and femora were observed in the ObVDR-KO mice. Marked growth plate disruption 
is a common feature of ObVDR-KO mice when fed LowCaP diet accompanied by 
increased cortical porosity in the region of distal metaphysis and mid-shaft (Figure 
5.2. C,D and F). Trabecular bone volume reduction and thinning of the femoral 
cortices (Figure 5.2. E and F) were also observed in the VDRfl/fl group. Interestingly, 
amongst the VDRfl/fl mice fed LowCaP diet, I observed a greater interindividual 
variation of the above features ranging from no effects in some animals to clearly 








Figure 5.1. Body Weight at 20w (A) and Growth Chart (B) of the ObVDR-KO 
Mouse Model during Calcium/Phosphorus Restriction Study 
Values are mean + SEM, Two-way ANOVA significant at p < 0.05 for 
Genotype (a), dietary (b), and interaction (c).  Post Hoc LSD p < 0.05 vs. 




Table 5.1.  Blood Biochemistry of VDRfl/fl and ObVDR –KO Mice 
 
 NormCaP  LowCaP 
 VDRfl/fl ObVDR-KO  VDRfl/fl ObVDR-KO 
(n)  (8) (10)  (7) (13) 
Calcium (mmol/L)  2.47 ± 0.09 2.45 ± 0.08  2.34 ± 0.07 2.33 ± 0.13 
Phosphate (mmol/L)(b)  1.69 ± 0.11 1.56 ± 0.13  1.22 ± 0.17 1.25 ± 0.12 
ALP (mmol/L) (a,b)  187.56 ± 21.24 134.75 ± 7.65*  376.58 ± 123.39 504.74 ± 77.29 
1,25D (pmol/L)(a,b,c)  289.0 ± 118.2 236.6 ± 48.0  1070.8 ± 158.2 2936.9 ± 291.5* 
FGF-23 (pg/mL) (b)  334.2 ± 40.2 389.8 ± 16.4  177.4 ± 35.3 122.2 ± 23.4 
PTH (pg/mL) (b,c)  201.34 ± 40.7 325.20 ± 40.7  709.63 ± 486.5 1351.74 ± 375.1* 
CrossLaps (ng/mL) (a,b)  26.70 ± 1.70 27.65 ± 1.46  44.31 ± 4.22 51.66 ± 3.82 
Values are mean + SEM, Two-way ANOVA significant at p < 0.05 for Genotype (a), dietary (b), and interaction (c). Post 




VDRfl/fl ObVDR –KO VDRfl/fl ObVDR –KO 
A. X-Ray Images of Flat Bone (Scapula)  
    
B. X-Ray Images of Long Bone (Femur)  
    
C. 3D Reconstruction of Growth Plate Region 
    
D. 3D Reconstruction of Distal Metaphysis Region 





E. 3D Reconstruction of Trabecular Bone at Distal Metaphysis 
  
  
F. 3D Reconstruction of Trabecular Bone at VBL1 
    
G. Transverse section at Mid-Point 
    
H. Transverse section of Vertebral Body L-1 (VBL1) at Caudal region 
    
I. Transverse section of Vertebral Body L-1 (VBL1) 
    
Figure 5.2. X-Ray Images of Flat Bone (Scapula) (A), and Long Bone (Femur) 
(B), 3D Reconstruction of femoral Growth Plate (C), Distal Metaphysis (D), 
Trabecular Region at Distal Metaphysis (E) and VBL-1 (D), and Micro-CT 
Images of Transaxial Section of Femur at Mid-Point (F), Caudal (G) and Mid 
Region (H) of VBL1 Following Dietary Treatments in VDRfl/fl and ObVDR-KO 
mice.   
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Femur length and total mineral content are not significantly different between VDRfl/fl 
and ObVDR-KO mice when fed the NormCaP diet (Figure 5.3. A and B). When fed 
LowCaP diet, femur length is significantly decreased in both VDRfl/fl and ObVDR-KO 
compared to NormCaP fed mice within the same genotype and is further decreased in 
ObVDR-KO mice compared to the VDRfl/fl mice. Femoral segmental analyses showed 
no significant changes between VDRfl/fl and ObVDR-KO fed NormCaP diet (Figure 
5.3. C). However, when fed LowCaP diet, significant increases of bone volume in the 
distal metaphysis, third trochanter and femoral head regions were evident in ObVDR-
KO mice compared to VDRfl/fl mice (Figure 5.3. D) associated with an apparent 
increase of total mineral content (Figure 5.3. B).  
 
Measurement of total mineral content is dependent on total volume of the bone, 
therefore, the reduced femur length of OBVDR-KO mice influences this measurement. 
Comparison of bone mineral content with data presented in Chapter 4 indicate that, 
with NormCaP diet, WT and VDRfl/fl have similar structural features (Figure 5.3. E). 
However, when fed LowCaP, VDRfl/fl demonstrate minor but statistically significant 
structural changes in the distal metaphysis compared to WT mice (Figure 5.3. F). 
While the ObVDR-B6 mouse line has higher mineral content in every segment 
compared to the ObVDR-KO fed NormCaP (Figure 5.3. G), the LowCaP fed 
ObVDR-KO mice demonstrated pronounced structural changes in metaphyseal, third 
















Figure 5.3. Femur length (A), Total Mineral Content (B) and Segmental Analyses 
Adjusted for Femur Length of VDRfl/fl and ObVDR –KO mice on NormCaP (C) 
and LowCaP (D) and Comparison Between WT and VDRfl/fl (E & F) and 
ObVDR-B6 and ObVDR-KO (G & H) on NormCaP and LowCaP diet. 
Values are mean + SEM, * p < 0.05 for VDRfl/fl vs. ObVDR-KO within same diet. # p 
< 0.05 for NormCaP vs. LowCaP within the same genotype. Red arrows indicates 
segment analysed in figure 5.4. 
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Mid-shaft cortical bone volumes are not different amongst the two mouse genotypes 
on either diet but there is a significant reduction with LowCaP diet (Table 5.2). 
Cortical thickness was unaffected in ObVDR-KO mice fed NormCaP diet, however 
the cortical quality might be reduced due to the presence of cortical porosity. When 
fed LowCaP diet, the VDRfl/fl mice experienced a significant reduction in cortical 
thickness due to changes in endosteal perimeter. The cortical thickness of the ObVDR-
KO mice were unchanged due to maintenance of periosteal perimeter with decrease of 
endosteal perimeter suggesting that endosteal bone resorption was reduced in this mice 
on this diet. Increased cortical porosity is observed in ObVDR-KO mice when fed 
LowCaP diet compared to the NormCaP fed mice (Table 5.2), and this contributes to 





Table 5.2 Femoral Mid-shaft Region Cortical Analyses of VDRfl/fl and ObVDR-
KO Mice 
 
 NormCaP  LowCaP 
 VDRfl/fl ObVDR-KO  VDRfl/fl ObVDR-KO 
(n)  (8) (10)  (7) (13) 
Cor.BV (mm3)(b)  1.51 + 0.04 1.51 + 0.04  1.11 + 0.08 1.00 + 0.03 
Cor.Th (μm)(a)  224.39 + 4.64 233.43 + 3.25  192.84 + 3.87 230.98 + 12.29* 
Ps.Pm (mm)  5.55 + 0.06 5.48 + 0.05  5.55 + 0.05 5.61 + 0.09 
Es.Pm (mm)(a,b,c)  4.09 + 0.06 3.98 + 0.03  4.13 + 0.07 3.70 + 0.06* 
Porosity (%)  None detected 0.14 + 0.14  0.05 + 0.05 23.04 + 10.36* 
Values are mean + SEM, Two-way ANOVA significant at p < 0.05 for Genotype (a), 
dietary (b), and interaction (c). Post Hoc LSD * p < 0.05 for VDRfl/fl vs. ObVDR –KO 




Detailed analyses on three segments of femoral cortical bone were conducted to 
identify effects of genotype and diet on the following regions; 1) the proximal end of 
the distal metaphysis (segment 12), 2) the diaphyseal mid-shaft (segment 18) and 3) 
the distal section of third trochanter (segment 25). Images in figure 5.4 show distinct 
structural changes on these mice. When fed NormCaP diets, the cortical bone area, 
thickness and periosteal and endosteal perimeters are unaffected by ablation of the 
VDR gene in mature osteoblasts in all 3 analysed segments. However, when fed 
LowCaP diet, the ObVDR-KO mice exhibited massive cortical trabecularization at the 
distal metaphysis region as observed in segment 12, formation of the ‘bone fin’ as 
observed in segment 18 and structural changes with trabecularization of the third 
trochanter as observed in segment 25 (Figure 5.4). These changes contribute to the 
differences in cortical bone volume, thickness, and perimeters of each analysed 
segments.  
 
Distal femoral metaphyseal and vertebral trabecular bone volumes (Table 5.3) were 
comparable between VDRfl/fl and ObVDR-KO mice when fed the same diet with a 
marked reduction in both genotypes with LowCaP diet feeding. Trabecular bone loss 
occurred as a result of decreased trabecular number and connectivity with increased 
trabecular spacing concomitant with an increase in SMI, indicating a change from plate 
to rod-like structure. Each of these changes is consistent with features of increased 
bone resorption. There was an increase in trabecular thickness within the femoral 
metaphysis on LowCaP diet with significantly greater increase in the VDRfl/fl 
compared to the ObVDR-KO mice. In the L1-vertebrae analyses, trabecular thickness 





VDRfl/fl ObVDR –KO SEGMENT 12 
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LowCaP 
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Figure 5.4. Micro-CT Transaxial Images of VDRfl/fl and ObVDR-KO Mice on 
Femoral Diaphyseal Region of Segment 12, 18 and 25 (left side) and 
Quantification of Cortical Bone Volume, Cortical Thickness, Periosteal 
Perimeter and Endosteal Perimeter of Each Segments (right side) Respectively.  
Values are mean + SEM, * p < 0.05 for VDRfl/fl vs. ObVDR-KO within same diet. # p 
< 0.05 for NormCaP vs. LowCaP within the same genotype  
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 Table 5.3. Trabecular Analyses of VDRfl/fl and ObVDR-KO Mice 
 
 NormCaP  LowCaP 
 VDRfl/fl ObVDR-KO  VDRfl/fl ObVDR-KO 
(n)  (8) (10)  (7) (13) 
DISTAL METAPHYSIS    
BV/TV (%)(b)  5.25 ±0.57 4.96 ±0.24  1.81 ±0.27 1.77 ±0.32 
Tb.Th (μm)(b)  49.08 ±1.01 49.58 ±0.68  60.63 ±3.51 54.72 ±1.03* 
Tb.Sp (μm) (b)  318.81 ±11.74 308.59 ±5.08  823.37 ±79.04 942.88 ±44.08 
Tb.N (#/mm) (b)  1.07 ±0.12 0.999 ±0.04  0.30 ±0.05 0.32 ±0.06 
SMI(b)  2.53 ±0.04 2.56 ±0.02  2.60 ±0.11 2.62 ±0.11 
Conn.D (#/mm3)(b)  20.47 ±6.12 16.92 ±2.48  3.81 ±1.11 7.93 ±1.82 
VERTEBRAL BODY of L-1    
Height (mm)  2.98 ±0.04 2.88 ±0.03  2.92 ±0.06 2.92 ±0.04 
BV/TV (%)(b)  30.28 ±1.71 28.45 ±1.00  12.15 ±1.55 14.48 ±1.45 
Tb.Th (μm)(b)  49.76 ±0.21 47.75 ±0.53  43.14 ±1.22 42.38 ±0.99 
Tb.Sp (μm)(b)  141.77 ±11.20 154.41 ±7.20  259.27 ±26.46 236.84 ±15.32 
Tb.N (#/mm)(b)  6.08 ±0.33 5.97 ±0.23  2.81 ±0.32 3.43 ±0.34 
SMI(b)  1.00 ±0.08 1.00 ±0.08  1.66 ±0.05 1.67 ±0.10 
Conn.D (#/mm3)(b)  945.78 ±58.53 1066.79 ±105.72  442.12 ±64.17 684.57 ±155.73 
Values are mean + SEM, Two-way ANOVA significant at p < 0.05 for Genotype (a), 
dietary (b), and interaction (c). Post Hoc LSD * p < 0.05, **p < 0.001 for VDRfl/fl and 





Histology sections of the distal femora are presented in figure 5.4 and figure 5.5. 
Images of the cortical bones using fluorescence microscope show distinct double 
fluorochrome labels in all NormCaP fed mice (Figure 5.4. B). Dynamic 
histomorphometry analyses in the trabecular region of distal metaphysis showed no 
significant changes in bone formation parameters between VDRfl/fl and ObVDR-KO 
fed NormCaP diet (Table 5.4).  
 
The LowCaP fed VDRfl/fl mice demonstrated variation between distinct (3 of 7) and 
indistinct (4 of 7) double labels amongst individual mice indicating a possible variation 
in the degree of mineralisation defect amongst these mice. The fluorochrome labels in 
the ObVDR-KO mice fed LowCaP diet were extensive and all mice demonstrated 
indistinct and very blurred first label (calcein) with little or no evidence of the second 
label (xylenol orange) in the cortical region (Figure 5.4. B and C).  
 
Mice fed LowCaP diet show very little trabecular bone (Table 5.3). Histological 
images of TRAP stain demonstrated no significant changes in any osteoclast variables 
between VDRfl/fl and ObVDR-KO on NormCaP diet (Table 5.4). Average osteoclast 
size was increased in ObVDR-KO mice fed LowCaP diet and on observation from 
TRAP stain slides, TRAP(+) cells were found on the surface of cortices and inside the 
cortical pores (Figure 5.5. C)  
 
Interestingly, I observed a difference in bone marrow cellularity of the femoral distal 
metaphysis between VDRfl/fl and ObVDR-KO mice when fed LowCaP diet. In the 
bone marrow area of the VDRfl/fl mice, there were less cells (lower cellular density) 
with more adipocytes compared to the ObVDR-KO mice (Figure 5.6. C and D). 
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Future studies could utilise staining with sudan-3 or oil red-O which stain adipocytes 
to investigate this difference between the mouse lines.  
 
Analyses of the cortical region of the distal metaphysis showed no effect of genotype 
or dietary treatment on osteocyte density (Figure 5.7). Increased cortical porosity and 
possible increase in vascularisation of the cortices in the ObVDR-KO mice fed 
LowCaP diet were observed. This is shown by the segregation of cortical bones with 
structures that were different from the usual bone porosity appearance on histological 






VDRfl/fl ObVDR-KO VDRfl/fl ObVDR-KO 
A. Full Length Fluorochrome Label at 40X Magnification 
    
B. Fluorochrome at Cortical Region (200X Magnification) 
    
C. Fluorochrome at Trabecular Region (200X Magnification) 
    
 
Figure 5.5. Images of Double Fluorochrome Labels of VDRfl/fl and ObVDR-KO 
mice Fed NormCaP and LowCaP diet on a Full Section (A), Cortical Region (B) 





VDRfl/fl ObVDR-KO VDRfl/fl ObVDR-KO 
A. Full Sagittal Section of Distal Metaphysis at 40X Magnification 
  
  
B. TRAP stain Images at Growth Plate Region (100X Magnification) 
    
C. TRAP Stain Images at Trabecular Region (200X Magnification) 
    
D. TRAP Stain Images at Cortical Region (200X Magnification) 
    
 
Figure 5.6. Images of TRAP Staining in VDRfl/fl and ObVDR-KO Dietary Study 
at Full Sagittal Section (A), Growth Plate Region (B), Trabecular (C) and Cortical 





Table 5.4 Dynamic Histomorphometry Analyses of VDRfl/fl and ObVDR–KO 
Mice  
 
 NormCaP  LowCaP 
 VDRfl/fl ObVDR-KO  VDRfl/fl ObVDR-KO 




MS/BS (%)  34.56 ±1.17 34.47 ±1.86  32.33±5.86  Indistinct label  
MAR (μm/day)  1.75 ±0.05 1.82 ±0.09  1.93  ±0.16 Indistinct label 
BFR/BV (%/t)  3.18  ±0.16 3.37 ±0.33  4.02 ±0.53 Indistinct label 














Oc.S/BS (%)  23.86 ±2.96 28.01 ±1.61  23.95 ±4.88 28.0 ±5.48 
N.Oc/B.Pm (#/mm)  8.33 ±1.05 10.23 ±0.73  9.18 ±1.92 10.48 ±2.09 
 
Values are mean + SEM, Two-way ANOVA significant at p < 0.05 for Genotype (a), 
dietary (b), and interaction (c). Post Hoc LSD * p < 0.05, **p < 0.001 for VDRfl/fl and 
ObVDR –KO,  p < 0.05 for NormCaP vs. LowCaP within the same genotype. Total 
Osteoclast Area (Oc.Ar), Average osteoclast size (AveOc.Ar), Osteoclast attachment 














Figure 5.7. Osteocyte Density and Images of Toluidine Blue Staining at the 
Cortical Distal Metaphysis Region in VDRfl/fl and ObVDR –KO Mice. 
Marked cortical porosity is observed in distal metaphysis of ObVDR-KO fed LowCaP. 
Osteocyte arrangement of the LowCaP fed animals on observation look smaller with 






Inactivation of VDR in the mature osteoblastic lineage (ObVDR-KO) at 6w of age 
produced a marked increase in both femoral trabecular and cortical bone volumes 
compared to the control littermates, which by 12w and 26w of age was lost (194). As 
presented in this chapter, at 20w of age, ObVDR-KO and control mice fed the 
NormCaP diet demonstrated similar growth, femur length, femur cortical bone and 
trabecular bone volumes in femoral distal metaphysis and the vertebrae. There were 
no significant differences in the bone formation or bone resorption variables on 
dynamic histomorphometry analyses suggesting that deletion of VDR does not exert 
major effects on bone remodelling with adequate dietary calcium and phosphate.  
 
Serum analyses demonstrated no significant differences between VDRfl/fl and 
ObVDR-KO mice fed NormCaP diet except for the mean serum ALP levels which 
was significantly lower in ObVDR-KO mice. This result can be considered consistent 
with an effect of decreased bone formation in the young, growing mice remaning 
detectable at 20w of age because of the longer time frame for formation compared to 
resorption. The major finding at 6w ObVDR-KO mice was impaired RANKL-
mediated bone resorption coupled with decrease bone formation (194). Specific VDR 
deletion in osteoblasts using the Col1a1-cre recombinase mouse line produced an 
increase in male bone volume at 16w of age associated with decreased RANKL 
expression and osteoclast numbers suggesting impaired bone resorption (167) in 
osteoblast specific VDR ablated mice. 
 
The above findings are in contrast to those reported in chapters 3 and 4 for mice 
overexpressing the gene for VDR in mature osteoblasts (ObVDR-B6 mice), which 
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have stronger and bigger bones when fed a NormCaP diet throughout the ages. The 
ObVDR-B6 phenotype is the result of decreased bone resorption in trabecular bone 
and effects on cortical bone perimeters suggesting both reduction of bone resorption 
and increased bone formation. 
 
Under extreme dietary calcium/phosphate restriction for 17w, a very different 
phenotype is observed with a significant decreases in body weight, poorer weight 
accrual and reduction in growth rate for both LowCaP VDRfl/fl and greater decreases 
for ObVDR-KO mice compared with the NormCaP fed mice. Both VDRfl/fl and the 
ObVDR-KO mice fed LowCaP diet demonstrated reduced femur length, splayed 
metaphysis, abnormalities of the scapulae and changes to the 3rd trochanter structure 
with macroscopic features visible in 4 of 7 VDRfl/fl animals and all ObVDR-KO 
animals. 
 
Increased ALP, PTH, 1,25D, and CrossLaps with decreased phosphate and FGF-23 
serum levels were observed in all mice fed LowCaP diet. Significant increases of 
serum 1,25D and PTH levels in ObVDR-KO mice compared to VDRfl/fl on the 
LowCaP diet were also found. These findings suggest a major role for osteoblast VDR 
activity in contributing to the regulation of calciotropic hormone serum levels when 
dietary calcium and phosphate are limited. Normocalcaemia was maintained by both 
mouse genotypes on the LowCa/P diet but serum phosphate levels were decreased. 
Low serum phosphate is likely to reduce serum FGF-23 levels (96) which would 





The most interesting changes are the increased serum 1,25D and PTH levels which 
were 3-fold and 2-fold higher respectively in ObVDR-KO mice fed LowCaP diet. 
These findings indicate that when the Vdr gene is deleted in mature osteoblasts, plasma 
calcium/PTH/1,25D homeostasis is significantly impaired with some contribution 
from the plasma phosphate/FGF-23/1,25D axis. The data suggest a primary effect of 
raised serum PTH levels and a secondary effect of both the increased serum PTH levels 
and reduced serum FGF-23 levels to raise serum 1,25D levels. Therefore, the VDR 
activity in mature osteoblast is the key regulator for calciotropic hormones to maintain 
plasma calcium homeostasis under severe dietary calcium and phosphate restrictions.  
 
Under the LowCaP dietary conditions, ObVDR-KO mice demonstrated marked 
macroscopic and microscopic skeletal changes over and above those seen in VDRfl/fl 
controls (Figure 5.2) with significant changes in bone volume at 3 distinct femoral 
regions, the distal metaphysis, the third trochanter and the femoral head (Figure 5.3D). 
Microscopic analyses of these three regions indicate considerable cortical 
trabecularization. Thus, while cortical thickness in these regions was apparently 
increased due to a decrease of endosteal perimeter, the cortical bone mineral content 
remained constant due to the increase of cortical porosity in the ObVDR-KO mice. 
Micro-CT measurements are likely to be confounded because of the inability of the 
computer software to deal with immense pores occurring in the cortical bone; therefore 
results from these region must be interpreted with caution.  
 
Clearly the LowCaP diet markedly increases the calciotropic hormone levels and the 
osteoblast alkaline phosphatase indicating high bone turnover driven by high PTH 
levels in the ObVDR-KO mice. The high level of fluorochrome labels particularly 
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surrounding the cortical pores (Figure 5.5. B) and osteoclasts visible within the 
cortical pores (Figure 5.6. D) clearly illustrate the high bone turnover. The nature of 
the fluorochrome labels is intriguing. In the mice fed the NormCaP diet and in 3 of 7 
VDRfl/fl mice fed LowCaP diet, the labels are distinct and sharp indicating a healthy 
mineralization process. Indistinct labels were present in all ObVDR-KO and 4 of 7 
VDRfl/fl mice fed LowCaP diet indicating a mineralization defect over the duration of 
the label injections (8 days).  
 
The variation in phenotype amongst the LowCaP VDRfl/fl mice is intriguing. Genotype 
analyses were conducted several times using several different methods and primers to 
assure that these findings were not due to misclassification of mice (data not shown). 
It has been shown that a floxed allele can be converted into a knockout in the absence 
of a Cre transgene such as in Vasa-cre strains which expressed Cre mRNA/protein in 
the absence of Cre transgene in the oocytes (195). Furthermore, a study on EIIa-cre, 
B6.FVB-Tg(EIIa-cre)C5379Lmgd/J mouse line indicated that maternal or paternal 
inheritance of the Cre transgene may affect Cre expression and activity (163). 
Although most of the Cre mouse lines do not have differences in the phenotypes when 
transferred maternally or paternally (196), to investigate this phenomena amongst the 
ObVDR-KO mice is worthwhile. I observed that although most of the LowCaP fed 
mice had maternal Cre transmission (10 out of 13), there was no obvious pattern to 
signify maternal Cre inheritance produces inferior bone structure than that of the 
paternal inheritance. Since sites of Cre activity can be unexpected such as excision 
within non-intended cells or exerting an unpredictable deletion efficiencies (197), 




Quantification of VDR protein level in various tissues would be a future study to 
evaluate this Cre activity on LowCaP fed diet. 
 
It is likely that the macroscopic changes to skeletal structures are arisen from the 
effects of mechanical forces exerted by the muscles during growth on poorly 
mineralised bone which is clearly undergoing a very high turnover. It is interesting 
that the major difference between the ObVDR-B6 mice (reported in Chapter 4) and 
the ObVDR-KO mice fed the LowCaP diet is the nature of the fluorochrome labels. In 
the ObVDR-B6 mice the double labels were distinct whereas in the ObVDR-KO mice 
the first label was clearly apparent but its edges were indistinct and the second label 
was not detected. However the effects on structure were very similar. Therefore while 
these observations suggest that the presence of VDR in mature osteoblasts allows for 
adequate mineralisation even under severe dietary calcium and phosphate restriction, 
the absence of VDR in mature osteoblasts curtailed the mineralization process under 
these conditions. Further evidence for a limitation of bone formation in the ObVDR-
KO mice is the inability of the metaphyseal trabeculae to increase thickness under 
conditions of marked reduction in number of trabeculae unlike the VDRfl/fl mice 
(Table 5.3). The mechanism by which the compromised bone mineralisation process 
occurred are not fully understood and warrant further evaluation and studies.  
 
5.5. CONCLUSION 
This study further confirmed that VDR in mature osteoblasts modulates bone cell 
activity and/or plasma calcium/phosphate homeostasis. During adequate dietary 
calcium and phosphate intake, VDR deletion in mature osteoblasts did not affect bone 
structures at 20w of age although there was a decrease of ALP consistent with reduced 
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osteoblast number arising from reduced RANKL and stimulation of bone turnover in 
young, growing mice. This effect is markedly reduced with maturation of the animals 
and then the bone phenotype is lost.  
 
In this study, prolonged severe dietary calcium/phosphate restriction was used to exert 
considerable stress on plasma calcium/phosphate homeostasis. VDR deletion in 
mature osteoblasts greatly affects bone structure, disrupts bone growth and growth 
plate, increases bone turnover and possibly reduced bone resorption and inhibits 
mineralisation. The markedly elevated PTH levels appear to stimulate high bone 
turnover and trabecularization of the cortical bone particularly in regions adjacent to 
the growth plates. Such high bone turnover provides sufficient calcium from the bone 
compartment to maintain calcium levels within the plasma compartment although the 
plasma phosphate levels declined significantly compared to the NormCaP fed animals 
irrespective of their osteoblast VDR status. The reduction of cortical endosteal 
perimeter is consistent with reduced bone resorption and the indistinct double 
fluorochrome labels are consistent with a limitation on bone formation.  
 
Further data on bone VDR protein levels in the VDRfl/fl mice fed LowCaP would be 
useful since the Cre/loxP model has some limitations which may arise under extreme 
physiological conditions and may have confounded the phenotype of the control mice 






CHAPTER 6: SUMMARY AND CONCLUSION 
 
6.1. SUMMARY   
6.1.1. Influence of Genetic Background on Activities of Osteoblast VDR 
The genetic background of mice significantly effects skeletal structure and bone 
mineral homeostasis (198). Therefore, confirmation of the anabolic physiological role 
of overexpression of the Vdr-gene in mature osteoblasts in mice on a genetic 
background distinct from the original report was necessary. Backcrossing of the 
transgenic mouse line over-expressing the human Vdr-gene in mature osteoblasts 
(OSVDR) from FVB/N genetic background to C57Bl6/J (ObVDR-B6) was conducted. 
Overexpression of the human Vdr gene in mature osteoblasts plays a significant role 
on bone mineral accrual at cortical and trabecular sites of the C57Bl6/J transgenic mice 
similar to that reported for the OSVDR mice on the FVB/N background. A consistent 
increased in cortical bone volume and strength for both female and male ObVDR-B6 
mice through the increased cortical thickness indicates the importance of VDR in 
cortical bone remodelling, possibly through enhancing VDR-mediated activities in 
osteocytes as well as osteoblasts. Most interestingly is the apparent sexual dimorphism 
of osteoblast VDR activities in adult mice (20w of age) where the female mice 
increased cortical bone volume largely due to increased periosteal expansion while the 
male mice have increased cortical bone volume due to the decrease in endosteal 
perimeter. These data suggest that in female mice VDR activity is stimulating 





6.1.2. Effects of Normal Dietary Calcium/Phosphate on Vitamin D Activities 
within Mature Osteoblasts 
When dietary calcium/phosphate was adequate, the ObVDR-B6 mice demonstrated 
increased bone mass and strength at 9 and 20w of age. This phenotype arose largely 
due to the decrease in bone resorption, on both trabecular and cortical bone, with a 
contribution of periosteal expansion suggesting an increase of bone formation. The 
decrease in bone resorption arose from decreased RANKL expression which reduces 
osteoclastogenesis. The mechanism by which periosteal expansion was achieved 
requires further study although Gardiner et al (36) reported increased periosteal bone 
formation rate with OSVDR mice on a similar diet.  
 
In the ObVDR-KO mouse model fed normal dietary calcium/phosphate diet, deletion 
of VDR in mature osteoblasts did not alter bone structure or dynamic bone 
histomorphometry at 20w of age. As published elsewhere, ObVDR-KO mice exhibit 
increased trabecular bone phenotype at 6w of age which was markedly reduced at 12w 
(194). In this instance, the bone phenotype arose from decreased induction of RANKL 
and decreased osteoclastic bone resorption. Further investigation on the mechanism by 
which this phenotype is lost with maturity when growth and bone turnover reduces is 
warranted. 
 
The only plasma calcium or phosphate regulating hormone modulated by the variation 
of VDR expression in mature osteoblasts when dietary calcium and phosphate are 
adequate is the lower serum FGF-23 levels in ObVDR-B6 mice. This effect is 
consistent with its synthesis being increased by increasing serum 1,25D levels and 




increasing the VDR activity in these cells. No significant effects of ablation of the 
VDR gene in mature osteoblasts on circulating levels of 1,25D, PTH or FGF-23 during 
adequate calcium/phosphate diet were detected although PTH did increase by about 
60 % but it did not achieve statistical significance. The effects of mature 
osteoblast/osteocyte VDR on PTH and FGF-23 serum levels require further 
investigation to elucidate the process and mechanisms involved in VDR activities of 
mature osteoblasts. 
 
These data confirm that increased VDR activity in mature osteoblasts/osteocytes has 
the capacity to improve bone mineral status through both inhibition of 
osteoclastogenesis and stimulation of periosteal bone formation. However the 
phenotype of the ObVDR-KO mouse indicates that such activity is not necessary in 
adult animals when the calcium and phosphate nutrition are adequate. 
 
6.1.3. Effects of Low Dietary Calcium/Phosphate on Vitamin D Activities 
within Mature Osteoblasts  
An extremely low dietary calcium/phosphate diet to induce secondary 
hyperparathyroidism and supra-physiological levels of serum 1,25D was used to 
investigate the interaction between these calciotropic hormones and mature osteoblast 
VDR activities on bone mineral content and plasma calcium and phosphate 
homeostasis. Under these conditions, increased serum PTH and 1,25D levels and 
reduced serum FGF-23 levels were observed without hypocalcaemia or marked 
hypophosphatemia, although the serum phosphate levels were reduced when 
compared to adequate calcium/phosphate diet fed animals. These changes are likely to 
arise from the primary effect of the low dietary calcium stimulating PTH synthesis and 
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secretion and low dietary phosphate reducing FGF-23 synthesis and secretion, both of 
which can act to increase renal 1,25D synthesis and raised plasma 1,25D levels.  
 
Femur length, femur total mineral content, femoral mid-shaft cortical bone volume, 
trabecular bone volume, and trabecular number in distal metaphysis and vertebrae 
were all significantly reduced in these mouse models. However, some features differed 
amongst the mouse models as depicted in the table 6.1. Differences between effects 
on appendicular and axial bone are also evident for VDR-mediated activity within the 
mature osteoblast. However, with regard to the ObVDR-KO model, such differences 
must be carefully examined and interpreted since conditional Cre/loxP models have 
limitations which may become evident under such supra-physiological or extreme 
conditions.  
 
The effects of increasing osteoblast VDR level are consistent with the current 
understanding of 1,25D as a calciotropic hormone to maintain plasma calcium 
homeostasis. When dietary calcium is adequate the osteoblast VDR enhances the flux 
of calcium from the plasma compartment into the skeletal compartment. When dietary 
calcium is deficient, osteoblast VDR contributes to high bone turnover to the extent of 






Table 6.1. Effects of Reducing Dietary Calcium/Phosphate from Normal to 
Extremely Low within the Same Genotype 
Variable WT ObVDR-B6 VDRfl/fl ObVDR-KO 
Body Weight ~ ~ ~  
Serum 1,25D     
Serum PTH N/A N/A   
Serum FGF-23     
Femur length     
Periosteal perimeter ~  ~ ~ 
Endosteal perimeter   ~  
Cortical porosity Undetected Observed () Observed () Observed () 
Tb. Th. Femur ~ ~   
SMI of Femur ~ ~   
Vertebral height ~ ~ ~ ~ 
Tb. Th. Vertebrae     


















It is interesting that these two mouse lines, ObVDR-B6 with overexpression of the Vdr 
gene in mature osteoblasts and ObVDR-KO with ablation of the Vdr gene in mature 
osteoblasts, demonstrate largely the same skeletal phenotype on extremely low 
calcium/phosphate diet with marked disruption of the growth plate and macro- and 
micro-architectural disruption of the skeleton to a greater extent than that found in 
control mice on this diet. Such an outcome clearly demonstrates the critical role of 
mature osteoblast VDR activity on bone growth. The overall evidence suggests that 
these models achieved this phenotype by different mechanisms. Both mouse lines 
maintained normocalcemia and only a minor decrease in serum phosphate levels by 
stimulating PTH and 1,25D secretion and decreasing FGF-23 levels. Unfortunately 
PTH levels are not available from ObVDR-B6 mice due to technical difficulties and 
therefore it is unknown whether these mice were similar to the ObVDR-KO mice with 
higher PTH levels than the controls; however the 1,25D levels were clearly increased 
over controls in both models. Therefore, high bone turnover phenotypes arise from the 
elevated levels of (probably) PTH and 1,25D in the ObVDR-B6 mice and PTH (and 
possibly 1,25D acting on immature osteoblasts) in the ObVDR-KO mice. 
 
The skeletal architecture demonstrated that even when dietary calcium and phosphate 
are very low, ObVDR-B6 mice maintained increased periosteal circumference 
compared to WT mice suggesting that the ability to increase periosteal bone formation 
is preserved even under these extreme conditions. It would be expected that if 
increasing mature osteoblast/osteocyte VDR activity stimulated periosteal bone 
formation then ablation of mature osteoblast/osteocyte activity would reduce or limit 
periosteal bone formation. As stated above there is no evidence for reduced periosteal 




that femoral metaphyseal trabecular thickness apparently increased in the control 
VDRfl/fl mice fed the LowCaP diet. This is presumably as a result of increased 
mechanical forces on each surviving trabeculum following the marked reduction of 
trabecular number with this diet. While trabecular thickness in ObVDR-KO mice fed 
similar diet was increased, it did not progress to the extent of the control mice. These 
data, as they stand, provide some evidence that bone formation may be limited in the 
ObVDR-KO mice. However the data may be confounded by the marked reduction of 
trabecular bone in this region and the difficulty to distinguish between true trabecular 
bone and bone arising from the trabecularization of the cortices, which is very 
extensive in these mice. Clearly further work is required to investigate any such effects 
in more detail.  
 
The dynamic histology data provide evidence to suggest that the marked disruption of 
skeletal structure between the mouse lines demonstrate different osteoclast and 
osteoblast activities.  ObVDR-B6 mice demonstrated increased osteoclast number 
associated with increased Rankl expression suggestive of the effects of increased 
1,25D and possibly PTH on osteoblast/osteocyte cells above the level of the control 
mice. Bone formation appeared to be adequate as indicated by extensive, distinct 
fluorochrome double labels, not different to the control mice. ObVDR-B6 mice appear 
to have demonstrated maintenance of the coupling between osteoclasts and osteoblasts 
even with the high bone turnover producing the marked reduction of bone volume 
similar to that observed with estrogen deficiency.  
 
In ObVDR-KO mice, the osteoclast numbers were not different to the control mice 
although given the marked reduction in trabecular bone surface, the total number of 
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osteoclasts available for assessment is small and therefore the data are not robust. 
Furthermore, the ObVDR-KO mice demonstrated markedly disturbed fluorochrome 
labels with a wide, blurry first label and undetectable second label indicating a 
mineralization defect. The difficulty in interpreting these data is the appearance of the 
control mice, the VDRfl/fl mice, in which as discussed previously, 3 mice demonstrated 
relatively distinct double labels and 4 mice demonstrated labels similar to the 
appearance of the ObVDR-KO mice with some variation on the extent of the 
disturbance of the labels. Therefore, the mineralisation defect could be simply due to 
the floxed Vdr gene was not properly expressed or there was unexplained ablation of 
the Vdr gene in these mice. The fact that all the labels in ObVDR-KO mice were 
consistent and those in the VDRfl/fl mice were variable suggest that this mineralisation 
defect arises from the ablation of osteoblast VDR and not just the floxed Vdr gene. 
Therefore the suggestion from these data is that the phenotype of the ObVDR-KO mice 
when fed extremely low calcium and phosphate diet arises from high bone turnover 
from the markedly increased PTH and a limitation on bone formation. 
 
6.2. LIMITATIONS 
The studies described in this thesis have some design and research limitations which 
can be improved in future studies. The limited or absence of data from young growing 
ObVDR-B6 and ObVDR-KO mice fed both diets limits the interpretation of the effects 
of VDR activities in mature osteoblasts during the period of bone modelling including 
the dynamic histomorphometry analyses and gene expressions of the short term dietary 
study. The WT mice used in some of the studies were not littermates which may 
influence some of the findings although, our measurements made on ObVDR-B6 and 




observed using littermate controls. As well, some data are missing from the study 
including mRNA and protein analyses as well as some serum measurements. All of 
these omissions were due to resource and time limitations for this project. 
 
There is also the issue of the status of the Vdr-floxed mice used as controls under the 
extreme condition of the low dietary calcium and phosphate which induced supra-
physiological levels of calciotropic hormones. As discussed, I did not directly measure 
Vdr gene expression or VDR protein levels, which limits the interpretation of the 
ObVDR-KO mice under these conditions. Assessment of the Cre expression, activity 
and potential for gene deletion in the VDRfl/fl mice would be most helpful.  
 
Although vertebral microCT analyses shown some significant differences in and 
between the mouse models, the omission of vertebral histomorphometry in the studies 
hampers the interpretation of these models especially the absence of double fluorescent 
label images to provide rate of bone formation analyses. Furthermore, the studies were 
conducted only on female mice, although preliminary studies have shown gender 
related differences in the activities of the VDR in mature osteoblasts.  
 
6.3.FUTURE DIRECTIONS 
The results in this thesis indicate that mature osteoblast VDR activities effect bone 
size, shape and structure as well as microarchitecture. They provide a rich source for 
generating new hypotheses regarding the cellular and molecular mechanisms involved. 
Further investigations of these mechanisms by which osteoblast VDR exerts these 
activities would be most useful. In particular further investigation of the periosteal 
bone formation rate, including any variation with age, is required to improve the 
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sensitivity of assessment as to whether such bone formation is reduced in the ObVDR-
KO mouse line. As well, the apparent sexual dimorphism of mature 
osteoblast/osteocyte VDR requires further investigation to identify the cellular and 
molecular mechanisms contributing to these outcomes possibly through the 
interactions between either the estrogen and androgen receptors in female and male 
mice respectively. 
 
On the extremely low calcium and phosphate diet, ObVDR-B6 have shown changes 
in growth plate width and area. Further investigation on the proliferative and 
hypertrophic zone of these mice and studies using 1,25D treatment could also uncover 
the role of mature osteoblasts VDR activities in chondrocytes activity and maturation. 
Further analyses using immunohistochemistry for osteocyte markers, nanoindentation, 
tissue mineral density, and mechanical strength analyses could be conducted to attest 
whether bone mineral accrual and changes of skeletal structure improves bone quality 
and strength especially in the LowCaP diet and or in 1,25D treated ObVDR-B6 for 
future studies. Similar studies and approaches can also be used in the ObVDR-KO 
mouse model to further strengthen the evidence of VDR in mature osteoblasts to 
modulate skeletal structure and mineral content. 
 
The ObVDR-KO mice demonstrated bone marrow changes including adiposity and 
bone marrow cellularity possibly indicating an altered bone marrow niche. These 
observations suggest a role for VDR in mature osteoblasts in contributing to the 
maintenance of bone marrow integrity. Future studies could carefully examine this 








The findings of this thesis demonstrate that mature osteoblast VDR exerts critical 
activities contributing to maintaining plasma calcium and phosphate homeostasis, 
skeletal growth particularly in the long bones, and bone cell activities. The effects on 
maintaining plasma calcium and phosphate homeostasis include effects on plasma 
levels of calciotropic hormones such as 1,25D, PTH, and FGF-23 as well as bone cell 
activities. The outcomes from feeding extremely low calcium and phosphate diet have 
demonstrated a markedly disrupted skeleton with critical input from osteoblast VDR 
to achieve adequate plasma calcium levels. Therefore, osteoblast VDR activities 
markedly respond to calcium and phosphate nutrition consistent with the overriding 
outcome to maintain plasma calcium homeostasis at the expense of bone structure and 
integrity. These findings add to the knowledge that a direct role of vitamin D receptor 
in skeletal health do persist and that the VDR in mature osteoblasts do able to change 
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3150 Great Eastern Hwy
Glen Forrest
Western Australia 6071
p: +61 8 9298 8111
F: +61 8 9298 8700
Email: info@specialtyfeeds.com
Diet
Meat Free Rat and Mouse Diet
A fixed formulation diet for Laboratory Rats and Mice fortified with vitamins and minerals to meet the 
requirements of breeding animals after the diet is autoclaved or irradiated.
• Minor modifications were made to this fixed formulation on 27 Jan 2009. Please contact us 
for details.
• All nutritional parameters of this diet meet or exceed the NRC guidelines for Rats and Mice.
• The diet has been designed as a general ration for breeding and early growth in all rat and 
mouse strains. The total fat content has been deliberately kept low at around 5%, to 
maximise the long term breeding performance of most strains.
• The formulation is designed to be fed ad-lib to rodents of all ages. There is some indication 
that growth performance in a minority of strains can be improved by increasing dietary energy 
(fat content). BalbC mice, DA rats and some of the modified strains appear to be most 
susceptible to this problem. Please contact us if you are concerned about this issue.
• Mammalian meals have been excluded from the diet, however the diet does contain fish 
meal. We have formulated totally vegetarian diets, and maintained colonies for some time on 
these diets. Please contact us if you require such a diet.
• The feed is manufactured in a cylindrical form with a diameter of around 12 mm, length is 
variable from 10 mm to 30 mm. We have found that this form is ideal for overhead hopper 
feeding, maximising the ease of handling whilst minimising fines formation and the risk of 
bridging in the feed hopper. Pellet strength has been kept lower than conventional pelletised 
diets. While this leads to a slight increase in transit and storage damage to the diet (fines 
generation), we have found that juvenile mice often have a lower feed intake on harder 
pellets.
• The diet is packed in permeable bags suitable for direct loading into an autoclave. It is 
recommended that the diet be autoclaved at 120O C for 20 minutes with a post autoclaving 
vacuum drying cycle. Some clumping of the diet can be expected, but the diet clumps can 
usually be easily broken. Modifying the drying time to leave some residual moisture in the diet 
can minimise the clumping. Do not autoclave at 1350 C as this will result in significant 
clumping that will be difficult to break.





Acid Detergent Fibre 7.60%
Neutral Detergent Fibre 16.40%
Total Carbohydrate 59.40%
Digestible Energy 14.0 MJ / Kg
% Total Calculated Energy From 
Protein
23.00%




A Fixed formula ration using the following 
ingredients:
Wheat, barley, Lupins, Soya meal, Fish meal, 
Mixed vegetable oils, Canola oil, Salt, Calcium 
carbonate, Dicalcium phosphate, Magnesium 
oxide, and a Vitamin and trace mineral premix.
Added Vitamins 
Vitamin A (Retinol) 10 000 IU/Kg
Vitamin D (Cholecalciferol) 2 000 IU/Kg
Vitamin E (a Tocopherol acetate) 100 mg/Kg
Vitamin K (Menadione) 20 mg/Kg
Vitamin B1 (Thiamine) 80 mg/Kg
Vitamin B2 (Riboflavin) 30 mg/Kg
Niacin (Nicotinic acid) 100 mg/Kg
Vitamin B6 (Pryridoxine) 25 mg/Kg
Calcium Pantothenate 50 mg/Kg
Biotin 300 ug/Kg
Folic Acid 5.0 mg/Kg
Vitamin B12 (Cyancobalamin) 150 ug/Kg
Diet Form and Features
• Cereal grain base diet. 12 mm diameter 
pellets. 
• Pack size 10 and 20 Kg Bags. 
• Diet suitable for irradiation, also suitable 
for autoclave.
• Lead time 2 weeks







































Vitamin A (Retinol) 10 950 IU/Kg
Vitamin D (Cholecalciferol) 2 000 IU/Kg
Vitamin E (a Tocopherol acetate) 110 mg/Kg
Vitamin K (Menadione) 20 mg/Kg
Vitamin C (Ascorbic acid) No data
Vitamin B1 (Thiamine) 80 mg/Kg
Vitamin B2 (Riboflavin) 30 mg/Kg
Niacin (Nicotinic acid) 145 mg/Kg
Vitamin B6 (Pryridoxine) 28 mg/Kg
Pantothenic Acid 60 mg/Kg
Biotin 410 ug/Kg
Folic Acid 5 mg/Kg
Inositol No data
Vitamin B12 (Cyancobalamin) 150 ug/Kg
Choline 1 640 mg/Kg
Calculated Fatty Acid Composition
Myristic Acid 14:0 0.03%
Palmitic Acid 16:0 0.50%
Stearic Acid 18:0 0.14%
Palmitoleic Acid 16:1 0.01%
Oleic Acid 18:1 1.90%
Gadoleic Acid 20:1 0.03%
Linoleic Acid 18:2 n6 1.30%
a Linolenic Acid 18:3 n3 0.30%
Arachadonic Acid 20:4 n6 0.01%
EPA 20:5 n3 0.02%
DHA 22:6 n3 0.05%
Total n3 0.37%
Total n6 1.31%
Total Mono Unsaturated Fats 2.00%
Total Polyunsaturated Fats 1.77%
Total Saturated Fats 0.74%
Calculated data uses information from typical raw material composition. It could be expected that 
individual batches of diet will vary from this figure. Diet post treatment by irradiation or auto clave 
could change these parameters. 
We are happy to provide full calculated nutritional information for all of our products, however we 
would like to emphasise that these diets have been specifically designed for manufacture by 
Specialty Feeds.
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Diet 1% Calcium 0.625% Phosphorous Whey Protein 
Isolate Modification of 
SF04-053 VDRKO Rescue Diet
SF12-076
A VDRKO semi-pure rodent diet designed based on Harlan Teklads TD96348 (SF04-053). 
• Casein has been replaced with Whey Protein Isolate
• Calcium has been reduced from 2.1 to 1%
• Phosphorous has been reduced from 1.26 to 0.625%
• Sodium and potassium levels have been kept constant against SF04-053






Digestible Energy 14.7 MJ / Kg
% Total calculated digestible 
energy from lipids
12.70%
% Total calculated digestible 
energy from protein
22.30%
Diet Form and Features
• Semi pure diet. 12 mm diameter pellets. 
• Pack size 5 Kg, vacuum packed in oxygen 
impermeable plastic bags, under nitrogen. 
Bags are packed into cardboard cartons 
to protect them during transit. Smaller 
pack quantity on request. 
• Diet suitable for irradiation but not suitable 
for autoclave.
• Lead time 2 weeks for non-irradiation or 4 
weeks  for irradiation.
Ingredients
Whey Protein Isolate 199 g/Kg
Sucrose 237 g/Kg
Lactose 200 g/Kg
Maize Oil 50 g/Kg
Cellulose 98 g/Kg
Maize Starch 150 g/Kg
DL Methionine 3.0 g/Kg
Calcium Carbonate 17.2 g/Kg
Sodium Chloride 2.3 g/Kg




Potassium Sulphate 1.2 g/Kg
MonoCalcium Phosphate 23.8 g/Kg
Magnesium Oxide 0.7 g/Kg
Choline Chloride (75%) 2.5 g/Kg
AIN93 Vitamins 10 g/Kg
Vitamin D Supplement (28 500 
IU/g)
0.04 g/Kg




































Vitamin A (Retinol) 4 000 IU/Kg
Vitamin D (Cholecalciferol) 2 140 IU/Kg
Vitamin E (a Tocopherol 
acetate)
76 mg/Kg
Vitamin K (Menadione) 1 mg/Kg
Vitamin C (Ascorbic acid) None added
Vitamin B1 (Thiamine) 6 mg/Kg
Vitamin B2 (Riboflavin) 6 mg/Kg
Niacin (Nicotinic acid) 30 mg/Kg
Vitamin B6 (Pryridoxine) 7 mg/Kg
Pantothenic Acid 16 mg/Kg
Biotin 200 ug/Kg
Folic Acid 2 mg/Kg
Inositol None added
Vitamin B12 (Cyancobalamin) 100 ug/Kg
Choline 1 410 mg/Kg
Calculated Fatty Acid Composition
Myristic Acid 14:0 No data
Palmitic Acid 16:0 0.55%
Stearic Acid 18:0 0.10%
Palmitoleic Acid 16:1 No data
Oleic Acid 18:1 1.21%
Gadoleic Acid 20:1 No data
Linoleic Acid 18:2 n6 2.90%
a Linolenic Acid 18:3 n3 0.04%
Arachadonic Acid 20:4 n6 No data
EPA 20:5 n3 No data
DHA 22:6 n3 No data
Total n3 0.04%
Total n6 2.90%
Total Mono Unsaturated Fats 1.21%
Total Polyunsaturated Fats 2.94%
Total Saturated Fats 0.64%
Calculated data uses information from typical raw material composition.  It could be expected that individual 
batches of diet will vary from this figure. Diet post treatment by irradiation or auto clave could change 
these parameters. We are happy to provide full calculated nutritional information for all of our products, 
however we would like to emphasise that these diets have been specifically designed for manufacture by 
Specialty Feeds.
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Diet 0.03% Calcium 0.08% Phosphorous Whey Protein 
Isolate Modification of 
SF04-053 VDRKO Rescue Diet
SF12-077
A VDRKO semi-pure rodent diet designed based on Harlan Teklads TD96348 (SF04-053). 
• Casein has been replaced with Whey Protein Isolate
• Calcium has been reduced from 2.1 to 0.03%
• Phosphorous has been reduced from 1.26 to 0.08%
• Sodium and potassium levels have been kept constant against SF04-053






Digestible Energy 14.7 MJ / Kg
% Total calculated digestible 
energy from lipids
12.70%
% Total calculated digestible 
energy from protein
22.30%
Diet Form and Features
• Semi pure diet. 12 mm diameter pellets. 
• Pack size 5 Kg, vacuum packed in oxygen 
impermeable plastic bags, under nitrogen. 
Bags are packed into cardboard cartons 
to protect them during transit. Smaller 
pack quantity on request. 
• Diet suitable for irradiation but not suitable 
for autoclave.
• Lead time 2 weeks for non-irradiation or 4 
weeks  for irradiation.
Ingredients
Whey Protein Isolate 199 g/Kg
Sucrose 231 g/Kg
Lactose 200 g/Kg
Maize Oil 50 g/Kg
Cellulose 145 g/Kg
Maize Starch 150 g/Kg
DL Methionine 3.0 g/Kg
Calcium Carbonate 0.2 g/Kg
Sodium Chloride 2.3 g/Kg
AIN93 Trace Minerals 1.4 g/Kg




Potassium Sulphate 1.2 g/Kg
Magnesium Oxide 1.7 g/Kg
Choline Chloride (75%) 2.5 g/Kg
AIN93 Vitamins 10 g/Kg
Vitamin D Supplement (28 500 
IU/g)
0.04 g/Kg




































Vitamin A (Retinol) 4 000 IU/Kg
Vitamin D (Cholecalciferol) 2 140 IU/Kg
Vitamin E (a Tocopherol 
acetate)
76 mg/Kg
Vitamin K (Menadione) 1 mg/Kg
Vitamin C (Ascorbic acid) None added
Vitamin B1 (Thiamine) 6 mg/Kg
Vitamin B2 (Riboflavin) 6 mg/Kg
Niacin (Nicotinic acid) 30 mg/Kg
Vitamin B6 (Pryridoxine) 7 mg/Kg
Pantothenic Acid 16 mg/Kg
Biotin 200 ug/Kg
Folic Acid 2 mg/Kg
Inositol None added
Vitamin B12 (Cyancobalamin) 100 ug/Kg
Choline 1 410 mg/Kg
Calculated Fatty Acid Composition
Myristic Acid 14:0 No data
Palmitic Acid 16:0 0.55%
Stearic Acid 18:0 0.10%
Palmitoleic Acid 16:1 No data
Oleic Acid 18:1 1.21%
Gadoleic Acid 20:1 No data
Linoleic Acid 18:2 n6 2.90%
a Linolenic Acid 18:3 n3 0.04%
Arachadonic Acid 20:4 n6 No data
EPA 20:5 n3 No data
DHA 22:6 n3 No data
Total n3 0.04%
Total n6 2.90%
Total Mono Unsaturated Fats 1.21%
Total Polyunsaturated Fats 2.94%
Total Saturated Fats 0.64%
Calculated data uses information from typical raw material composition.  It could be expected that individual 
batches of diet will vary from this figure. Diet post treatment by irradiation or auto clave could change 
these parameters. We are happy to provide full calculated nutritional information for all of our products, 
however we would like to emphasise that these diets have been specifically designed for manufacture by 
Specialty Feeds.
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